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1. Abbreviations  
AA arachidonic acid 
AB antibody 
Ada adenosine deaminase3 
AKBA  3-O-acetyl-11-keto-boswellic acid 
ALP alkaline phosphatase 
AP  activator protein 
APS ammonium persulfate 
ATLs  aspirin-triggered lipoxins 
ATP adenosine triphosphate 
ATR-FTIR attenuated total reflection Fourier transform infrared 
BCIP 5-Bromo-4-chloro-3-indolyl phosphate 
BSA bovine serum albumine 
cAMP  cyclic adenosine monophosphate 
C/EBP beta  CCAAT/enhancer binding protein beta 
CLP coactosin-like protein 
COX cyclooxygenase 
cPLA2 cytosolic phospholipase A2 
CYP450 cytochrome P450 
DAG diacylglyceride 
DHET dihydroxyeicosatrienoic acid 
DMEM Dulbecco's modified Eagle's medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
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DPPH diphenylpicrylhydrazyl 
DTT dithiothreitol 
ECL electrochemiluminescence 
E. coli Escherichia coli 
EDTA ethylenediamine-tetraacetic acid 
EET epoxyeicosatrienoic acid 
EIA enzyme-linked immunosorbent assay 
ERK extracellular signal-regulated kinase 
FAD flavin adenine dinucleotide 
FCS fetal calf serum 
FLAP 5-lipoxygenase activating protein 
fMLP N-formyl-methionyl-leucyl-phenylalanine 
GM-CSF  granulocyte/macrophage colony-stimulating factor 
GPCR G protein-coupled receptor 
GPx glutathione peroxidases 
Grb  growth factor receptor-bound protein 
GSH glutathione 
HEDH  hydroxyeicosanoid dehydrogenase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HETE hydroxyeicosatetraenoic acid 
12-HHT 12-hydroxy-5,8,10-heptadecatrienoic acid 
HpETE hydroperoxy-6-trans-8,11,14-cis-eicosatetranoic acid 
HPLC high performance liquid chromatography 
13-(S)-HpODE 13S-hydroperoxy-9Z,11E-octadecadienoic acid 
IC50 inhibiting concentration (50% of inhibition) 
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Ig immunoglobuline 
ICAM inter-cellular adhesion molecule  
IL interleukin 
IPTG isopropyl-β-D-thio-galactoside 
JNK c-Jun NH2-terminal kinase 
LB-medium Luria Broth base - medium 
LO lipoxygenase 
LOOH lipid hydroperoxide 
LPS lipopolysaccharide 
LT leukotriene 
LX lipoxin 
MAPEG  membrane-associated proteins in eicosanoid and glutathione  
 metabolism 
MAPK mitogen-activated protein kinase 
MBP maltose-binding protein 
MK  mitogen-activated protein kinase activated protein kinase 
mPGES microsomal prostaglandin E2-synthase 
MS mass spectrometry 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaCl sodium chloride 
NBT nitro-blue tetrazolium 
NES  nuclear export sequence 
NFAT  nuclear factor of activated T-cells 
NLS  nuclear localization sequence 
NP40 Nonidet P-40 
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NQO2 NAD(P)H dehydrogenase, quinone 2 
NSAIDs non-steroidal anti-inflammatory drugs 
OAG 1-oleoyl-2-acetyl-sn-glycerol 
PA pirinixic acid 
PAF platelet activating factor 
PAI  plasminogen activator inhibitor 
PA-P  phosphatidic acid phosphatase 
PBS phosphate buffered saline 
PC phosphatidylcholine 
PE phosphatidylethanolamine 
PG prostaglandin 
PGI prostacyclin 
PG buffer PBS-glucose buffer 
PGC buffer PBS-glucose-Ca2+ buffer 
PI phosphatidylinositol 
PK protein kinase 
PL phospholipid 
PMA phorbol 12-myristate 13-acetate  
PMNL polymorphonuclear leukocytes 
PMSF phenylmethyl sulfonyl fluoride 
PPAR  peroxisome proliferator-activated receptor 
PPRE  peroxisome proliferator response element 
PS phosphatidylserine 
ROS reactive oxygen species 
RT room temperature 
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RXR  retinoid X receptor 
SDS sodium dodecyl sulfate 
SDS-b 2× SDS loading buffer 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SH  Src homology 
SPPARM selective PPAR receptor modulator 
SPR surface plasmon resonance 
STAT signal transducer and activator of transcription 
STI soybean trypsin inhibitor 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TG  thapsigargin 
TGF transforming growth factor 
TNF tumor necrosis factor 
TRAP  TGFβ receptor-I-associated protein 
TX thromboxane 
VCAM  vascular cell adhesion molecule 
WB Western Blot 
w/o without 
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2. Introduction 
2.1. Inflammation 
Acute inflammation is a beneficial host response to external or internal stimuli (e.g. infection, 
toxins, irritants or tissue injury) and is accompanied by the classic cardinal signs heat, redness, 
swelling and pain (Fig. 1) [1]. These manifestations reflect an increased regional blood flow 
caused by vasodilatation as well as an increase in microvascular permeability. In general, this 
process is self-limited due to endogenous anti-inflammatory and proresolving mediators (e.g. 
lipoxins, resolvins, protectins and maresins [2]), but if the host cannot manage to abrogate the 
inflammatory reaction, chronic conditions may arise, resulting in a loss of tissue or organ 
function. A variety of chronic diseases like asthma, rheumatoid arthritis, cardiovascular diseases, 
atherosclerosis, inflammatory bowel diseases, Alzheimer’s disease and also cancer are associated 
with such an inappropriate inflammatory response [3], [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Cardinal signs of inflammation (adopted from Lawrence, T. et al. Nat 
Rev Immunol, 2(10) 787-95, 2002). The characteristics of inflammation - heat, 
redness, swelling, pain, and loss of function (in case of a chronic state) - were 
defined by Celsus AD40.  
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Exposure to an inflammatory challenge leads to the release of early mediators such as 
complement factors C3a and C5a, vasoactive substances (histamine, bradykinin) and eicosanoids 
(prostaglandins (PGs) and leukotrienes (LTs)) within the injured tissue, promoting exudate 
formation and edema. Subsequently, proinflammatory cytokines (interleukin (IL)-1, tumor-
necrosis factor (TNF), and chemokines like IL-8) are produced, inducing an upregulation of 
adhesion molecules (selectins, intercellular adhesion molecule (ICAM) 1 and vascular cell 
adhesion molecule (VCAM) 1) in the endothelium and enabling the recruitment of circulating 
neutrophils. These short-lived phagocytic cells clean the damaged tissue from cell debris, harmful 
material and microorganisms with the help of reactive oxygen species (ROS) and degradative 
enzymes [5]. In the course of inflammation, monocytes (which mature into macrophages) migrate 
to the respective tissue and ingest apoptotic neutrophils. Finally, anti-inflammatory mediators are 
released, and normal tissue function is restored. 
2.2. Arachidonic acid cascade 
As mentioned above, PGs and LTs are important signaling molecules in inflammation. Both 
classes of compounds are metabolites of all-cis 5,8,11,14-eicosatetraenoic acid (arachidonic acid, 
AA) liberated from the sn-2 position of membrane phospholipids by phospholipase A2 (PLA2) 
upon cellular activation by an appropriate stimulus. A variety of PLA2 enzymes has been 
described based on primary structure, localization and Ca2+ requirement [6], but cytosolic PLA2α 
(cPLA2) is believed to be mainly responsible for the biosynthesis of eicosanoids [7]. 
Liberated AA can serve as a substrate for cyclooxygenases (COX-1 and COX-2) that produce 
PGs, thromboxanes (TX) and prostacyclin (PGI) - summarized as prostanoids. Alternatively, 
lipoxygenases (5-LO, 12-LO and 15-LO - their distinct actions are described in 2.3.) catalyze the 
formation of LTs, lipoxins (LXs) and H(p)ETE, or cytochrome P450 (CYP450) enzymes convert 
AA into epoxyeicosatrienoic acid (EET) and dihydroxyeicosatrienoic acid (DHET) [8] (Fig. 2 
gives an overview of the AA cascade). The generated products excite distinct biological effects 
that are mediated via selective G protein-coupled receptors (GPCRs). Moreover, the short living 
AA can serve as a second messenger by affecting signaling pathways itself [9], forms isoprostane 
by reacting with free radicals, or is finally reincorporated into membrane phospholipids. 
Prostanoids mediate fever, pain and inflammation, but they are also of importance in the 
regulation of the cardiovascular system, the gastrointestinal tract [10], renal functions, 
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angiogenesis and reproduction [11], [12]. The constitutively expressed COX-1 is supposed to be 
preferentially involved in physiological processes, whereas COX-2 is inducible and is found 
mainly in inflammatory cells in response to cytokine release [13]. The widely used non-steroidal 
anti-inflammatory drugs (NSAIDs) possess potent anti-inflammatory and analgetic properties, 
but also cause severe side-effects in the gastrointestinal tract [14] and in the kidney [15]. These 
complications have been ascribed to the suppression of physiologically relevant (COX-1 derived) 
prostanoids such as the cytoprotective PGE2 and PGI2 in the gastroduodenal epithelium. Selective 
COX-2 inhibitors, called coxibs, have been developed to overcome the gastrointestinal side-
effects of traditional NSAIDs. However, in recent studies these drugs have been associated to an 
increased risk for cardiovascular events (e.g., myocardial infarction, stroke, systemic and 
pulmonary hypertension, congestive heart failure and sudden cardiac death [16]), and some of 
these drugs had to be withdrawn from market. The side effects of coxibs are thought to be related 
to an imbalance of anti-thrombotic and vasodilatory PGI2 versus the prothrombotic TXA2. To 
overcome the disadvantages of a complete suppression of PGs, selective inhibition of microsomal 
prostaglandin E2 synthase (mPGES)-1 has been suggested [17], [18]. mPGES-1, which is 
functionally coupled to COX-2 [19], [20], is responsible for excessive PGE2 synthesis upon 
cellular stimulation by IL-1β, TNFα and lipopolysaccharides (LPS), and seems to play an 
important role in pain, fever, inflammation, atherosclerosis and tumorigenesis [21], [22], [23]. 
EETs derived from CYP450 possess anti-inflammatory effects in the regulation of vascular 
functions [24], but they are also involved in endothelial cell proliferation and angiogenesis [25]. 
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Fig. 2 Arachidonic acid (AA) cascade. AA is released from membrane phospholipids 
by cytosolic phospholipase A2 (cPLA2), and is further converted to prostanoids by 
cyclooxygenases (COX-1 and COX-2), to leukotrienes (LTs), lipoxins (LXs) and 
hydro(pero)xy-eicosatetranoic acid (H(p)ETE) by lipoxygenases (LOs), or to 
epoxyeicosatrienoic acid (EET) and dihydroxyeicosatrienoic acid (DHET) by 
cytochrome P450 (CYP450). Moreover, AA can react with free radicals to give 
isoprostane. 
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2.3. Lipoxygenases 
LOs are non-heme iron-containing dioxygenases that catalyze the insertion of molecular oxygen 
into AA and other polyunsaturated fatty acids yielding distinct hydroperoxyeicosatetraenoic acids 
(HpETEs) which are then transformed into its corresponding alcohol (HETE). The following LOs 
are expressed in humans: 5(S)-LO, platelet-type p12(S)-LO, reticulocyte type 12/15(S)-LO I (in 
reticulocytes and eosinophils [26], [27]), 15(S)-LO II and epidermis type e12(R)-LO. The 
number in the name of the respective LO reflects the position at which oxygen is introduced (5-, 
12-, 15-LO).  
5-LO catalyzes the first two steps in the formation of LTs. These potent lipid mediators play 
crucial roles in the innate immune response and are involved in inflammatory diseases such as 
asthma, allergic rhinitis, inflammatory bowel disease, psoriasis and shock, but they have also 
been related to cardiovascular diseases and certain types of cancer (for review, see [28]). 
12-LO derived 12-HpETE can be reduced to 12-HETE, or further metabolized to diHETEs and 
hepoxilins. 12-HETE promotes cell proliferation in cancer cells [29], cell motility [30], 
angiogenesis [31] and renal vasoconstriction. Increased levels of 12-HETE have been observed in 
patients with diabetes mellitus [32] and essential hypertension [33]. Hepoxilins induce 
chemotaxis of neutrophils and facilitate migration across intestinal epithelia [34]. 
15-HETE plays an important role in certain inflammatory diseases (e.g. proctocolitis) [35], but 
also certain anti-inflammatory actions of this 15-LO metabolite have been discussed. Thus, it 
decreases superoxide formation, exocytosis and migration of neutrophils. Moreover, it may block 
LTB4 formation and induce apoptosis [36].  
Lipoxins are formed through the concerted action of different LOs and, in case of aspirin-
triggered lipoxins (ATLs), also of COX enzymes [37]. They belong to the pro-resolving lipid 
mediators that contribute to the resolution of an inflammatory reaction and are typically produced 
by transcellular biosynthesis (for review, see [38]). 
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2.3.1. 5-Lipoxygenase  
5-LO was described for the first time in 1976 as the enzyme that catalyzes the formation of 5-
HpETE and 5-HETE in rabbit polymorphonuclear leukocytes (PMNL) [39], and only three years 
later, the same group discovered 5-HETE and LTB4 released from human leukocytes [40]. 
2.3.1.1. 5-LO reaction and leukotriene formation 
5-LO catalyzes two distinct reactions: first, molecular oxygen is incorporated into AA 
(oxygenase activity), and subsequently, the LTA4 synthase activity of the enzyme yields the 5,6 
epoxide LTA4 [41], [42] (Fig. 3). 5-HpETE is obtained by an abstraction of the pro-S hydrogen at 
C-7 of AA, followed by insertion of molecular oxygen at position C-5 [43]. In the next step, the 
pro-R hydrogen from C-10 of 5-HpETE is abstracted, and the radical is shifted to C-6 yielding 
LTA4 [44]. Another metabolite of 5-HpETE is its corresponding alcohol 5-HETE which is the 
precursor of 5-oxo-ETE [45] and the lipoxins [46]. 5-oxo-ETE formation is catalyzed by the 
microsomal NADP+-dependent enzyme 5-hydroxyeicosanoid dehydrogenase (5-HEDH), whereas 
lipoxins are generated by the combined action of 5-LO and 12-LO or 15-LO. The assay 
conditions such as the relative concentrations of free AA and 5-HpETE, membrane association, 
the amount of 5-LO, and the presence of 5-LO activating protein (FLAP) determine the ratio of 
LTA4 to 5-HpETE [47], [48], [49], [50]. The unstable LTA4 is either converted to LTB4 by LTA4-
hydrolase or conjugated with reduced glutathione (GSH) yielding LTC4 (mediated by LTC4 
synthase (LTC4S)) [51]. Both LTB4 and LTC4 are released from the cell, and LTC4 is hydrolyzed 
subsequently to LTD4 which is then converted to LTE4. 
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Fig. 3. LT biosynthesis. Free arachidonic acid (AA) is converted to the hydroperoxide 5(S)-
hydroperoxy-6-trans-8,11,14-cis-eicosatetranoic acid (5-HpETE) by the oxygenase activity of 
5-lipoxygenase (5-LO). Then, the LTA4 synthase activity of 5-LO catalyzes the formation of 
the unstable epoxide LTA4 that is either converted to LTB4 by LTA4 hydrolase, or conjugated 
with glutathione (GSH) to LTC4 by LTC4 synthase. LTC4 is the precursor of the other 
cysteinyl-LTs D4 and E4. 5-HpETE can also be reduced to 5(S)-hydroxy-6-trans-8,11,14-cis-
eicosatetranoic acid (5-HETE) and further oxidation by 5-hydroxyeicosanoid dehydrogenase 
(5-HEDH) leads 5-oxo-ETE. 
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The iron of 5-LO is in the ferrous state (Fe2+) when the enzyme is inactive and is oxidized after 
treatment with lipid hydroperoxides (LOOHs) [52], [53]. Notably, hydrogen peroxide is not able 
to stimulate 5-LO. The course of the 5-LO reaction can be divided into three phases: i) an 
initiation phase where the iron is converted to the ferric form; ii) a linear propagation phase with 
a high turnover; and iii) a terminal phase of irreversible inactivation (Fig. 4). The rapid 
inactivation of 5-LO may be provoked by LOOHs generated during catalysis, although these 
molecules are important to initialize the enzyme reaction as well [54]. If glutathione peroxidases 
(GPx) are added to cell-free 5-LO activity assays, they inhibit product formation but also stabilize 
5-LO because of their reducing effect on LOOHs [55], [28]. 
Reduction of 5-HpETE is thought to be mediated by a pseudoperoxidase activity of 5-LO [56], 
[57] which is stimulated by certain derivatives of diphenyl-N-hydroxyureas, 4-
hydroxybenzofurans and 5-hydroxydihydrobenzofurans [58]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. The catalytic cycle of 5-LO. Activation of 5-LO requires oxidation of Fe2+ 
to Fe3+ mediated by lipid hydroperoxides (LOOHs), but LOOHs also terminate the 
catalytic cycle of the 5-LO reaction.  
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2.3.1.2. 5-LO gene and expression 
The human 5-LO gene (ALOX5, 71.9 kbp) consists of 14 exons and is located on chromosome 
10 [59]. Eight GC-boxes can be found in the promoter region (five of them are arranged in 
tandem), but no TATA and CAT boxes have been detected (Fig. 5). Although this pattern 
resembles typical housekeeping genes, 5-LO is expressed mainly in leukocytes, and suppression 
of its expression in other cell types is mediated by DNA methylation [60]. It has been discussed if 
variant DNA methylation may lead to an upregulation of 5-LO in epithelial tumor cells since the 
protein has been found there as well [61]. The transcription factors Sp1 and Egr-1 bind to the five 
tandem GC-boxes mentioned above, and for Sp1, a novel binding site upstream of the major 
transcription initiation site of the 5-LO gene was described in 2005 [62]. Mutations in the Sp1-
binding sites provoke alterations in 5-LO expression, associated to physiological changes. Thus, 
carriers of ALOX5 variants are more susceptible to tuberculosis [63], and variations in the GC-
boxes are related to atherosclerosis because of an increased intima-media thickness and an 
elevated plasma level of C-reactive protein [64].  
 
 
 
 
 
 
 
 
 
 
Fig. 5. The human 5-LO gene. The human 5-LO gene is located on chromosome 10, consists 
of 14 exons, and possesses several transcription initiation sites with the principal one (position 
0) located 65 bp upstream of ATG. The regulatory sites of the gene are indicated in the figure. 
Abbreviations: TGFRE, TGF-β-response element. (from Radmark, O. et al. Trends Biochem 
Sci 32, 332-41, 2007) 
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5-LO expression occurs in granulocytes, monocytes/macrophages, mast cells, dentritic cells, 
mantle zone B lymphocytes (but hardly in germinal B cells and plasma cells) [65] and 
Langerhans cells as well as in fibroblasts in the skin, whereas the enzyme has not been found in 
platelets, endothelial cells and erythrocytes [66], [67]. In contrast, it has not been finally clarified 
yet if T lymphocytes express 5-LO. Moreover, 5-LO was detected in rat hippocampus and 
hippocampus of patients with Alzheimer’s disease [68], [69]. Interestingly, differentiated myeloid 
cells and cell lines express significantly higher amounts of 5-LO as undifferentiated cells. This 
upregulation during leukocyte differentiation has been  associated with certain inducers such as 
dimethyl sulfoxide (DMSO), retinoic acid, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] and 
transforming growth factor β (TGFβ) [70]. In addition, a stimulatory effect of 
granulocyte/macrophage colony-stimulating factor (GM-CSF) on 5-LO expression was observed 
in mature blood leukocytes. Interestingly, tissue macrophages produce higher amounts of 5-LO 
than monocytes in the blood [71], whereas if kept in culture, human monocytes lose 5-LO as well 
as FLAP over time [72], and additional growth factors are needed to maintain the expression. 
2.3.1.3. 5-LO structure 
Mammalian 5-LOs are monomeric, soluble proteins composed of 672 or 673 amino acids (for 
review, see [73]) resulting in a molecular mass of 72 to 80 kDa [74]. The amino acid sequence of 
human 5-LO was described already in 1988 [75] but the intrinsic instability of the enzyme 
hampered clarification of its three-dimensional structure for a long time, and 5-LO was only 
modeled based on the crystal structure of rabbit reticulocyte 15-LO (a 12/15-LO that shares 40 % 
sequence homology with 5-LO) [76], [77]. In 2011 Gilbert et. al. identified a 5-LO specific 
destabilizing sequence near the C terminus. By replacement of K653KK655 with ENL (the 
corresponding sequence from 8R-LO from Plexaura homomalla) together with exchange of 
several amino acids thought to be responsible for membrane-insertion as well as mutation of 
Cys240 and C561, stability of 5-LO could be strongly increased so that crystallization of the 
enzyme was possible [78]. 5-LO consists of two domains: an N-terminal C2-like ß-sandwich and 
an iron-containing catalytic domain at the C-terminus (residues 121-673) which is mainly helical 
in structure (Fig. 6). The non-heme catalytic iron is anchored by three histidine residues (His372, 
His367 and His550) and by the C-terminal Ile673. The active site is flanked by an arched helix as 
well as by helix α2 providing distinct residues which help to form an elongated cavity and 
prevent access to the catalytic iron. Besides several invariant residues which have also been 
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found in the active sites of other LOs [79], a number amino acids are specific for 5-LO, and some 
of them contribute to the formation of a “cork” which closes the catalytic cavity so that a 
conformational change is needed to allow access of the substrate [78].  
5-LO activity can be influenced by phosphorylation on three serine residues in the catalytic 
domain: on Ser271 by mitogen-activated protein kinase (MAPK)-activated protein kinase (MK)-
2/3 [80], on Ser663 by extracellular signal-regulated kinase (ERK)-2 [81] and on Ser523 by 
protein kinase (PK) A [82]. The β-sandwich of the smaller N-terminal domain (residues 1-114) 
possesses several ligand-binding loops [83]. Ca2+ has been shown to bind to Asn43, Asp44 and 
Glu46 within the C2-like domain, whereas other stimulatory factors of 5-LO, namely 
phosphatidylcholine (PC), glycerides (e.g. 1-oleoyl-2-acetyl-snglycerol, OAG) and coactosin-like 
protein (CLP) rely on three tryptophane residues (Trp13, 75 and 102).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Structure of human 5-LO. 
Structure of stable 5-LO as 
crystallized by Gilbert, N.C. et al.. 
The enzyme is composed of a C-
terminal catalytic domain (residues 
121-673; light gray) that is mainly 
helical, and an N-terminal C2-like β 
sandwich (dark gray). The putative 
membrane insertion residues 
mutated in stable 5-LO are shown in 
green. The active site is flanked by 
an arched helix (colored in blue) 
and by helix α2 (shown in red). The 
active site cavity is coloured in pink 
and the catalytic iron is presented as 
an orange sphere. The KKKENL 
substitution is indicated in mesh 
blue and the mutated proximal 
cysteines are colored in yellow 
(from Gilbert, N.C. et al. Science 
331(6014), 217-9, 2011). 
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2.3.1.4. Regulation of 5-LO 
5-LO catalysis is controlled in a complex manner and involves a variety of factors that influence 
the enzyme activity. Studies in cell free systems (isolated 5-LO, whole cell homogenates, 
subcellular fractions) have been useful to get an idea about the regulation of 5-LO activity. 
However, in intact cells 5-LO product formation is even more complicated than in cell-free 
systems. Thus, factors like subcellular localization of 5-LO, phosphorylation events and 
interaction with cellular proteins play an important role for the enzyme activity and have been 
subjected to multiple studies in the last decades (for review, see [66], [84]). 
2.3.1.5. Factors determining 5-LO activity in vitro 
Factors that stimulate 5-LO activity seem to facilitate binding of AA to the enzyme and to 
maintain the catalytic redox cycle. Most of these factors act at the N-terminal β sandwich (Ca2+, 
PC, glycerides and CLP), whereas the binding site for adenosine triphosphate (ATP) has not been 
demonstrated yet (Fig. 7). 
Calcium 
Early studies on 5-LO purified from human leukocytes demonstrated that Ca2+ is able to induce 
the enzyme activity [85]. Full activation is reached at 4-10 µM Ca2+, and the EC50 was 
determined between 1 and 2 µM. 5-LO binds Ca2+ (about two ions per 5-LO) in a reversible 
manner with a Kd of approximately 6 µM (for the native enzyme) [86], [87], and a similar 
dissociation constant (7-9 µM) was found for the His-tagged C2-like domain [88]. Notably, also 
Mg2+ (at millimolar concentrations present in cells) was shown to stimulate 5-LO activity in vitro 
[89]. However, neither Ca2+ nor Mg2+ is part of the catalytic mechanism, and 5-LO possesses 
basal activity also in absence of these cations. It was shown in mutagenesis studies that Asn43, 
Asp44 and Glu46 in the ligand binding loop 2 of the β sandwich are essential for activation of 5-
LO by Ca2+ [83].  
Stimulation of 5-LO by Ca2+ occurs only in presence of PC or CLP, and Ca2+ might be necessary 
for a ‘productive’ binding of these factors to the enzyme. Moreover, Ca2+ is needed for the 
interaction of 5-LO with membranes and stimulates its translocation to the nuclear envelope 
which is rich in PC [88]. It was found in a phase partition assay that Ca2+ increases the 
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hydrophobicity of 5-LO. Ca2+ binding also causes a higher affinity of 5-LO towards AA and thus 
provokes a change in the reaction kinetics resulting in substrate inhibition. 
Finally, a low level of LOOHs is sufficient for 5-LO activation if Ca2+ is present, since inhibition 
of 5-LO by GPx is attenuated in this case [90]. In affinity labeling studies of rabbit 12/15-LO, an 
AA analog bound not only within the catalytic domain, but also to the N-terminal β sandwich 
[91]. This suggests that LOs might possess a second, regulatory fatty acid binding site, where 
also LOOHs could bind, possibly in a Ca2+ dependent manner. 
Phosphatidylcholine 
A common feature for C2 domains is their Ca2+-induced association to membranes [92]. 5-LO 
activity is stimulated by microsomal membranes as well as by synthetic lipid vesicles that contain 
PC [85], [93]. Importantly, PC could not be replaced by phosphatidylserine (PS), phosphatidyl-
ethanolamine (PE) or phosphatidylinositol (PI). Three Trp residues in the ligand binding loops of 
the β sandwich (Trp13, 75 and 102) are important for PC binding, and selectivity for this 
phospholipid is assumed to account for 5-LO translocation to the nucleus [88]. Pande et. al. 
demonstrated that also a cationic diacylglycerophospholipid is able to increase the membrane 
affinity of 5-LO, but it hardly stimulates the enzyme activity, possibly due to a ‘non-productive’ 
binding to the membrane [94]. This suggests that the proper orientation of 5-LO at the membrane 
might be extremely important for its catalytic activity. Moreover, it was shown by attenuated 
total reflection Fourier transform infrared (ATR-FTIR) spectroscopy that membrane binding of 5-
LO leads to a dehydration of the membrane surface, and both the enzyme and lipids within the 
membrane gain stability upon their interaction. In subsequent studies, increases in the membrane 
fluidity were shown to facilitate 5-LO association, and it was proposed that this is the reason for a 
selective direction of 5-LO to the AA enriched nuclear envelope [95]. Notably, if a membrane 
preparation was supplemented with cholesterol, a decrease in 5-LO product formation was 
observed in cell free assays [95], and the same effect was shown in intact cells after treatment 
with cholesterol sulfate [96]. 
Glycerides 
5-LO product formation in isolated human PMNL (supplemented with exogenous AA) can be 
stimulated upon addition of the cell-permeable OAG [97]. The intracellular Ca2+ level is not 
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increased under these conditions, and neither activation of MAPK nor translocation to the nuclear 
membrane is affected by OAG. Several glycerides were shown to activate 5-LO in a direct 
manner with OAG as the most effective compound [98]. Addition of Ca2+, phospholipids or 
cellular membranes turned out to prevent the stimulatory effect of OAG. It was demonstrated that 
binding of glycerides is mediated by the same three Trp residues that are involved in PC 
association to 5-LO. Hence, a W13A/W75A/W102A triple mutant of 5-LO is not affected by 
OAG. In contrast to Ca2+-induced PC binding, association of the uncharged glycerides to the C2-
like domain of 5-LO may occur in absence of charge neutralization or changes in side chain 
orientations [88]. As observed for Ca2+, OAG is able to protect 5-LO from inhibition by GPx 
[98]. 
Treatment of PMNL with 5-LO product synthesis-inducing stimuli such as Ca2+-ionophore 
A23187, thapsigargin (TG) or chemokines leads to a formation of diacylglycerides (DAGs) [99], 
[100], [101], [102], [103], [104]. Pharmacological intervention with DAG generation via 
phospholipase D (PLD) and phosphatidic acid phosphatase (PA-P) in ionophore- or TG-activated 
PMNL causes a significant decrease of 5-LO translocation and product formation. The inhibitory 
effect can be reversed by addition of exogenous OAG. Therefore, it has been suggested that the 
formation of DAGs via the PLD/PA-P pathway after appropriate stimulation is one possible 
mechanism to activate cellular 5-LO.  
Coactosin-like protein 
In the course of a yeast two-hybrid assay, CLP was identified as a 5-LO binding protein [105]. 
Human CLP consists of 142 amino acids and shows similarity with the actin-binding coactosin of 
the slime mold Dictyostelium discoideum. An in vitro stoichiometry of 1:1 was determined for 
CLP binding to 5-LO, and interaction between the two proteins in intact cells was confirmed by 
co-immunoprecipitation experiments [106]. 
CLP can also bind F-actin (with a 1:2 stoichiometry), and it was found that two lysine residues 
(Lys75 and 131) close-by in the CLP sequence are necessary for binding to F-actin and to 5-LO, 
respectively [107]. Consequently, the binding sites overlap, and F-actin competes with 5-LO for 
association to CLP. 
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Ca2+-induced 5-LO product formation is stimulated by CLP in the absence of PC, but this effect 
is increased upon simultaneous application with the phospholipid [108]. Similarly as membranes, 
CLP might act as a scaffold for 5-LO and increases its activity. Recently, the importance of 5-
LO-Trp102 for binding to CLP was demonstrated by mutagenesis experiments [109]. Although 
CLP is not needed for Ca2+ to bind to 5-LO, activation of the enzyme only occurs in presence of 
Ca2+ [106], and the mode of binding is believed to be similar to the ’productive’ or ‘non-
productive’ type for membranes that was mentioned above. 
It has been assumed that in intact cells, CLP is always bound to 5-LO, since both proteins are 
located in the cytosol in resting cells and translocate to the nuclear envelope upon activation by 
Ca2+ [108], [109]. Finally, it was suggested that simultaneous binding of 5-LO to CLP and the 
nuclear membrane may promote catalysis of the second step of LTA4 synthesis: the abstraction of 
hydrogen at C-10 of 5-HpETE. 
Adenosine triphosphate 
5-LO catalysis is stimulated by several nucleotides with ATP as the most prominent 
representative [110], [111], [112], whereas other LOs do not bind nucleotides. It was shown that 
addition of 0.1-2 mM ATP causes a 2- to 6-fold increase in 5-LO activity, and Kα values of 30-
100 µM were determined for ATP binding [113], [114]. Stimulation of 5-LO by ATP does not 
necessarily depend on divalent cations, but Ca2+ as well as Mg2+ clearly increase the enzyme 
activity [115], [116]. Since most of the intracellular ATP is bound to Mg2+, it is most likely that a 
MgATP2- complex instead of free ATP is responsible for 5-LO activation [89]. 
ATP binding to 5-LO can be utilized for affinity purification of the protein from different sources 
[117], [118]. Although an ATP binding site within the 5-LO amino acid sequence has not been 
determined yet, two tryptophan residues (Trp75 and 201) might be involved in ATP association. 
Thus, analogs of ATP bind specifically to these moieties, and simultaneous application together 
with ATP prevents 5-LO stimulation by the latter [119]. However, Trp75 could be mutated 
without a significant alteration in ATP-affinity. A Trp201Arg mutant, in contrast, was hardly 
expressed, and a clearly attenuated ATP-column yield as well as a dramatically reduced 5-LO 
activity was received upon replacement of Trp201 by Ala or Ser. The reason of this phenomenon 
might be a deranged 5-LO structure. 
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Notably, ATP does not have to be hydrolyzed to exert its stimulatory action on 5-LO, and energy 
consumption or (auto-)phosphorylation do not occur [112]. Eventually, ATP seems to act on 5-
LO by stabilizing its protein structure.  
Lipid hydroperoxides 
Oxidation of the ferrous iron by LOOHs is essential for 5-LO activation. 5-HpETE, 12-HpETE 
and 13-HpODE are able to stimulate crude 5-LO in homogenates from PMNL, whereas certain 
hydroperoxides such as tert-butyl hydroperoxide or cumene hydroperoxide show no efficacy 
[53], [120]. In addition, 5-LO activity is increased under conditions that elevate lipid 
peroxidation, and the lag phase of 5-LO that is observed in cell-free assays after addition of AA 
is shortened upon addition of LOOHs [121]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Factors that influence 5-LO activity in cell-free systems and in intact cells. 
Abbreviations: ATP, adenosine triphosphate; CLP, coactosin-like protein; cPLA2, cytosolic 
phospholipase A2; FLAP, 5-LO activating protein. (from Werz, O. et al. Expert Opin Ther 
Patents 15, 2005)  
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2.3.1.6. Regulation of 5-LO activity in the cell 
5-LO activity in the cell is subject to a variety of control mechanisms, and the amount of free AA 
[122] as well as its accessibility to 5-LO [123] influence the extent of product formation (Fig. 7). 
Hence, cellular 5-LO catalysis depends on the release of AA by cPLA2, localization of 5-LO 
inside the cell, phosphorylation events, interaction with FLAP and/or other cellular proteins and 
on the redox tone within the cell. It was shown that most of the stimuli that activate 5-LO (e.g. N-
formyl-methionyl-leucyl-phenylalanine (fMLP), platelet activating factor (PAF), opsonized 
zymosan, LTB4, C5a, IL-8 and ionophores) also possess a stimulatory potential on cPLA2 [124]. 
Actually, similarities in the structure (C2 domain) and also the regulation of both enzymes 
(activation by Ca2+ and by phosphorylation) have been demonstrated [125], [28], [55], and both 
5-LO and cPLA2 bind to the nuclear membrane after activation of leukocytes. 
Subcellular localization and mobility of 5-LO 
A variety of studies described 5-LO as a soluble enzyme in resting cells. In particular, the protein 
was found to be cytosolic in neutrophils, eosinophils and peritoneal macrophages, whereas it was 
located in the nucleosol associated with chromatin in alveolar macrophages, Langerhans cells or 
rat basophilic leukaemia cells [124]. Activation of the cell by an appropriate stimulus leads to a 
translocation of 5-LO (and cPLA2) to the nuclear membrane, a process that is mediated by 
several factors like Ca2+, phosphorylations and interaction with CLP (Fig. 8). Subsequently, 
transfer of AA liberated from membrane phospholipids by cPLA2 is facilitated by FLAP, and LT 
formation is initiated. In contrast, addition of exogenous AA does not require 5-LO translocation 
but occurs in the cytosol. Moreover, transcellular mechanisms allow a supply with AA from 
neighboring cells [126].  
The position of 5-LO in unstimulated cells might be important for redistribution after stimulation. 
Thus, cytosolic 5-LO seems to translocate to the outer nuclear membrane, whereas association 
with the inner membrane of the nuclear envelope occurs in cells where 5-LO is inside the nucleus 
prior to application of a stimulus [123]. In general, cell-types where 5-LO is located in the 
nuclear matrix (except eosinophils) show a higher tendency to produce LTs than cells with 
cytosolic 5-LO. Nuclear import of 5-LO is mediated by three nuclear localization sequences 
(NLS) present in the N-terminal domain and close to the C-terminus [127], [128], [129], [130], 
[131], [132], [133]. 5-LO was found in the nucleus after treatment of resting cells with glycogen 
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or cytokines [134], [135] as well as after adherence to surfaces [136], [137]. In addition, 
recruitment of leukocytes to inflammatory sites seems to be attended by a shift of 5-LO into the 
nucleus [136], [138]. The regulation of nuclear export is not fully elucidated yet, but it is thought 
to be mediated by an exportin-l-like mechanism that binds a nuclear export sequence (NES) 
within 5-LO [139]. It has been proposed already in earlier studies that phosphorylation events are 
involved in the regulation of nuclear import/export of 5-LO [140], [141], and recently, Flamand 
et. al. showed that phosphorylation of Ser271 by MK-2/3 retains 5-LO inside the nucleus thus 
facilitating LT biosynthesis upon 5-LO activation [142]. In contrast, phosphorylation on Ser523 
by PKA prevents nuclear import resulting in a suppression of 5-LO catalysis [82], [143]. 
Regarding 5-LO translocation from a cytosolic location to the nuclear membrane, a gender 
difference in 5-LO localization and LT biosynthesis was revealed recently. In accordance with 
previous observations, 5-LO in resting human PMNL from females was found in the cytosol, 
whereas in male cells, a considerable amount of the enzyme was already present at the 
perinuclear region prior to activation [144]. It has been suggested in previous findings that 5-LO 
may be hard to activate if it has already bound to the nuclear membrane [145], [146]. 
Consequently, LT formation was clearly reduced by androgens in an ERK-dependent manner 
after stimulation of whole blood or PMNL with fMLP. This effect might explain gender 
differences in the occurrence of inflammatory diseases involving LTs. Thus, it is well known that 
asthma or allergic rhinitis are dominant in females [147], [148]. Notably, a gender-specific 
reduction of atheroma formation in female dual 5-LO and 12/15-LO deficient mice was 
demonstrated in an animal model of atherosclerosis [149]. 
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Phosphorylation of 5-LO 
LT formation is not only increased upon elevation of intracellular Ca2+, but also after cell stress-
or phorbol ester-induced 5-LO phosphorylation by p38 MAPK regulated MK-2/3 (at Ser271) or 
ERK (at Ser663), respectively [66]. Respective kinase inhibitors abrogated this stimulatory effect 
on 5-LO product formation [28]. Also, mutation of Ser271 and/or Ser663 to Ala reduced LT 
synthesis in transfected cells stimulated with AA (that activates MAPK). However, 
phosphorylation of 5-LO by MK-2/3 or ERK does not increase the product formation in cell-free 
Fig. 8. 5-LO activation in the cell. Unstimulated 5-LO is found either in the cytosol or in a 
soluble compartment inside the nucleus. Upon activation, 5-LO translocates to the nuclear 
envelope where cPLA2 and FLAP are involved in 5-LO product formation. AA from 
phospholipids is liberated by cPLA2, and membrane-bound FLAP is thought to facilitate the 
transfer of AA to 5-LO. CLP can translocate together with 5-LO. Nuclear import sequences 
(NIS) in the 5-LO sequence mediate import into the nucleus. Addition of an appropriate 
stimulus leads to an increase in Ca2+ and/or activation of MAPK. LOOHs oxidize the iron to 
the ferric form (Fe3+). In 5-LO, Ser271 is phosphorylated by MK-2/3 downstream of p38 
MAPK. ERK phosphorylates 5-LO on Ser663. PKA is activated by an increase in cAMP 
levels and exerts an inhibitory function on 5-LO. (from Radmark, O. et al. Trends Biochem 
Sci 32, 332-41, 2007) 
 
  
2 Introduction  25 
 
 
assays [80], [81]. Interestingly, it was found that in Chinese hamster ovary (CHO-K1) cells and 
human embryonic kidney 293 (HEK293) cells, 5-LO is exported from the nucleus after cell 
stress-induced phosphorylation of Ser271 [150], whereas it was recently demonstrated that in 
NIH 3T3 cells, phosphorylation at this position results in an inhibition of nuclear export of 5-LO 
[142]. Thus, instead of directly affecting 5-LO, phosphorylation events at Ser271 or Ser663 
rather modulate the interaction of 5-LO with other cellular components. 
Increased cyclic adenosine monophosphate (cAMP) levels in response to agents such as 
adenosine, PGE2 or β-adrenergic agonists lead to an activation of PKA that phosphorylates 5-LO 
at Ser523. This implicates an attenuated LT formation in cell free systems as well as in intact 
cells [82], [151]. It was shown that nuclear import is prevented upon phosphorylation at this site, 
and the direct inhibitory effect was suggested to be ascribed to allosteric changes close to the 
active site [143]. Interestingly, exogenous AA is able to prevent the inhibitory effect of cAMP-
mediated 5-LO phosphorylation [152]. Also, moderate stimulation of ERK by androgens was 
shown to attenuate LT formation in PMNL due to an induction of 5-LO translocation to the 
perinuclear region (as described above) [144]. 
Influence of the cellular redox tone 
The redox tone within cells is a critical parameter for LT synthesis since the active site iron has to 
be oxidated to induce 5-LO activity (see above). 5-LO product formation is increased under 
conditions that promote lipid peroxidation (e.g. elevation of ROS by phorbol 12-myristate 13-
acetate (PMA), addition of peroxides, inhibition of GPx, or reduced glutathione levels). In 
contrast, GPx-1 and -4 reduce 5-LO activity by diminishing LOOH levels [124]. Moreover, 
oxidative stress leads to a phosphorylation of 5-LO mediated by p38 MAPK. Interestingly, the 
efficacy of certain nonredox-type 5-LO inhibitors (see below) is reduced under these conditions, 
and it was demonstrated that for potent 5-LO inhibition, these compounds require the presence of 
GPx activity leading to lowered hydroperoxide levels [153], [154]. It was described that in 
presence of Ca2+ or OAG, LT synthesis occurs also at a low redox tone. Thus, both agents might 
reduce the amount of LOOHs needed for 5-LO activation, probably because of an increased 
affinity of the enzyme towards LOOHs [90], [98]. 
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Interaction with 5-LO activating protein and other cellular proteins 
In 1990, Miller et al. discovered the membrane bound FLAP as target of a new class of indoles 
that inhibit cellular LT formation but do not affect the activity of soluble 5-LO [155]. The 18 kDa 
FLAP belongs to the membrane-associated proteins in eicosanoid and glutathione metabolism 
(MAPEG) family, and its crystal structure has been determined in 2007 [156]. The protein 
crystallizes as a homotrimer that consists of four transmembrane helices linked by two elongated 
cytosolic loops and one short luminal loop. A direct binding of FLAP and 5-LO has not been 
shown yet, whereas an in vitro association between FLAP and LTC4S (as well as between 5-LO 
and LTC4S) was demonstrated recently [157]. 5-LO and FLAP are often expressed 
simultaneously [158], [159]. However, upregulation of FLAP but not 5-LO was observed as well 
[160], [134], and there are some 5-LO negative cells that do express FLAP [161], [162]. 
Nevertheless, in transfection experiments with a human osteosarcoma cell line, 5-LO alone was 
not sufficient for LT production although the enzyme was active in homogenates of these cells 
[163]. Only after cotransfection with FLAP cells were able to synthesize LTs. These findings are 
supported by the fact that FLAP deficient macrophages from knock-out mice do not produce LTs 
[164]. Hence, coexistence of FLAP and 5-LO at the nuclear membrane seems to be essential for 
cellular LT synthesis from membrane phospholipids [50], and it was shown that the efficacy of 
the FLAP inhibitors MK-886 and licofelone in human PMNL is reduced upon addition of 
exogenous AA [165]. Taken together, FLAP seems to facilitate the transfer of AA to 5-LO and is 
therefore required for efficient cellular LT formation. 
5-LO contains a Src homology 3 (SH3)-binding motif that mediates association with the SH3-
domain of growth factor receptor-bound protein 2 (Grb2), an adaptor protein that is involved in 
cell signaling by tyrosine kinases [166]. A contribution of the SH3 binding motif in nuclear 
translocation of 5-LO has been discussed, since a peptide corresponding to this sequence was 
able to abrogate redistribution of the enzyme to the nuclear envelope after stimulation of PMNL. 
In addition, apart from being a key enzyme in lipid mediator formation, 5-LO might play a role in 
tyrosine kinase signaling. 
Co-immunoprecipitation experiments in HL-60 cell lysates revealed an interaction of 5-LO with 
NF-κB [130], preferentially in ionophore stimulated cells. Therefore, it was assumed that 5-LO 
might be of importance in cellular NF-κB responsiveness. 
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In a yeast two hybrid screening of a human lung cDNA library with 5-LO as a bait, three proteins 
that interact with 5-LO were found: i) CLP (as mentioned above); ii) TGFβ receptor-I-associated 
protein I (TRAP-1); and iii) the ribonuclease Dicer [105], [167]. TGFβ increases 5-LO 
expression and activity in maturing myeloid cells, and TRAP-1 might functionally interfere with 
5-LO. Dicer is involved in the biogenesis of microRNAs (miRNA), and its C-terminus was 
shown to interact with Trp13, 75 and 102 in the C2-like domain of 5-LO, leading to an enhanced 
LT synthesis [168]. Besides, 5-LO was able to modify the miRNA precursor processing activity 
of Dicer so that there might be a relation between miRNA caused regulation of gene expression 
and chronic inflammation. 
2.3.1.7. Receptors and pathophysiological roles of 5-LO products 
LTs exert their biological functions via specific GPCRs of the rhodopsin class. These 
heptahelical receptors can be found on the outer plasma membrane of structural and 
inflammatory cells. LTB4 activates BLT1 and BLT2 receptors, whereas cys-LTs act on CysLT1 
and CysLT2 receptors [169]. Recently, a third cys-LT receptor that binds preferentially LTE4 has 
been discovered in animal studies [170]. Finally, 5-Oxo-ETE acts via a highly selective Gi 
protein-coupled OXE receptor that is expressed in eosinophils, neutrophils and monocytes [171]. 
5-Oxo-ETE induces chemotaxis, actin polymerization, Ca2+ mobilization, integrin expression, 
and degranulation [172], [45], and although the pathophysiological role of this metabolite of 5-
HpETE is not completely clarified, it seems to be involved in asthma, allergic diseases, cancer 
and cardiovascular diseases [173]. 
LTB4 induces migration of granulocytes and T cells to inflammatory sites and causes activation 
of these cells. Consequently, granulocytes attach to vessel walls, degranulate and release 
superoxides as well as the cathelicidin LL-37 [174], [175]. Moreover, LTB4 increases 
phagocytosis of neutrophils and macrophages [176] and the secretion of immunoglobulins by 
lymphocytes [177]. The chemotactic effect of LTB4 is mediated by the BLT1 receptor, and it is 
assumed that atherogenesis, asthma, glomerulonephritis, arthritis and chronic inflammatory 
bowel diseases require signal transduction via this receptor subtype [178]. The effect of BLT2 
activation, in contrast, is not completely understood, but it might be a kind of substitute receptor 
for BLT1 at high LTB4 levels if the other receptor is desensitized. However, LTB4 also possesses 
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anti-inflammatory effects that are exerted through activation of peroxisome proliferator-activated 
receptor (PPAR)α [179], [180]. 
Formation of Cys-LTs implicates smooth muscle contraction, plasma extravasation, mucus 
secretion, vasoconstriction, recruitment of eosinophils and fibrocyte proliferation [174], [181], 
[182]. It is still unclear if the Gq-protein coupled Cys-LT receptors form homo- and/or hetero-
dimers, and how this fact influences their functions [183]. CysLT1 can be found in peripheral 
blood leukocytes, spleen, lung tissue, smooth muscle cells and macrophages [184], and mediates 
bronchoconstriction, mucus secretion, and airway edema. The more ubiquitously expressed 
CysLT2 (present in eosinophils, peripheral blood monocytes, lung macrophages, endothelial cells, 
etc.) rather contributes to inflammation, tissue fibrosis and endothelial cell activation [51], [185], 
[186]. 
Because of their multiple actions, LTs are suggested to be involved in the regulation of the 
immune response and in the pathogenesis of a variety of inflammatory diseases. The most 
validated role of these lipid mediators can be found in asthma [187], [188] and allergic rhinitis, 
but numerous studies in animals and/or humans also indicate a relation between the 5-LO 
pathway and rheumatoid arthritis, inflammatory bowel disease, psoriasis, shock [189], 
osteoporosis [190] and certain types of cancer (in particular colon, prostate and pancreatic cancer 
[191]) (for review, see [28]). Furthermore, LTs seem to essentially contribute to the development 
of cardiovascular diseases such as atherosclerosis, stroke and myocardial infection (for review, 
see [192]), and interference with the LT pathway therefore is a promising strategy in the 
treatment of these widespread diseases [193]. Anti-LT therapy can be pursued either by a 
suppression of LT synthesis or by the use of LT receptor antagonists. CysLTs antagonists such as 
montelukast or zafirlukast are successfully used in the treatment of asthma since the late 1990s. 
However, many LT related diseases may require the concerted suppression of all LTs instead of 
exclusive interaction with one receptor subtype, and since 5-LO is the key enzyme in LT 
biosynthesis, intervention with 5-LO product formation proposes a great therapeutic benefit in a 
variety of inflammatory diseases. 
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2.3.1.8. Inhibitors of 5-LO product formation 
5-LO product formation can be reduced by inhibition of cPLA2, FLAP or 5-LO itself. Blockade 
of cPLA2 (e.g., by glucocorticoids) leads to a decrease in the availability of AA and thus 
suppresses the formation of all eicosanoids [7]. Notably, it was shown that neither 
glucocorticoids nor selective cPLA2 inhibitors exert their anti-inflammatory actions via an 
inhibition of LT formation [174], [194], [195], [196]. FLAP inhibitors prevent substrate transfer 
to 5-LO at the nuclear membrane and therefore potently suppress LT formation in intact cells. 
Notably, most of the compounds developed so far seem to strongly bind to plasma proteins 
and/or compete with AA and other cis-unsaturated fatty acids. However, a very promising 
candidate is AM103 (Fig. 9) that selectively inhibited FLAP in animal models of acute and 
chronic inflammation [197] and dose dependently reduced blood LTB4 production in phase II 
studies [198]. Licofelone (Fig. 9), a compound that was originally developed as dual 5-LO and 
COX inhibitor, has been shown to target FLAP, COX-1 and mPGES-1 but not 5-LO or COX-2 
[165], [199] and is currently undergoing phase III of clinical trials for osteoarthritis.  
Four different types of direct 5-LO inhibitors can be categorized: redox-active compounds that 
reduce the active site iron of the enzyme, iron ligand inhibitiors, nonredox-type inhibitors that 
compete with AA or LOOHs for binding to 5-LO and a novel class of compounds that act in 
different ways [200].   
 
 
 
 
 
 
 
 
N OH
O
Cl
Licofelone
Fig. 9. Chemical structures of the FLAP inhibitors licofelone and AM103 
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Redox-active 5-LO inhibitors 
Many lipophilic plant-derived substances including flavonoids, coumarins, caffeic acid, 
nordihydroguaretic acid and several polyphenols possess reducing properties and are therefore 
able to keep the active site iron of 5-LO in the ferrous state [201]. Besides, several synthetic 
compounds such as AA-861 (Fig. 10) act by uncoupling the catalytic cycle of the enzyme. A 
major disadvantage of both natural and rationally developed redox-active inhibitors is their poor 
selectivity for 5-LO. In addition, most of the compounds are ineffective in vivo due to oxidation 
during absorption or a rapid metabolism, and interference with other biological redox systems as 
well as the production of reactive radical species may cause severe side effects such as the 
formation of methemoglobin [200]. 
 
 
 
 
 
 
Iron-ligand 5-LO inhibitors 
Several hydroxamic acids or hydroxyurea derivatives are able to chelate the active site iron of 5-
LO. Among those compounds (and in fact among all LT synthesis inhibitors), zileuton (Fig. 11) 
is the only representative that is available on the (US-) market for the treatment of asthma. The 
drug inhibits 5-LO in stimulated leukocytes with an IC50 of 0.5-1 µM and clearly improves 
airway functions, but nevertheless, no significant benefit was found in allergic rhinitis, 
rheumatoid arthritis and inflammatory bowel disease [124]. Zileuton was structurally optimized, 
and its fivefold more potent successor ABT-761 (VIA-2291) (Fig. 11) is currently investigated in 
clinical trials for atherosclerosis and cardiovascular diseases [202]. 
Fig. 10. Chemical structure of the redox-active 5-LO inhibitor AA-861 
O
O
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The hydroxamic acid BWA4C (Fig. 11) selectively inhibits 5-LO (IC50 = 40 nM, in intact 
granulocytes) [203], but is rapidly inactivated in vivo and forms toxic nitric oxide radicals. 
However, the compound is widely used as a research tool for in vitro experiments. 
 
 
 
 
 
 
 
 
Nonredox-type 5-LO inhibitors 
A class of structurally diverse molecules that do not possess any redox or iron chelating 
properties has been designated nonredox-type 5-LO inhibitors. These compounds compete with 
AA or LOOHs for binding to 5-LO, possibly in an allosteric manner [200]. Of interest, the 
efficacy of some nonredox-type inhibitors (e.g. ZM 230487, Fig. 12) is impaired at elevated 
peroxide levels and/or if 5-LO is activated by phosphorylation [153], [154], both conditions that 
occur during inflammatory reactions. 
However, not all of the nonredox-type 5-LO inhibitors depend on reducing conditions and need 
5-LO activation by Ca2+. For example, the more recently developed RBx 7796 [204], [205] and 
CJ-13,610 [206], [207], [208] (Fig. 12) potently suppress 5-LO product formation regardless of 
the assay conditions, and both of them show in vivo effectiveness. Several other nonredox-type 
inhibitors have been patented during the last years, but none of them has been approved by public 
authorities so far [200]. 
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Fig. 11. Chemical structures of the 
iron ligand 5-LO inhibitors 
zileuton, ABT-761, and BWA4C 
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Diverse 5-LO inhibitors and dual inhibitors of LT and PG formation 
A naturally occurring 5-LO inhibitor is the polyprenylated acylphloroglucinol hyperforin, a 
lipophilic ingredient of Hypericum perforatum (St John’s wort, Fig. 13.). Hyperforin was shown 
to inhibit 5-LO (and also COX-1 [209]) in the low micromolar range, and in vivo effectiveness 
was demonstrated in a carrageenan-induced pleurisy model in rats [210]. The compound does not 
possess any redox or iron-chelating properties, and its characteristics are different from those of 
nonredox-type 5-LO inhibitors. It was recently shown that the potency of hyperforin is 
significantly decreased in presence of PC and also when W13, W75 and W102 are mutated to 
alanine [210]. In addition, the interaction between 5-LO and CLP was diminished, and 
translocation of the enzyme to the nuclear membrane was inhibited suggesting an interference of 
hyperforin with the C2-like domain of 5-LO.  
 
 
 
Fig. 12. Chemical structures of the 
nonredox-type 5-LO inhibitors ZM 230487, 
CJ-13,610 and RBx 7796 
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Blockade of both LT and PG synthesis is thought to be more effective in the treatment of 
inflammatory diseases than inhibition of only one eicosanoid pathway [211], [212]. In addition, 
dual COX/5-LO inhibitors have been associated with a lower incidence of unwanted side effects 
on the gastrointestinal tract than classical NSAIDs. This might be ascribed to the concurrent 
suppression of LTs that were shown to contribute to gastric epithelial injury [51]. 
It has been demonstrated that the selective COX-2 inhibitor celecoxib as well as the unspecific 
COX inhibitor sulindac (Fig. 14) also influence 5-LO [213], [214], [215], and a variety of 
compounds that affect both enzymes (some of them show structural similarities with coxibs) have 
been synthesized during the last years (for review, see [200]). However, COX-2 inhibition may 
be accompanied by severe cardiovascular side effects [216], and therefore, exclusive suppression 
of PGE2 formation in combination with 5-LO inhibition is considered a beneficial alternative to 
dual COX/5-LO inhibition [18], [217]. Certain lipophilic natural compounds with phenolic 
structures (e.g. curcumin [218], myrtucommulone from Myrtus communis [219] and 
epigallocatechin-3-gallate from green tea (Camellia sinensis) [220] (Fig. 14)) have been 
identified as potent dual inhibitors of 5-LO and mPGES-1 without significant effects on COX 
enzymes, and anti-inflammatory activities of these compounds have been demonstrated in 
preclinical or clinical studies. 
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Fig. 13. Chemical structure of 
the 5-LO inhibitor hyperforin 
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2.4. Peroxisome proliferator-activated receptors 
PPARs belong to the superfamily of ligand-activated transcription factors and play crucial roles 
in the regulation of lipid and glucose metabolism but also in inflammatory processes [221]. 
Transcriptional control occurs after heterodimerization with the retinoid X receptor (RXR) and 
subsequent binding to a specific DNA sequence element, called peroxisome proliferator response 
element (PPRE) [222]. Three subtypes of PPAR with different tissue distribution and physiology 
have been identified. PPARα is expressed in liver, kidney, heart, muscle and cells of the arterial 
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Fig. 14. Chemical structures of 
the dual inhibitors of 
leukotriene and prostaglandin 
formation: celecoxib, sulindac, 
curcumin, myrtucommulone, 
and epigallocatechin-3-gallate. 
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wall and regulates genes involved in fatty acid uptake and storage, inflammation and glucose 
metabolism. The receptor is activated endogenously by fatty acids, in particular LTB4 [180], and 
pharmacologically by drugs of the fibrate class [223]. PPARβ/δ can be found in endothelial cells, 
smooth muscle cells and macrophages. Activation of this receptor leads to a reduction of 
inflammation and apoptosis in the respective cell type [224]. No synthetic PPARβ/δ ligand could 
enter the market up to now, but strong efforts are made to develop drugs that act on this receptor 
subtype for the treatment of metabolic syndrome. Glitazones, a class of insulin-sensitizing drugs 
used against type-2 diabetes target the PPARγ receptor. Activation of this subtype increases fatty 
acid storage in adipocytes so that plasma free fatty acid levels are reduced, resulting in an 
improvement of insulin sensitivity in liver and skeletal muscle [225]. Since many patients 
suffering from type 2 diabetes also exhibit dyslipidemia, the idea came up to develop dual 
PPARα/γ agonists several years ago. Nevertheless, the so called glitazares (i.e. ragaglitazar, 
muraglitazar and tesaglitazar) revealed severe side effects like cardiovascular events, anemia or 
urothelial cancer in clinical studies and had to be withdrawn from phase 3 trials [224]. However, 
novel dual PPARα/γ agonists with a better safety profile as well as dual PPARγ/δ and PPARα/δ 
agonists are currently under investigation. In addition, development of tissue and target gene-
selective PPAR receptor modulators (SPPARMs) is a promising strategy to overcome adverse 
effects of full agonists.  
The anti-inflammatory effect upon PPAR activation is mediated by a repression of different 
pathways such as NF-κB, activator protein 1 (AP-1), CCAAT/enhancer binding protein beta 
(C/EBP beta), signal transducer and activator of transcription 1 (STAT-1) and nuclear factor of 
activated T-cells (NFAT) signaling [221]. Consequently, the expression of inflammatory 
cytokines, chemokine receptors and adhesion molecules is reduced, and cell recruitment to 
inflammatory sites is prevented. Therefore PPAR agonists might also be beneficial in the 
treatment of chronic inflammatory diseases such as atherosclerosis [226]. 
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2.5. Pirinixic acid and derivatives 
4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643), also referred to as pirinixic 
acid (PA) belongs to the lipid-lowering fibrates that activate PPARα and, to a lower extend, 
PPARγ. PA was first described in 1974 as an antihypercholesterolemic, but subsequent studies 
revealed that it rather causes a reduction of triglyceride- than of cholesterol levels, and it was 
demonstrated in 1990 that its target is PPARα [227], [228], [229]. Despite its high potency in 
reducing serum lipid levels, PA could never enter the market as a hypolipidemic drug, since a 
hepatocarcinogenic effect was obvious in rodent animal studies [230]. However, although this 
effect turned out to be related to receptor activation and was observed for a variety of PPARα 
agonists in mice and rats, a promotion of liver tumors in humans by these compounds has not 
been demonstrated so far [231], [232], [233]. 
Besides acting as a PPARα agonist, PA was shown to upregulate the expression of the TRB3 
gene in lymphocytes, resulting in a delay of the G2 phase in the cell cycle and thus a blockade of 
cell proliferation [234]. Moreover, induction of plasminogen activator inhibitor 1 (PAI-1) gene 
expression in HepG2 cells was reported [235]. This effect was synergistic with insulin and 
independent of PPARα, but associated with an activation of MAPKs. While interference of PA 
with genomic pathways has been demonstrated in numerous studies, little is known about 
immediate effects of this substance (e.g. a reduction of the activity of human aldose reductase 
[236] and its ability to uncouple mitochondrial oxidative phosphorylation in isolated 
mitochondria [237]). 
PA is unsubstituted in α-position of the carboxylic group, whereas other fibrates possess a di-
methyl group at this site. The group of Prof. Dr. M. Schubert-Zsilavecz (University of Frankfurt) 
synthesized a series of α-substituted PA derivatives with enlarged hydrophobic aromatic 
extension (Fig. 15) that act as dual PPARα/γ agonists with low micromolar activities [238], 
[239]. Additional structural variations led to derivatives of 2-(bis-(phenethoxy)-pyrimidine-2-
ylthio)-hexananoic acid that influence only PPARγ [240], whereas a series of highly active 
PPARα agonists was developed based on the structure of 2-(phenylthio)hexanoic acid [241]. 
 
 
  
2 Introduction  37 
 
 
Besides acting as PPAR agonists, these novel compounds turned out to potently inhibit LT 
biosynthesis in PMNL with IC50 values in the low micromolar range although PA itself was 
ineffective in this respect [242], [243], [244]. 
 
 
 
 
 
 
Fig. 15. Chemical structures of PA, PA derivatives and 2-
(phenylthio)hexanoic acid. X: S or C; R1: alkyl chain or aryl 
residue, R2: hydrophobic aromatic residue; R3: Cl, phenylalkyloxy 
or alkyloxy residue 
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3. Aim of the study 
LTs are potent bioactive lipids that are involved in a variety of pathological conditions such as 
inflammation, allergy, cardiovascular diseases, cancer and osteoporosis [51], [191]. Since 5-LO 
catalyzes the first step in LT biosynthesis, it is a promising target for the pharmacological 
treatment of disorders related to an excess of these lipid mediators [66].  
By introducing alkyl chains or aryl groups in α-position of the carboxylic residue of the PPAR 
agonist PA and by enlarging the hydrophobic part of the molecule, the group of Prof. Dr. M. 
Schubert-Zsilavecz (University of Frankfurt) synthesized a variety of compounds that do not only 
possess an increased activity on PPARs but also potently inhibit 5-LO product formation in 
human PMNL. In addition, a series of highly active PPAR agonists that also suppress 5-LO 
product formation was developed based on the structure of 2-(phenylthio)hexanoic acid. In the 
course of this work, structural features that are important for the inhibitory effect on LT 
biosynthesis were identified, and structure-activity relationships (SARs) of the derivatives were 
determined. 
For the successful development of drugs that are effective in 5-LO related diseases, the complex 
regulation of 5-LO has to be taken into account, and distinguished experimental settings should 
be applied for in vitro investigations. Thus, the enzymatic activity of 5-LO in cell-free assays is 
stimulated by Ca2+, PC, glycerides and CLP that all act via the C2-like domain, but also by 
LOOHs and ATP. All these factors may influence the inhibitory potency of a potential drug 
candidate. In intact cells, interaction with FLAP or cPLA2, but also interference with 5-LO 
translocation and the activation pathway of 5-LO have to be considered. Therefore, a detailed 
biological characterization of 5-LO inhibition was performed with selected compounds out of 
four different subcategories of PA derivatives or 2-(phenylthio)hexanoic acid derivatives, 
respectively. Their pharmacological profile was examined regarding characteristics of 
redoxactive-, iron ligand- or nonredox-type 5-LO inhibitors as well as qualities of C2-like 
domain-interacting substances. Thus, radical scavenging properties of the compounds, selectivity 
towards other LOs as well as reversibility of the inhibitory effect were investigated, and 
dependence on the substrate concentration was determined. In addition, the influence of the cell 
stimulus and different 5-LO stimulatory factors was addressed, and interference with 5-LO 
translocation to the nuclear membrane was evaluated. Finally, the effect on 5-LO product 
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formation in human whole blood was analyzed, and in vivo activity of selected derivatives was 
studied in cooperation with the group of Prof. Dr. L. Sautebin (University of Naples, Italy). 
Pharmacological interference with both PGs and LTs is thought to be more effective than 
inhibition of one single pathway, and in terms of gastrointestinal and cardiovascular side effects, 
dual 5-LO/mPGES-1 inhibitors seem to be superior over dual 5-LO/COX inhibitors. To exclude 
interference with COX enzymes, several PA derivatives and 2-(phenylthio)hexanoic acid 
derivatives were assessed in cell-free assays with isolated ovine COX-1 and human recombinant 
COX-2 [240]. Parallel to this work, A. Koeberle et al. and M. Hieke et al. investigated inhibition 
of cell-free mPGES-1 by a variety of compounds, and most of them turned out to affect both 5-
LO and mPGES-1 [243]. 
Interestingly, previous findings in our group revealed quinolinic α-alkyl substituted PA 
derivatives as potent inhibitors of typical neutrophil functions such as ROS formation, HLE 
secretion and intracellular Ca2+ mobilization [245]. Since most of these functions are elicited 
after activation of p38 MAPK and ERKs, interference of the compounds with these kinases was 
investigated in this work. 
Finally, it was interesting to know if PA derivatives and 2-(phenylthio)hexanoic acid derivatives 
also interfere with other targets in neutrophils. Therefore, selected compounds were either 
immobilized directly to an insoluble resin via their carboxylic function, or a linker group was 
synthetically introduced (in the group of Prof. Dr. M. Schubert-Zsilavecz) and the compound was 
subsequently bound to an insoluble polymeric matrix. These constructs were incubated with cell 
lysates from neutrophils, and proteins that bound specifically to the bait molecule could be 
precipitated, separated by SDS-PAGE or 2-D-DIGE, and identified by MALDI mass 
spectrometry. Since fishing experiments can only reveal a physical interaction of two binding 
partners but do not provide information about the functional consequences, the physiological 
relevance of this interaction should be clarified in appropriate assay systems. 
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4. Materials and methods 
4.1. Materials 
10% non-immune goat serum Invitrogen (Darmstadt, Germany) 
11β-PGE2 Cayman Chemical (Ann Arbor, MI, USA) 
13(S)-HpODE Cayman Chemical (Ann Arbor, MI, USA) 
5-LO antibody generous gift by Prof. Dr. O. Rådmark,  
(affinity-purified anti-5-LO antiserum, Karolinska Institute (Stockholm, Sweden) 
1551, AK7)   
AA Sigma-Aldrich (Deisenhofen, Germany) 
Acetonitrile Sigma-Aldrich (Deisenhofen, Germany) 
Acrylamide solution 30% (37.5:1) AppliChem (Darmstadt, Germany) 
Ada Merck (Darmstadt, Germany) 
AG® 501-X8 Resin Bio-Rad Laboratories, Inc. (Hercules, CA, USA) 
Agar-Agar Merck (Darmstadt, Germany) 
Alexa Fluor 488 goat anti-rabbit IgG Invitrogen (Darmstadt, Germany) 
ALP-conjugated IgGs Sigma-Aldrich (Deisenhofen, Germany) 
AmershamTM ECL Western Blotting GE Healthcare (Freiburg, Germany) 
detection reagent  
Amersham HyperfilmTM ECL GE Healthcare (Freiburg, Germany) 
APS AppliChem (Darmstadt, Germany) 
Ampholyte Bio-Lyte3/10® Bio-Rad Laboratories, Inc. (Hercules, CA, USA) 
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ATP Roche Diagnostics (Mannheim, Germany) 
ATP-Agarose Sigma-Aldrich (Deisenhofen, Germany) 
BCIP AppliChem (Darmstadt, Germany) 
BioRad DC Protein Assay Kit Bio-Rad Laboratories, Inc. (Hercules, CA, USA) 
β-mercaptoethanol Carl Roth (Karlsruhe, Germany) 
Bromophenol blue Merck (Darmstadt, Germany) 
BWA4C generous gift by Dr. L. G. Garland (Wellcome  
 Research Laboratories, London, UK) 
Ca2+-ionophore A23187 Sigma-Aldrich (Deisenhofen, Germany) 
Celecoxib WITEGA Laboratories (Berlin, Germany) 
Chaps AppliChem (Darmstadt, Germany) 
Coomassie brilliant blue G250 AppliChem (Darmstadt, Germany) 
COX-1 (ovine) Cayman Chemical (Ann Arbor, MI, USA) 
COX-2 (human recombinant) Cayman Chemical (Ann Arbor, MI, USA) 
CyDye DIGE Fluor, minimal labeling kit GE Healthcare (Freiburg, Germany) 
Dextrane Sigma-Aldrich Inc. (St. Luis, MO, USA) 
DMEM/High glucose (4.5 g/l) medium PAA (Coelbe, Germany) 
DMF 99,8% extra dry Acros Organics (Geel, Belgium) 
DMEM with high glucose (4.5 g/l)  PAA (Pasching, Austria) 
DMSO Carl Roth (Karlsruhe, Germany) 
DPPH Sigma-Aldrich (Deisenhofen, Germany) 
  
4 Materials and methods  42 
 
 
DTT Sigma-Aldrich (Deisenhofen, Germany) 
Dulbeccos buffer substance Serva Electrophoresis (Heidelberg, Germany) 
ECL Plex goat-anti-mouse IgG-Cy3 GE Healthcare (Munich, Germany) 
ECL Plex goat-anti-rabbit IgG-Cy5 GE Healthcare (Munich, Germany) 
EDTA Sigma-Aldrich (Deisenhofen, Germany) 
FAD Sigma-Aldrich (Deisenhofen, Germany) 
Fatty acid-free BSA Sigma-Aldrich (Deisenhofen, Germany) 
FCS Sigma-Aldrich (St. Luis, MO, USA) 
fMLP Sigma-Aldrich (Deisenhofen, Germany) 
GSH, reduced Sigma-Aldrich (Deisenhofen, Germany) 
GSH-SepharoseTM4B GE Healthcare (Freiburg, Germany) 
HBS-P buffer GE Healthcare (Freiburg, Germany) 
HEPES solution PAA (Pasching, Austria) 
HybondTM-C Extra GE Healthcare (Freiburg, Germany) 
nitrocellulose membranes   
Hyperforin dicyclohexylammonium  Generous gift by Dr. Willmar Schwabe 
GmbH&Co  
 (Karlsruhe, Germany) 
IL-1 β ReproTech (Hamburg, Germany) 
Indomethacin  Sigma-Aldrich (Deisenhofen, Germany) 
IPG Strips (ReadyStrip™) 17 cm 3-10NL Bio-Rad Laboratories, Inc. (Hercules, CA, USA) 
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IPTG Applichem (Darmstadt, Germany) 
Lamin B antibody Abcam (Cambridge, UK) 
Leupeptin AppliChem (Darmstadt, Germany) 
LPS Sigma-Aldrich (Deisenhofen, Germany) 
LSM 1077 Lymphocyte                                                                                                              
Separation Medium PAA (Coelbe, Germany) 
LTB4 EIA kit Assay Designs (Ann Arbor, MI, USA) 
LTB4 RIA kit Assay Designs (Ann Arbor, MI, USA) 
Lysozyme from chicken egg white Sigma-Aldrich (Deisenhofen, Germany) 
MBP-5-LO kindly provided by Prof. Dr. D. Steinhilber  
 (University of Frankfurt, Germany) 
Methanol Merck (Darmstadt, Germany) 
Mineral oil Bio-Rad Laboratories, Inc. (Hercules, CA, USA) 
MK-886 BioTrend Chemicals (Cologne, Germany) 
Mowiol Merck (Darmstadt, Germany) 
MTT Sigma-Aldrich (Deisenhofen, Germany) 
NBT Roche Diagnostics (Mannheim, Germany) 
N,N'-Diisopropylcarbodiimide Acros Organics (Geel, Belgium) 
Nonidet® P40 AppliChem (Darmstadt, Germany) 
NQO2 human recombinant Sigma-Aldrich (Deisenhofen, Germany) 
NQO2 polyclonal antibody (mouse) Abcam (Cambridge, UK)  
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OAG Sigma-Aldrich (Deisenhofen, Germany) 
p38 MAPK antibody Abcam (Cambridge, UK)  
PAF C-16 Cayman Chemical (Ann Arbor, MI, USA) 
PC Sigma-Aldrich (Deisenhofen, Germany) 
Penicillin / Streptomycin solution PAA (Coelbe, Germany) 
peqGold Protein Marker IV peqLab Biotechnology (Erlangen, Germany) 
Peroxidase-conjugated IgGs Sigma-Aldrich (Deisenhofen, Germany) 
PGB1 Sigma-Aldrich (Deisenhofen, Germany) 
PGH2 Larodan (Malmö, Sweden) 
phospho-ERK1/2 (Thr202/Tyr204) Cell Signalling (Boston, MA, USA)                                                                            
antibody  
phospho-p38 MAPK (Thr180/Tyr182)  Cell Signalling (Boston, MA, USA)             
antibody  
PMSF Sigma-Aldrich (Deisenhofen, Germany) 
Ponceau S red Sigma-Aldrich (St. Luis, MO, USA) 
Poly-L-lysine (MW 150,000-300,000) Sigma-Aldrich (Deisenhofen, Germany) 
Protease Inhibitor Cocktail P8340 Sigma-Aldrich (St. Luis, MO, USA) 
PS Sigma-Aldrich (Deisenhofen, Germany) 
SDS Carl Roth (Karlsruhe, Germany) 
Sensor Chip CM 5  GE Healthcare (Freiburg, Germany) 
Silver nitrate Sigma-Aldrich (St. Luis, MO, USA) 
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STI Sigma-Aldrich (Deisenhofen, Germany) 
Streptomycin  PAA (Pasching, Austria) 
TFA AppliChem (Darmstadt, Germany) 
THF Carl Roth (Karlsruhe, Germany) 
Thiourea AppliChem (Darmstadt, Germany) 
Toyopearl AF-Amino 650M Tosho Bioscience (Stuttgart, Germany) 
Toyopearl AF-Epoxy 650M Tosho Bioscience (Stuttgart, Germany) 
Triton X-100 Carl Roth (Karlsruhe, Germany) 
Trypan Blue AppliChem (Darmstadt, Germany) 
Trypsin/EDTA solution  PAA (Pasching, Austria) 
Tween 20 Carl Roth (Karlsruhe, Germany) 
Urea AppliChem (Darmstadt, Germany) 
WY-14643 (Pirinixic Acid) Sigma-Aldrich (Deisenhofen, Germany) 
ZM230487 generous gifts by Dr. R. M. McMillan (Zeneca  
 Pharmaceuticals, Macclesfield, UK) 
λ-carrageenan type IV isolated from Sigma-Aldrich (Milan, Italy) 
Gigartina aciculaire and Gigartina pistillata  
All other chemicals were purchased in analytical grade from Sigma-Aldrich (Deisenhofen, 
Germany) unless stated otherwise. 
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Pirinixic acid derivatives and 2-(phenylthio)hexanoic acid derivatives  
PA derivatives and 2-(phenylthio)hexanoic acid derivatives were synthesized by M. Dittrich, M. 
Hieke, L. Popescu, Y. Syha, T. Thieme and H. Zettl in the group of Prof. Dr. M. Schubert-
Zsilavecz (University of Frankfurt, Germany) as described [238], [239], [243], [240], [241], 
[246]. Stocks of the compounds were prepared at concentrations ≤ 30 mM in DMSO and kept at -
20 °C. Freezing-thawing cycles were kept to a minimum. 
4.2. Animalsa 
Wistar Han rats (190-200 g, Harlan, Milan, Italy) and CD-1 mice (26-30 g) were housed in a 
controlled environment and provided with standard rodent chow and water. Animal care 
complied with Italian regulations on protection of animals used for experimental and other 
scientific purpose (Ministerial Decree 116192) as well as with the European Economic 
Community regulations (Official Journal of E.C. L 358/1 12/18/1986). 
aIn cooperation with Prof. Dr. L. Sautebin (University of Naples, Italy) 
4.3. Methods 
4.3.1. Isolation of human PMNL 
Human PMNL were freshly isolated from leukocyte concentrates obtained at the Blood Center of 
the University Hospital Tuebingen (Germany). In brief, venous blood was taken from healthy 
adult donors, and leukocyte concentrates were prepared by centrifugation at 4,000×g for 20 min 
at 20 °C. PMNL were immediately isolated by dextran sedimentation, centrifugation on LSM 
1077 Lymphocyte Separation Medium and hypotonic lysis of erythrocytes as described 
previously [247]. Cells were finally resuspended in phosphate-buffered saline pH 7.4 (PBS) 
containing 1 mg/ml glucose and 1 mM CaCl2 (PGC buffer). 
4.3.2. Determination of product formation of 5-LO, 15-LO and 12-LO in intact cells 
For assays of intact cells stimulated with Ca2+-ionophore A23187 or NaCl, 5 × 106 freshly 
isolated PMNL were resuspended in 1 ml PGC buffer. After preincubation with test compounds 
for 15 min at 37 °C (and addition of further compounds as specified), 5-LO product formation 
was started by addition of 2.5 µM Ca2+-ionophore A23187 and exogenous AA as indicated. 
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Alternatively, 0.3 M NaCl was supplemented 3 min before addition of AA (without A23187). 
After 10 min at 37 °C, the reaction was stopped with 1 ml MeOH and 30 µl HCl (1 N), 200 ng 
PGB1 as well as 500 µl of PBS were added. Formed 5-LO metabolites were extracted and 
analyzed by HPLC as described [248]. 5-LO product formation is expressed as ng of 5-LO 
products per 106 cells, which includes LTB4
 
and its all-trans isomers 5(S),12(S)-DiHETE and 5-
H(p)ETE. Cysteinyl LTC4, -D4 and -E4 were not detected, and oxidation products of LTB4 were 
not determined. 15-H(p)ETE was analyzed as product of 15-LO and 12-H(p)ETE as product of 
12-LO. To assess 5-LO product formation in cells stimulated with fMLP, 2 × 107 freshly isolated 
PMNL were resuspended in 1 ml PBS/glucose. Cells were primed with 1 µg LPS for 10 min at 
37 °C and 0.3 U Ada was added. After another 10 min, cells were treated with test compounds 
for 10 min, and 1 µM fMLP was added to start 5-LO product formation. The reaction was 
stopped on ice after 5 min, and cells were centrifuged (800×g, 10 min). The amount of released 
LTB4 was determined by EIA according to the manufacturer’s protocol. 
4.3.3. Expression and purification of human recombinant 5-LO from E. coli 
E.coli BL21 cells were transformed with pT3-5LO plasmid, and recombinant 5-LO was 
expressed at 37 °C as described [249]. For isolation of 5-LO protein, E.coli were lysed by 
incubation in 50 mM triethanolamine (TEA)/HCl pH 8.0, 5 mM EDTA, soybean trypsin inhibitor 
(STI, 60 µg/ml), 1 mM phenylmethylsulfonyl fluoride (PMSF) and lysozyme (500 µg/ml), 
homogenized by sonication (3 × 15 s) and centrifuged at 40,000×g for 20 min. To partially purify 
5-LO, the 40,000×g supernatant (S40) was applied to an ATP-agarose column. The column was 
eluted as described previously [250]. Purified 5-LO or S40 were immediately used for 5-LO 
activity assays.  
4.3.4. Determination of 5-LO product formation in cell-free systems 
When whole cell homogenates were assayed, 5 × 106 freshly isolated PMNL were resuspended in 
1 ml of PBS containing 1 mM EDTA and sonicated (3 × 10 s). Cell disruption was verified by 
trypan blue staining. Cell homogenates were either used immediately for 5-LO activity assays, or 
centrifuged at 100,000×g for 1 h at 4 °C, and 5-LO products in the resulting supernatant (S100) 
were assessed. For determination of the activity of recombinant 5-LO, either the S40 supernatants 
from E.coli lysates (corresponding to 4 ml E.coli culture) or 0.5 µg partially purified 5-LO were 
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diluted with PBS/EDTA. Aliquots from PMNL homogenates or recombinant 5-LO were 
supplemented with 1 mM ATP and pre-incubated with test compounds and additional reagents 
(e.g., DTT, OAG or PLs) as indicated. After 5-10 min at 4 °C, samples were pre-warmed for 30 s 
at 37 °C, and 2 mM CaCl2 (if indicated) and the appropriate amounts of AA with or without 
13(S)-HpODE or 30 µM AA alone were added to start 5-LO product formation. The reaction was 
stopped after 10 min at 37 °C by addition of 1 ml ice-cold methanol, and the formed metabolites 
were analyzed by HPLC as described for intact cells.  
4.3.5. Determination of 5-LO activity in human whole blood 
Freshly withdrawn venous blood was collected by the Blood Center, University Hospital 
(Tübingen, Germany) in heparinized tubes (S-Monovettes Sarstedt, 13.1628, 16 I.E. Heparin/mL 
blood) by venipuncture from fasted (12 h) male and female volunteers, with consent. The blood 
was divided in 2 mL aliquots in glass vials, pre-incubated 10 min at 37° C with test compounds 
and then stimulated with Ca2+-ionophore A23187 (30 µM) for 10 min. The reaction was stopped 
on ice, and samples were centrifuged at 600×g, 10 min, 4° C. Aliquots of plasma (500 µL of 
supernatant) were mixed with 2 ml methanol, and PGB1 (200 ng) was added as internal standard. 
Samples were put at -20° C for 2 h and then centrifuged again (600×g, 15 min, 4° C). 
Supernatants were collected and diluted with 2.5 ml PBS plus 75 µL HCl 1N. Formed 5-LO 
metabolites were extracted and analyzed by HPLC as described for PMNL. 
4.3.6. Analysis of subcellular redistribution of 5-LO  
PMNL (3 × 107) in 1 ml PGC buffer were pre-incubated with test compounds for 15 min at 37 
°C, stimulated with 2.5 µM Ca2+-ionophore A23187 for 5 min or primed with LPS (1 µg/ml) and 
Ada (0.3 U/ml) followed by stimulation with fMLP (1 µM) for 5 min at 37 °C and chilled on ice. 
Alternatively, cells were incubated with test compounds in presence of 0.3 U Ada for 20 min at 
37 °C and immediately chilled on ice. Subcellular localization of 5-LO was determined either by 
mild detergent (0.1% nonidet P-40) lysis [251] or by sonication of the cells followed by 
preparation of soluble (S100) and membrane (P100) fractions by 100,000×g centrifugation [252], 
respectively. 5-LO in these fractions was analyzed by SDS-PAGE and Western Blot using 5-LO 
antibody.  
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4.3.7. Indirect Immunofluorescence Microscopy 
Human PMNL (1.5 × 106, freshly isolated from buffy coats of female donors), were resuspended 
in 1 mL ice-cold PGC buffer. Cells were pretreated with test compounds for 15 min at 37 °C and 
then centrifuged at 30×g for 1 minute onto poly-L-lysine (MW 150,000-300,000)-coated glass 
coverslips in the wells of a 12-well plate. Cells were activated by addition of 2.5 µM Ca2+-
ionophore A23187, for 3 min at 37° C. Cells were fixed in methanol (-20° C, 30 min) and 
permeabilized with 0.1% Tween 20 in Dulbecco’s PBS (RT, 10 min), followed by 3 washing 
steps with PBS. Samples were blocked with 10% non-immune goat serum for 10 min at RT and 
then washed again twice with PBS. 5-LO staining was performed by incubating the coverslips 
with 5-LO antibody for 1 h at RT. The coverslips were washed ten times with PBS, incubated 
with Alexa Fluor 488 goat anti-rabbit IgG (diluted 1:1,500 in PBS) for 10 min at RT in the dark 
and washed ten times with PBS. The DNA was stained with 0.1 µg/ml diamidino-2-phenylindole 
(DAPI) in PBS for 3 min at RT in the dark. The coverslips were washed ten times and mounted 
on glass slides with Mowiol containing 2.5% n-propyl gallate. Fluorescence was visualized with 
a Zeiss Axiovert 200M microscope using a 100X oilimmersion objective. 
4.3.8. Glutathione-S-transferase (GST) pull-down assay 
Recombinant human CLP was expressed as GST fusion protein using the plasmid pGEX-5X-1-
CLP and purified as described [106], [107]. 20 µg of purified GST-CLP linked to GSH-
Sepharose 4B beads (20 µl of 50% slurry) was incubated with partially purified 5-LO protein (5 
µg) in the presence of 50 µg bovine serum albumin (BSA) and the indicated amount of test 
compounds in 200 µl buffer A (2 mM Tris-HCl pH 8.0, 0.2 mM ATP, 0.2 mM CaCl2, 2 mM 
MgCl2, 50 mM KCl, 0.5 mM β-mercaptoethanol). After 30 min gentle rotation at RT, beads were 
washed five times with buffer A (without BSA). Bound proteins were eluted from the beads with 
200 µl of elution buffer (10 mM GSH in 50 mM Tris-HCl, pH 8.0), for 60–90 min at RT. Beads 
were sedimented, and 5-LO in the supernatant was analyzed by SDS-PAGE and Western Blot 
using 5-LO antibody. 
4.3.9. Surface plasmon resonance (SPR) experiments 
Recombinant human 5-LO expressed as MBP fusion protein was kindly provided by Prof. Dr. D. 
Steinhilber (University of Frankfurt, Germany) [253]. SPR experiments were carried out on a 
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BIAcore® X device (GE Healthcare Freiburg, Germany). MBP-5-LO (75 µg/ml) in 10 mM Na-
acetate pH 4.5 was coupled to a carboxymethylated dextran surface (CM-5 chip) using standard 
amine coupling chemistry according to the manufacturer’s directions. There are two flow cells on 
each chip: MBP-5-LO (5.25 µg) was immobilized to flow cell 2 corresponding to 6400 resonance 
units (RU), whereas flow cell 1 was loaded with the equivalent amount of substance of MPB 
alone (corresponding to 2327 RU) as reference. Equilibration of the baseline was completed by 
passing a continuous flow of HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.01% surfactant 
P20 and 1% DMSO, pH 7.4) through the chip for 2 h. During the SPR experiments, the stock 
solution of test compounds (dissolved in DMSO) was diluted into assay buffer. All measurements 
were performed at 25 °C and a flow rate of 30 µl/min. 
After recording association, the liquid phase was replaced by assay buffer, and the dissociation 
was monitored. The binding profiles were obtained after subtracting the response signal of the 
MBP reference cell 1, and sensograms were processed using automatic correction for nonspecific 
bulk refractive index effects using BIAEVALUATION Version 3.1 software (GE Healthcare).  
4.3.10. Determination of antioxidant activity 
The indicated amounts of test compounds were incubated with 50 µM diphenylpicrylhydrazyl 
(DPPH) in ethanol for 30 min at RT in a 96 well plate, shaking. Reduction of the absorbance at 
520 nm was measured with a multiwell scanning spectrophotometer (Victor plate reader, 
PerkinElmer) [254]. 
4.3.11. Carrageenan-induced pleurisy in rats 
Experiments were conducted by F. Dehm in the laboratory of Prof. Dr. L. Sautebin (University of 
Naples, Italy). Male Wistar Han rats (200-220 g, Harlan, Milan, Italy) were anesthetized with 
enflurane 4% mixed with O2, 0.5 l/min, N2O, 0.5 l/min and submitted to a skin incision at the 
level of the left sixth intercostal space. The underlying muscle was dissected, and saline (0.2 ml) 
or λ-carrageenan type IV 1% (w/v) (0.2 ml) was injected into the pleural cavity. The skin incision 
was closed with a suture, and the animals were allowed to recover. At 4 h after the injection of λ-
carrageenan, the animals were killed by inhalation of CO2. The chest was carefully opened, and 
the pleural cavity was rinsed with 2 ml saline solution containing heparin (5 U/ml). The exudate 
and washing solution were removed by aspiration, and the total volume was measured. Any 
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exudate that was contaminated with blood was discarded. The amount of exudate was calculated 
by subtracting the volume injected (2 ml) from the total volume recovered. Leukocytes in the 
exudate were resuspended in PBS and counted with an optical light microscope in a Burker’s 
chamber after vital trypan blue staining. In the treated group of animals, test compound 22 and 37 
(1.5 mg/kg, each) was given i.p. 30 min before carrageenan. Indomethacin (5 mg/kg) was used as 
reference compound, and vehicle-treated group of rats received DMSO (4% (v/v), i.p.) 30 min 
before carrageenan. The amount of PGE2, 6-keto-PGF1α and LTB4 in the supernatant of 
centrifuged exudate (800×g for 10 min) was assayed by radioimmunoassay (RIA) and enzyme 
immunoassay (EIA), respectively, according to manufacturer’s protocol.  
4.3.12. Platelet activating factor (PAF)-induced shock in mice 
Experiments were conducted by A. Rossi in the laboratory of Prof. Dr. L. Sautebin (University of 
Naples, Italy). PAF was injected intravenously into female mice at a dose of 200 µg/kg. Test 
compound 39 (1.5, 5, 10 mg/kg) or vehicle control (saline solution containing 2% DMSO) were 
administered i.p. 30 min prior to PAF. The animals were monitored closely for 1-2 h, and the 
number of surviving animals was assessed. 
4.3.13. Cell culture - A549 cells 
A549 (human lung epithelial carcinoma cell line) cells were obtained from Prof. Dr. O. Rådmark 
(Karolinska Institute, Stockholm, Sweden). Cells were cultured in DMEM/High glucose (4.5 g/l) 
medium supplemented with FCS (10%, v/v), penicillin (100 U/ml) and streptomycin (100 µg/ml). 
After 3 days, confluent cells were detached using 1× trypsin/ethylenediaminetetraacetate (EDTA) 
solution and reseeded at 2 × 106 cells in 20 ml medium. 
4.3.14. Cell viabilityb 
Cell viability of A549 cells was measured using the colorimetric 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye reduction assay [255] in a 96-well format. Briefly, 
A549 cells (4 × 104 cells/100 µl medium) were plated into a 96-well microplate and incubated at 
37 °C and 5% CO2 for 16 h. Then, 30 µM of test compound or solvent (DMSO) was added, and 
samples were incubated for another 5 h. MTT (20 µl, 5 mg/ml) was added, and the incubations 
were continued for 4 h. Alternatively, A549 cells were stimulated with IL-1β (2 ng/ ml) and 
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incubated with test compounds or vehicle for 24 h at 37 °C. MTT (20 µl, 5 mg/ml) was added, 
and the incubations were continued for 1 h. The formazan product was solubilized with sodium 
dodecylsulfate (SDS) (10%, (w/v) in 20 mM HCl), and the absorbance of each sample was 
measured at 595 nm relative to that of vehicle (DMSO)-treated control cells using a multiwall 
scanning spectrophotometer (Victor3 plate reader, PerkinElmer, Rodgau-Juegesheim, Germany). 
Neither PA nor any of the tested derivatives (22, 30, 37, 39, 25, 136 or 86 at 10 µM final 
concentration, each) significantly reduced cell viability versus DMSO as vehicle (data not 
shown), excluding possible acute cytotoxic effects of the compounds in the cellular assays using 
A549 cells.  
b
 performed by A. Koeberle in the lab of Prof. Dr. O. Werz (University Tuebingen, Germany) 
4.3.15. Induction of mPGES-1 in A549 cells and isolation of microsomes 
Preparation of A549 cells was performed as described [17]. In brief, cells (2 × 106 cells in 20 ml 
DMEM/High glucose (4.5 g/l) medium containing FCS (2%, v/v) were incubated for 16 h at 37 
°C and 5% CO2. Subsequently, the culture medium was replaced by fresh medium, IL-1β (1 
ng/ml) was added, and cells were incubated for another 72 h. Thereafter, cells were detached with 
trypsin/EDTA, washed with PBS and frozen in liquid nitrogen. Ice-cold homogenization buffer 
(0.1 M potassium phosphate buffer pH 7.4, 1 mM PMSF, 60 µg/ml STI, 1 µg/ml leupeptin, 2.5 
mM GSH and 250 mM sucrose) was added, and after 15 min, cells were resuspended and 
sonicated on ice (3 × 20 s). The homogenate was subjected to differential centrifugation at 
10,000×g for 10 min and at 174,000×g for 1 h at 4 °C. The pellet (microsomal fraction) was 
resuspended in 1 ml homogenization buffer, and the protein concentration was determined by 
Coomassie protein assay. 
4.3.16. Determination of PGE2 synthase activity in microsomes of A549 cells 
Microsomal membranes of A549 cells were diluted in potassium phosphate buffer (0.1 M, pH 
7.4) containing 2.5 mM GSH (100 µl total volume), and test compounds or vehicle (DMSO) were 
added. After 15 min, PGE2 formation was initiated by addition of PGH2 (20 µM, final 
concentration). After 1 min at 4 °C, the reaction was terminated with 100 µl of stop solution (40 
mM FeCl2, 80 mM citric acid, and 10 µM 11β-PGE2), PGE2 was separated by solid phase 
extraction on reversed phase (RP)-C18 material using acetonitrile (200 µl) as eluent and analyzed 
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by RP-HPLC (30% acetonitrile aqueous + 0.007% TFA (v/v), Nova-Pak® C18 column, 5 × 100 
mm, 4 µm particle size, flow rate 1 ml/min) with UV detection at 195 nm. 11β-PGE2 was used as 
internal standard to quantify PGE2 product formation by integration of the area under the peaks. 
4.3.17. Activity assays of isolated COX-1 and COX-2 
Inhibition of the activities of isolated ovine COX-1 and human recombinant COX-2 was 
performed as described [256], [257]. Though not of human origin, ovine COX-1 is generally used 
for inhibitor studies when examining the effectiveness of compounds on the activity of isolated 
COX-1 enzyme [257]. Briefly, purified COX-1 (ovine, 50 units) or COX-2 (human recombinant, 
20 units) were diluted in 1 ml reaction mixture containing 100 mM Tris-HCl pH 8, 5 mM GSH, 5 
µM hemoglobin, 100 µM EDTA at 4 °C and pre-incubated with the test compounds for 5 min. 
Samples were pre-warmed for 60 s at 37 °C, and AA (5 µM for COX-1, 2 µM for COX-2) was 
added. After 5 min at 37 °C, the reaction was terminated by addition of 1 ml methanol, and the 
COX product 12-HHT was extracted and analyzed by HPLC as described [209], [258]. 
4.3.18. Determination of MAPK activation 
Human PMNL (107/100 µl PGC buffer) were preincubated with test compounds (or 0.3% DMSO 
as vehicle) for 15 min. Then, fMLP (1 µM) was added for 1.5 min at 37 °C, the reaction was 
stopped by addition of 100 µl of 2× SDS loading buffer (20 mM Tris-HCl, pH 8, 2 mM EDTA, 
5% (m/v) SDS, 10% (v/v) β-mercaptoethanol). Samples were vortexed and boiled for 6 min at 
95° C. Total cell lysates were analyzed for phosphorylated ERK1/2, phosphorylated p38 MAPK 
and p38 MAPK by SDS-PAGE and Western Blot. 
4.3.19. Preparation of whole cell lysates from PMNL 
Human PMNL were lysed in 1 ml lysis buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 50 µl P8340 protease inhibitor cocktail) per g drained cell pellet. After 
sonification on ice (5 × 10 s) and centrifugation (100,000×g, 1 h, 4 °C), the supernatants were 
immediately used for protein fishing experiments. 
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4.3.20. Immobilisation of PA derivatives to amino-functionalised matrix 
500 µl Toyopearl AF-Amino-650M dry beads were prewashed with Milli-Q water, 50% DMF 
and DMF (5 ml each). Compounds 24, 143, 144 or PA, respectively, were solubilized in DMF 
(100 µmol/500 µl) and mixed with washed beads. After addition of 65 µl N,N′-
Diisopropylcarbodiimide (DIC), the pH was adjusted to 4.5, and samples were rotated at RT for 
48 h. Afterwards, the resin was washed with DMF, 50% DMF and Milli-Q water (10 ml each), 
and after resuspension in 1 ml Milli-Q water, remaining free amino groups were blocked with 
42.5 µl acetic acid (10%) and 100 µl DIC at RT over night. Then, beads were washed three times 
with 1 ml DMF and three times with 2 ml acetate buffer (0.1 M sodium acetate, 0.1 M acetic 
acid, pH 4, 0.5 M NaCl) and Tris buffer (0.1 M Tris-HCl pH 8, 0.5 M NaCl), alternatively, to 
remove ionic bound ligand. The beads were finally washed with 1 ml Milli-Q water and 1 ml 
20% (v/v) ethanol and stored at 4 °C in 20% (v/v) ethanol until use. 
4.3.21. Deprotection of the ester groups of compounds 143 and 144 
100 µmol Toyopearl AF-Amino-650M coupled with compound 143 or 144, respectively, was 
mixed with 300 µmol LiOH in 2.68 ml THF (75%) and rotated for 24 h at RT to cleave the 
ethylester of the compounds. Beads were washed three times with 1 ml THF and three times with 
2 ml acetate buffer (0.1 M sodium acetate, 0.1 M acetic acid, pH 4, 0.5 M NaCl) and Tris buffer 
(0.1 M Tris-HCl pH 8, 0.5 M NaCl), alternatively. The beads were finally washed with 1 ml 
Milli-Q water and 1 ml 20% (v/v) ethanol, and stored at 4 °C in 20% (v/v) ethanol until use. 
4.3.22. Immobilisation of 2-(phenylthio)hexanoic acid derivatives to epoxy-functionalised 
matrix 
75 mg Toyopearl AF-Epoxy-650M dry beads were prewashed with Milli-Q water, 50% DMF and 
DMF (5 ml each). Compound 145 or 146, respectively, were solubilized in DMF (40 µmol/400 
µl) and mixed with washed beads. After addition of 100 µl NaOH (1 M), samples were rotated at 
RT for 72 h. The resin was washed with DMF, 50% DMF and Milli-Q water (3 ml each), and 
after resuspension in 1 ml Milli-Q water, remaining free epoxy groups were blocked with 60 µl 
ethanolamine plus 10 µl NaOH (1 M) at RT over night. Afterwards, beads were washed and 
stored as described in 4.3.20. 
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4.3.23. Protein fishing assays 
50 µl compound-coupled beads were mixed with 500 µl Milli-Q water, washed three times by 
centrifugation (7,000×g, 7 min, 4 °C) and finally resuspended in 500 µl Milli-Q water. The beads 
were incubated with PMNL lysate (corresponding to the indicated amount of cells) in 700 µl 
binding buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM EDTA) with the indicated amount 
of Triton X-100 for 12 h at 4 °C, rotating. After three washing steps with 500 µl binding buffer 
plus Triton X-100 1%), fished proteins were eluted by addition of 50 µl SDS-PAGE loading 
buffer (20 mM Tris pH 8.0, 2 mM EDTA, 0.5% (w/v) SDS, 10% (v/v) β-mercaptoethanol) 
followed by 5 min boiling at 96 °C and separation from beads by centrifugation (11,000×g, 10 
min, 4 °C). Alternatively, proteins were eluted by incubation with 50 µl 4 M urea (purified from 
carbamoylated contaminations and salt impurities by ion exchange resin) for 30 min at 4 °C, 
centrifugation of the beads and subsequent boiling (as described above). Fished proteins were 
separated either by one dimensional gel electrophoresis (SDS-PAGE) or by two-dimensional gel 
electrophoresis (2D-PAGE). 
4.3.24. SDS-PAGE  
Aliqots of protein sample preparations (10 µl) were mixed with the same volume of 2× SDS 
loading buffer, boiled for 6 min at 95 °C and sonified if necessary. Samples were mixed with 5 µl 
of glycerol/0.1% bromophenol blue (1:1, v/v), and SDS-PAGE was performed on 8%, 10% or 
12% polyacrylamide (PAA) gels using a Mini Trans-Blot Cell system or a Protean II xi Cell 
system (both from Bio-Rad, Hercules, CA, USA). Molecular weight of the proteins was 
estimated by comparison with the prestained broad range molecular weight marker peqGOLD IV. 
4.3.25. Silver staining 
Silver staining was performed by fixing the gels immediately after SDS-PAGE in fixing solution 
(50% (v/v) ethanol, 40% (v/v) Milli-Q water, 10% (v/v) acetic acid) for 30 min. All steps from 
then on were performed on ice. Gels were washed for 30 min with Milli-Q water and sensitized 
by addition of sensitizing solution (30% (v/v) ethanol, 8 mM Na2S2O3, 500 mM C2H3NaO2, 60% 
(v/v) Milli-Q water) for 30 min. Again, gels were washed (three times for 5 min with Milli-Q 
water), and staining solution (30 mM AgNO3) was added for 30 min. After another washing step 
with Milli-Q water (5 min), the developing solution (235 mM Na2CO3, 0.0185% formaldehyde, 
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0.0025% Na2S2O3 in Milli-Q water) was added until an optimal intensity of the staining was 
reached. Then, gels were quenched in stopping solution (5% acetic acid) and washed with Milli-
Q water for 5 min. Pictures of the stained gels were taken with a CCD camera system (CabUVis, 
Hitachi HV-C20M 3CCD, Sarstedt AG Co., Nümbrecht, Germany). 
4.3.26. Western Blot 
Gels were electroblotted to nitrocellulose membranes (tank blotting method) after SDS-PAGE, 
and correct loading of the gels was confirmed by Ponceau S staining. Membranes were blocked 
with 5% (w/v) BSA blocking buffer (50 mM Tris-HCl, pH 7.4 and 100 mM NaCl (Tris-buffered 
saline (TBS)) plus 0.1% Tween 20 (TBS-Tween)) for 1 h at RT, washed and incubated with 
primary antibodies (diluted 1:1,000 in TBS-Tween containing 5% BSA) over night at 4 °C. After 
several washing steps with TBS-Tween, membranes were incubated with 1:1,000 dilution of 
alkaline phosphatase (ALP)-conjugated IgGs for 3 h at room temperature. After washing with 
TBS-Tween and TBS, proteins were visualized with nitro blue tetrazolium (NBT) and 5-bromo-
4-chloro-3-indolylphosphate (BCIP) in detection buffer (100 mM Tris-HCl, pH 9.5, 100 mM 
NaCl, 5 mM MgCl2). Alternatively, development was performed via fluorescence detection. 
Therefore, membranes were incubated with ECL Plex CyDye-conjugated secondary antibodies 
(Cy5-conjugated anti-rabbit or Cy3-conjugated anti-mouse) diluted 1:2,500 in TBS-Tween for 1 
h at RT. After washing, the membranes were dried at 37° C for 1 h in the dark and then scanned 
in the Cy3 (Excitation Filter: 540 nm; Emission Filter: 595 nm) or in the Cy5 (Excitation Filter: 
635 nm; Emission Filter: 680 nm) channels, respectively, using an EttanTM DIGE imaging system 
(GE-Healthcare). In some experiments, membranes were developed via chemoluminescence. In 
this case, peroxidase-conjugated secondary antibodies were applied in a 1:10,000 dilution for 1 h 
at RT. After washing (2 × 5 min, 1 × 15 min and 2 × 5 min with TBST buffer), proteins were  
visualized by addition of AmershamTM ECL Western Blotting detection reagent. Exposed 
chemoluminescence films (Amersham HyperfilmTM ECL) were developed using an X-Ray table-
top processor (CP 1000, AGFA Healthcare N.V., Mortsel, Belgium). 
4.3.27. CyDyeTM DIGE Fluor labeling for differential gel electrophoresis (DIGE) 
The protein concentration of urea eluted fishing-samples was determined using an urea-
compatible protein determination kit (BioRad DC Assay-Kit). CyDyeTM DIGE Fluors (Cy3 and 
Cy5) were diluted 1:2.5 with 3 µl water-free DMF (<0.005 ppm water), and pH was adjusted to 
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pH 8.5-9.5. This CyDyeTM DIGE Fluor working solution (1 µl for 10 µg protein) was added to 
the samples (Cy5 to the sample with proteins of interest and Cy3 to the negative control) and 
incubated for 30 min at 4 °C. The reaction was stopped by addition of 1 µl 10 mM lysine. 
CyDyeTM DIGE Fluor labeled samples were stored at -80 °C until isoelectric focusing (IEF). 
4.3.28. 2D-PAGE/DIGE 
The first dimension of the protein separation was performed by isoelectric focusing (IEF) on 
immobilized pH gradient (IPG) strips (17 cm, non linear pH gradient from pH 3-10). Cy5- and 
Cy3-labeled samples were mixed and diluted with PCT buffer (8 M urea, 2 M thiourea, 4% (w/v) 
CHAPS, ampholyte pH 3-10 0.7% (v/v), 65 mM DTT, 10 µg/ml bromophenol blue, 50 µl P8340 
protease inhibitor cocktail per g protein) to a total volume of 300 µl. The solution was pipetted in 
a 17 cm focusing tray, and an IPG strip was placed on the sample and covered with mineral oil. 
Rehydration of the strip was performed at 50 V (12 h, 10 °C) in an IEF cell (BioRad Protein® 
IEF cell, Herecules, CA). Afterwards, the electrode wicks were moistened with 5 µl Milli-Q 
water and placed on the electrodes. IEF was performed over 17 h with a programmed voltage 
slope from 0 to 10,000 V. Focused strips were stored at -80 °C until performance of SDS-PAGE. 
For development of the second dimension, thawed IPG-strips were incubated two times with 
equilibration buffer I (6 M urea, 4% (w/v) SDS, 0.05 M Tris pH 8.8, 30% (v/v) glycerol, 1% 
(w/v) DTT) for 7 min and two times with equilibration buffer II (6 M urea, 4% (w/v) SDS, 0.05 
M Tris pH 8.8, 30% (v/v) glycerol, 4% (w/v) iodoacetamide) for 7 min followed by 1 × 10 s 
shaking in SDS-PAGE running buffer (200 mM glycine, 25 mM Tris, 3 mM SDS). The IPG strip 
was placed on top of a 18 × 20 cm PAA gel (8%, 10% or 12%) and ingrained in an agarose gel 
(0.5% (w/v) agarose, 0.001% bromophenol blue in SDS-PAGE running buffer (25 mM Tris, 190 
mM glycine, 3,5 mM SDS)). Gel electrophoresis was performed using a Protean II xi Cell 
System. Molecular weight of the proteins was estimated by comparison with a prestained broad 
range molecular weight marker peqGOLD IV that was applied on a filter paper and placed 
besides the IPG strip into the agarose gel. Gels were scanned in the Cy3 (Excitation Filter: 540 
nm; Emission Filter: 595 nm) and in the Cy5 (Excitation Filter: 635 nm; Emission Filter: 680 nm) 
channels by an EttanTM DIGE imaging system (GE-Healthcare). 
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4.3.29. Mass spectrometry (MS) 
MS analysis of fished proteins was performed in cooperation with the Proteom Center Tuebingen 
via in-gel digestion and nanoflow liquid chromatography tandem MS (nano-LC-ESI-MS/MS) on 
a QSTAR Pulsar hybrid qTOF mass spectrometer (AB-MDS Sciex) as described previously 
[259]. Bioinformatic analysis of the identified peptides was subsequently carried out with Matrix 
Science Mascot. 
4.3.30. NRH:quinone oxidoreductase 2 (NQO2) pull-down assay 
Toyopearl AF-Amino-650M coupled with compound 24 (50 µl) was incubated with 0.5 µg 
human recombinant NQO2 in 500 µl binding buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 
mM EDTA) plus 1% Triton X-100 in the presence of 0.1 µg/ml BSA for 12 h at 4 °C under 
rotation. Beads were washed three times with binding buffer + 1% Triton X-100, boiled with 2× 
SDS loading buffer for 5 min at 96 °C, and Western Blot was performed using anti-NQO2 
polyclonal antibody .  
4.3.31. NQO2 activity assay 
Human recombinant NQO2 (10 ng) was pretreated with test compounds, resveratrol (10 µM 
each) or vehicle in 200 µl assay buffer (25 mM Tris-HCl pH 7.5, 0.01% Tween 20, 0.18 mg/ml 
BSA, 1 µM flavin adenine dinucleotide (FAD) and 0.5 mM 1-(3-sulfonatopropyl)-3-carbamoyl-
1,4-dihydropyrimidine (SCHP)) for 5 min at RT. The enzyme reaction was started with 
menadione (100 µM) plus 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(0.134 mg/ml), and the absorbance (at 590 nm) was measured at the indicated times. 
4.3.32. Statistics 
Statistical evaluation of the data was performed by one-way ANOVA followed by Bonferroni or 
Tukey-Kramer post-hoc test for multiple comparisons, respectively. A p value < 0.05 (*) was 
considered significant.  
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5. Results 
5.1. Investigation of the 5-LO inhibitory effect of PA derivatives and 2-(phenylthio)hexanoic 
acid derivatives 
5.1.1. SARs of PA derivatives 
Inhibition of 5-LO product formation was first investigated in a cell-based assay with intact 
PMNL. Cells were preincubated with test compounds or vehicle for 15 min at 37 °C and then 
stimulated with 2.5 µM ionophore A23187 in presence of 20 µM AA (to circumvent substrate 
supply by cPLA2). As shown in Table 1, PA (10 µM) itself did not suppress 5-LO product 
formation whereas esterification of the carboxylic acid (1) led to a weak inhibitory effect. 
Replacement of the o-dimethylaniline moiety of PA by 6-aminoquinoline (2, 3) was beneficial 
but only for the esterified form (3) (see also [242]). Exchange of nitrogen by oxygen as bridging 
atom (4, 5) almost abolished the influence on 5-LO product formation, but insertion of an 
additional methylene bridge restored the inhibitory potency (6). Interestingly, substitution of o-
dimethylaniline by 2,3-dihydro-indene (7, 8) led to IC50 values between 3 and 4 µM for the ester 
as well as for the free acid. It was previously shown that introduction of alkyl residues in α-
position of the carboxylic group of PA increased the potency at PPARα/γ [239]. A similar effect 
was evident for 5-LO inhibition. Thus, the α-methyl substituted compound 10 was able to reduce 
5-LO product synthesis much more efficiently than compound 1 but again the acidic form was 
inactive. The α-methyl substituted ester carrying a 6-aminoquinoline moiety instead of the o-
dimethylaniline (12) was equipotent with its unsubstituted form, whereas insertion of n-butyl- or 
n-hexyl-substituents increased the potency leading to IC50 values of 1.1 µM (16) and 0.6 µM 
(25), respectively. Of interest, with n-alkyl chains longer than methyl (11), the free acids (15, 24) 
became active as well. This effect was also observed for dimethyl (13), n-hexyl (22) and n-octyl 
(44) (but not n-butyl, 14) substituted PA (see also [243]). 
In addition, further exchanges of the o-dimethylaniline residue of α-alkyl substituted PA were 
performed. Introduction of 3-pyridylethylamine (17, 18) was detrimental compared to 6-
aminoquinoline (15, 16) at the n-butyl-substituted compound. Exchange of the o-dimethylaniline 
of the n-hexyl substituted 22 or its ester 23 by phenethylamine (19) or phenoxyethylamine (20, 
21) failed to increase the potency on 5-LO as well. In contrast, esterified compounds with 
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quinoline residues (27 and 29) were highly active (IC50 = 1.7 and 1.4 µM, respectively), 
regardless of the exact linkage to the pyrimidine ring. The corresponding acids (26, 28) were 
significantly less potent whereas the opposite effect was observed when quinoline was replaced 
by other aromatic residues. The 3,5-bis(2,2,2-trifluoroethoxy)-aniline-substituted derivative 30, 
for example, inhibited cellular 5-LO product formation by 50% at 1 µM while its esterified 
analog 31 was essentially inactive. Along these lines, insertion of 4-(4-chlorophenyl)thiazol-2-
ylamine (32, 33) or 4-(phenylamino)phenylamine (34, 35) yielded 5-LO inhibitors that act in 
nanomolar concentrations, but only in their acidic form (32, 34). In contrast, an IC50 of 4.4 µM 
was found for compound 36 possessing a 2-(trifluormethyl)-1H-benzo[d]imidazol-5-ylamino 
residue.  Replacement of the o-dimethylaniline by biphenylamine moieties led to a series of very 
potent derivatives. The free acids of compounds with a biphenyl-4-yl-methane amine (37), a 
biphenyl-4-yl-amine (39) or a biphenyl-3-yl-amine (43) residue but not their corresponding esters 
(38, 40) showed IC50 values below 1 µM, and substitutions at the biphenylic residue were 
tolerated as well. Thus, a cyano group in para position of the biphenyl (41) even increased the 
potency to inhibit 5-LO with an IC50 of 0.4 µM. For this compound, the influence of the stereo 
center in α-position of the carboxylic group was determined. Both enantiomeric forms (separated 
by preparative enantioselective HPLC) inhibited 5-LO product synthesis, but the R-form (41a) 
was slightly superior over the S-configurated form (41b) (IC50 = 0.15 versus 0.7 µM). 5-
methoxy-2-methyl-substitution at the biphenyl residue (42) yielded an IC50 of 0.5 µM. 
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Table 1: Inhibition of 5-LO product formation by α-alkyl substituted PA derivatives  
 
 
 
compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
                R1                     R2             R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL              purif.     
                           5-LO 
PA            
(WY-
14,643) 
CH3
CH3 N
H
 
-Cl -H -H n.i.a,b n.i.b 
1  
CH3
CH3 N
H
 
-Cl -H -C2H5 77.7 %       
(± 0.8)  
n.d. 
2  N
N
H
 
-Cl -H -H n.i. b n.d. 
3 N
N
H
 
-Cl -H -C2H5 5.6 
 
n.d. 
4 N
O
 
-Cl -H -H n.i. b n.d. 
5 N
O
 
-Cl -H -C2H5 77.6 %  
(± 5.8)b 
n.d. 
6 O
N
 
-Cl -H -C2H5 4.5 n.d. 
7 
N
H
 
-Cl -H -H 3.9 b 0.8 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL              purif.     
                           5-LO 
8 
N
H
 
-Cl -H -C2H5 3.2 b 81.4 % 
(± 6.0) 
9 
CH3
CH3 N
H
 
-Cl -CH3 -H n.i. b n.d. 
10 
CH3
CH3 N
H
 
-Cl -CH3 -C2H5 22.8 % 
(± 3.3) b 
n.d. 
11 N
N
H
 
-Cl -CH3 -H n.i. b n.d. 
12 N
N
H
 
-Cl -CH3 -C2H5 12.0 % 
(± 3.6)b 
n.d. 
13 
CH3
CH3 N
H
 
-Cl -(CH3)2 -H 83.8 % 
(± 7.4)b 
n.i.b 
14 
CH3
CH3 N
H
 
-Cl CH3
 
-H n.i.b n.d. 
15 N
N
H
 
-Cl CH3
 
-H 10.0b n.d. 
16 N
N
H
 
-Cl CH3
 
-C2H5 1.1 b n.d. 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL             purif.     
                          5-LO 
17 N
N
H
 
-Cl CH3
 
-H 81.7 % 
(± 3.7) 
57.3 % 
(± 3.5) 
18 N
N
H
 
-Cl CH3
 
-C2H5 51.7 % 
(± 6.4)        
n.i. 
19 
N
H
 
-Cl CH3
 
-H 3.0 n.i. 
20 N
H
O
 
-Cl CH3
 
-H 4.5 
 
53.7 % 
(± 7.1) 
21 N
H
O
 
-Cl CH3
 
-C2H5 7 
 
55.0 % 
(± 9.7) 
22 
CH3
CH3 N
H
 
-Cl CH3
 
-H 4.1 b 7.0 
23 
CH3
CH3 N
H
 
-Cl CH3
 
-C2H5 7.0 n.d. 
24 N
N
H
 
-Cl CH3
 
-H 20.1 % 
(± 1.9) b  
53.0 % 
(± 5.6) 
25 N
N
H
 
-Cl CH3
 
-C2H5 0.6 b 90.6 % 
(± 4.2) 
26 N
O
 
-Cl CH3
 
-H 5.8 n.d. 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL              purif.     
                           5-LO 
27 N
O
 
-Cl CH3
 
-C2H5 1.7 b n.d. 
28 N
H
N
 
-Cl CH3
 
-H 7.0 69.1 % 
(± 0.7) 
29 N
H
N
 
-Cl CH3
 
-C2H5 1.4b n.i. 
30 
N
H
O
O
CF3
CF3
 
-Cl CH3
 
-H 1.0 b 1.9 
31 
N
H
O
O
CF3
CF3
 
-Cl CH3
 
-C2H5 n.i. b n.d. 
32 
N
S
N
HCl
 
-Cl CH3
 
-H 0.6 
 
2.7        
33 
N
S
N
HCl
 
-Cl CH3
 
-C2H5 92.3 % 
(± 6.0) 
88.6 % 
(± 14.7) 
34 
N
H
N
H
 
-Cl CH3
 
-H 0.26     1.6 
35 
N
H
N
H
 
-Cl CH3
 
-C2H5 52.4 % 
(± 12.4) 
51.2 % 
(± 15.7)  
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL             purif.     
                          5-LO 
36 
 
H
N
H
N
F3C
N
 
-Cl CH3
 
-H 4.4  65.9 % 
(± 11.8) 
37 
N
H
 
-Cl CH3
 
-H 0.9 2.1 
38 
N
H
 
-Cl CH3
 
-C2H5 80.2 % 
(± 9.9) 
79.0 % 
(± 10.1) 
39 
N
H
 
-Cl CH3
 
-H 0.7 1.5 
40 
N
H
 
-Cl CH3
 
-C2H5 91.2 % 
(± 4.3) 
79.9 % 
(± 12.0) 
41 
N
H
NC
 
-Cl CH3
 
-H 0.4 2 
41a 
N
H
NC
 
-Cl CH3
 
-H 0.15 1.0 
41b 
N
H
NC
 
-Cl CH3
 
-H 0.7 1.8 
42 
 
N
H
O
CH3
 
-Cl CH3
 
-H 0.5 1.5 
43 
N
H
 
-Cl CH3
 
-H 0.6     2.0 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
  PMNL             purif.     
                          5-LO 
44 
CH3
CH3 N
H
 
-Cl CH3
 
-H 1.1 93.2 %  
(± 9.8) 
n.i. = no inhibition; n.d. = not determined; S.E. = standard error 
bdata was performed in the lab of Prof. Dr. D. Steinhilber (University of Frankfurt, Germany) 
 
Another synthetic approach was the introduction of phenyl moieties in α-position instead of n-
alkyl groups (Table 2). While the esters of α-phenyl-substituted PA (46) and the corresponding 
6-aminoquinoline derivative (48) potently suppressed 5-LO product formation, the respective 
acids (45 and 47) were ineffective. Compounds with a phenethylamine residue also showed a 
better inhibition when the carboxylic group was esterified (50 versus 49). The α-phenyl-
substituted 3,5-bis(2,2,2-trifluoroethoxy)-aniline derivative (51) was slightly more potent than the 
corresponding n-hexyl-substituted form (30). Remarkably, the corresponding ester (52) showed a 
similar efficacy in this case. Insertion of a biphenyl-4-methane amine moiety at the pyrimidine 
core together with α-phenyl-substitution (52) led to an IC50 of 1.8 µM versus 0.9 µM for the 
compound with the hexyl chain in α-position (37). Furthermore, 4′-cyano-biphenyl-4-yl-oxy (55) 
as well as 3′-cyanobiphenyl-4-yl-oxy (57) residues were tolerated with only a slight loss of the 
potency (IC50 between 2 and 3 µM). It has to be emphasized that for biphenylic compounds with 
α-phenyl residues, the esters were less potent than the free acids as it was found for derivatives 
with α-alkyl substituents. 
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Table 2: Inhibition of 5-LO product formation by α-phenyl substituted PA derivatives  
 
 
 
compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
45 
CH3
CH3 N
H
 
-Cl 
 
-H n.i. b n.d. 
46 
CH3
CH3 N
H
 
-Cl 
 
-C2H5 1.8 b 
 
n.i. 
47 N
N
H
 
-Cl 
 
-H 69.1 % 
(± 8.9) b 
n.d. 
48 N
N
H
 
-Cl 
 
-C2H5 1.2 b 93.0 % 
(± 10.4) 
49 
N
H
 
-Cl 
 
-H 64.5 %  
(± 16.4) 
77.1 % 
(± 5.6) 
 
50 
N
H
 
-Cl 
 
-C2H5 6.0 83.8 % 
(± 12.3) 
 
51 
N
H
O
O
CF3
CF3
 
-Cl 
 
-H 0.7 
        
6.5 
52 
N
H
O
O
CF3
CF3
 
-Cl 
 
-C2H5 0.5 76.1 % 
(± 5.5) 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
53 
N
H
 
-Cl 
 
-H 
 
1.8 7.3 % 
(± 1.4)  
54 
N
H
 
-Cl 
 
-C2H5 56.1 % 
(± 7.8) 
77.3 % 
(± 9.3) 
55 
ONC
 
-Cl 
 
-H 
 
2.9 9.5 
56 
ONC
 
-Cl 
 
-C2H5 88.2 % 
(± 8.5) 
88.8 % 
(± 6.7) 
57 
O
NC
 
-Cl 
 
-H 
 
2.1 64.8 % 
(± 16.2) 
58 
O
NC
 
-Cl 
 
-C2H5 89.5 % 
(± 19.6) 
n.i. 
n.i. = no inhibition; n.d. = not determined; S.E. = standard error 
bdata was performed in the lab of Prof. Dr. D. Steinhilber (University of Frankfurt, Germany) 
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In the next step, a series of PA derivatives with α-naphthyl residues was synthesized and 
subjected to SAR evaluations (Table 3, see also [260]). IC50 values around 2.5 µM were obtained 
when the o-dimethylaniline moiety of PA was replaced by n-butylamine (59), isopentylamine 
(60) or phenethylamine (61). Prolongation of phenethylamine to phenylpropylamine (62) slightly 
increased the inhibitory effect on 5-LO product formation (IC50 = 1.8 µM). α-Naphthyl 
substituted PA possessed an IC50 value of only 5 µM but interestingly, exchange to a 3,4-
dimethylaniline-residue (64) lowered the IC50 to 0.7 µM. Bulkier substituents like 4-
isopropylphenylamine (65) or 3,5-di-tert-butylphenylamine (66) even enhanced the efficacy 
against 5-LO (IC50 = 0.26 µM for both compounds). Upon insertion of chloride in para- or meta-
position of the phenylamine residue (67, 68), the IC50 was still below 1 µM, whereas fluoride was 
less tolerated (69). Compound 70 possesses a 4-benzamidophenylamine group and still blocks 5-
LO with a high efficacy (IC50 = 0.6 µM). A biphenyl-4-yl-methane amine at the pyrimidine (71) 
was as active as the corresponding α-hexyl derivative. Deletion of the methylene bridge yielded 
72 that was even more potent than the α-hexyl-substituted 39. With an IC50 of 100 nM, this 
compound represented the most active PA derivative tested so far (equipotent with BWA4C in 
the cellular 5-LO assay). Repositioning of the biphenyl into biphenyl-3-yl-amine (73) as well as 
bridging of the two rings of the biphenyl (74) impaired the potency (IC50 = 0.5 µM and 0.24 µM, 
respectively). The α-naphthyl analog of 41, namely 75, with a cyano group in para-position of the 
biphenyl moiety suppressed 5-LO almost as good as 72 (IC50 = 0.17 µM). In addition, several 
other compounds with different aromatic moieties were tested in this assay. Thus, 
cyclohexylphenylamine (76), phenoxyphenylamine (77) and benzylphenylamine (78) reduced 5-
LO product formation to 50% in concentrations below 0.5 µM. Also compounds with 2,3-
dihydro-1H-inden-5-yl-amine (79) and naphthalene-2-yl-amine (80) did not forfeit their capacity 
to decrease 5-LO product synthesis. Exchange of naphthylamine to 6-aminoquinoline (81) was 
unfavorable. However, based on the structure of 24, naphthyl-substitution in α-position of the 
carboxylic group (81) was advantageous compared to hexyl- or phenyl-residues. Finally, an IC50 
of 0.4 µM was determined for the α-4-phenylnaphthalen-1-yl substituted derivative of PA (82).  
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Table 3: Inhibition of 5-LO product formation by α-naphthyl substituted PA derivatives  
 
 
 
compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
59 
 
N
H
 
-Cl 
 
-H 2.4 70.6  % 
(± 15.2) 
60 
 
N
H
 
-Cl 
 
-H 2.5 54.8 % 
(± 8.2)     
61 
 
N
H
 
-Cl 
 
-H 2.5 44.2 % 
(± 12.3) 
62 
N
H
 
-Cl 
 
-H 1.8 68.9 %     
(± 3.5) 
63 
CH3
CH3 N
H
 
-Cl 
 
-H 5.0b n.d. 
64 
CH3
CH3
N
H
 
-Cl 
 
-H 0.7 
 
8.5 
 
65 
N
H
 
-Cl 
 
-H 0.26 
 
5.8 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
66 
N
H
 
-Cl 
 
-H 0.26 
 
1.9 
 
67 
N
H
Cl
 
-Cl 
 
-H 0.8 
 
8.9 
 
68 
N
H
Cl
 
-Cl 
 
-H 0.7 
 
5.0 
 
69 
N
H
F
 
-Cl 
 
-H 3.1 67.3  %    
(± 2.9)     
70 
N
H
N
H
O
 
-Cl 
 
-H 0.6 
 
5.2 
 
71 N
H
 
-Cl 
 
-H 0.7 
 
3.0 
 
72 
N
H
 
-Cl 
 
-H 0.1 
 
2.3 
 
73 
N
H
 
-Cl 
 
-H 0.5 
 
5.0 
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
74 
N
H
 
-Cl 
 
-H 0.24 
 
1.6 
 
75 
N
H
NC
 
-Cl 
 
-H 0.17 
 
2.3 
 
76 
N
H
 
-Cl 
 
-H 0.4 
 
2.0 
 
77 
N
H
O
 
-Cl 
 
-H 0.4 3.1 
 
78 
N
H
 
-Cl 
 
-H 0.3 2.2 
79 
N
H
 
-Cl 
 
-H 0.5 4.2 
80 
N
H
 
-Cl 
 
-H 0.5 2.9 
81 N
N
H
 
-Cl 
 
-H 4.4 19.0 % 
(± 2.5)    
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compound 
                        
N
N S
O
O
R4
R2
R1
R3
                               
              
               R1                      R2            R3                  R4 
5-LO product formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
 PMNL              purif.     
                          5-LO 
82 
CH3
CH3 N
H
 
-Cl 
 
-H 0.4 2.2 
n.i. = no inhibition; n.d. = not determined; S.E. = standard error 
bdata was performed in the lab of Prof. Dr. D. Steinhilber (University of Frankfurt, Germany) 
 
Inhibition of LT synthesis in cellular assays can occur due to direct 5-LO inhibition but also as 
the result of FLAP or cPLA2 inhibition, interference with MAPKs or Ca2+ release or suppressed 
5-LO translocation to the nuclear membrane [200]. To investigate if 5-LO is directly affected by 
PA derivatives, a cell-free assay was performed with human recombinant 5-LO that was partially 
purified from E. coli lysates. Notably, none of the esterified compounds was able to suppress 
isolated 5-LO effectively. Thus, 21 and 35 were the only active esters with IC50 values of 
approximately 10 µM. The acidic PA derivatives emerged as direct 5-LO inhibitors although they 
were about 2- to 10-fold less efficient in cell-free assays than in PMNL. For the majority of the 
free acids, the IC50 values at partially purified 5-LO were determined between 1 and 10 µM with 
7 as the most active compound (IC50 = 0.8 µM). 
Taken together, replacement of the o-dimethylaniline of PA by bulky lipophilic substituents 
(especially biphenylic residues) together with introduction of a hexyl chain or a naphthyl moiety 
in α-position yielded potent 5-LO inhibitors with IC50 values in the nanomolar range. 
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Precedent SARs of PA derivatives included exchanges of the o-dimethylaniline moiety and 
insertion of lipophilic residues in α-position of the carboxylic group of PA. In order to further 
expand the SARs, derivatives containing two phenethoxy residues at the pyrimidine core 
(exemplified by 2-(bis-(phenethoxy)-pyrimidine-2-ylthio)-hexananoic acid, 87) were synthesized 
and emerged as very potent 5-LO inhibitors [261] (Table 4). Therefore, a novel series of 
compounds with broad variations of i) the two residues at the pyrimidine and ii) of the length of 
the alkylic chain in α-position was set up based on 87. Due to the poor efficacy of the ester of 87 
(i.e. 88), the carboxylic acid group was kept for all the other compounds. The R-form of 87a 
possesses only a slightly lower IC50 value (0.8 µM versus 1.3 µM for the S-form 87b) so that the 
absolute configuration seems not to be essential for the inhibitory effect.  
Since the lipophilic chain in α-position of the carboxylic acid was a crucial factor for the potency 
of PA derivatives (as shown in chapter in 5.1.1.), its importance for bis-phenethoxy-substituted 
compounds was evaluated as well. As expected, the unsubstituted compound 83 and the ethyl-
substituted compound 85 (IC50 = 7.6 and 2.8 µM, respectively) were inferior to compound 87, 
whereas introduction of α-hexyl (86) and α-phenyl (84) did not impair 5-LO inhibition (IC50 = 
0.4 and 0.8 µM, respectively). 
In the next step, the two phenethoxy moieties were subjected to shortening or elongation of their 
ethylene-spacers. While phenylmethoxy residues (89) were detrimental, insertion of propylene 
(90) or butylene (91) spacers retained efficacy of the derivatives. α-Butyl-substitution was kept 
constant for further variations at the lipophilic backbone because of a better solubility and a lower 
molecular weight compared to hexyl or phenyl-substituted compounds. 
Further optimization of 87 could be reached by insertion of different substituents in para-position 
of both phenethoxy moieties. Thus, electron pushing (methyl (92), methoxy (93)) as well as 
electron drawing (trifluormethyl (94), trifluormethoxy (95), nitro (96), cyano (97)) groups were 
beneficial with IC50 values between 0.3 (93) and 0.7 µM (97). Additionally, replacement of both 
phenyl groups by bioisosteric thiophenes (98) resulted in a comparable potency (IC50 = 0.6 µM). 
Moreover, the necessity for aromatic moieties at the lipophilic backbone was investigated. 
Introduction of isopropyl (99) or cyclopropyl (100) residues instead of the phenyl groups of 87 
lead to a slightly decreased effect on 5-LO (IC50 = 1.2 µM for both of them). Enlargement of the 
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aliphatic ring size to cyclopentyl (101) or cycloheptyl (103) was detrimental whereas cyclohexyl 
(102) possesses almost the same potency as 87. 
 
Table 4: Inhibition of 5-LO product formation by PA derivatives with two phenylalkyloxy or 
alkyloxy residues: 
 
 
 
comp. 
                        
N
N S
O
O
R4
R2
R1
R3
                                                            
              
               R1                                R2                         R3                R4 
5-LO product 
formation 
IC50 [µM] 
or remaining 
activity (± S.E.) 
at 10 µM 
PMNL      purif.     
                 5-LO 
83 
O
 
O
 
-H -H 7.6 57.0 % 
(± 9.6) 
84 
O
 
O
 
 
-H 0.8 4.9 
85 
O
 
O
 
CH3
 
-H 2.8 9.0 
86 
O
 
O
 
CH3
 
-H 0.4    2.8 
87 
O
 
O
 
CH3
 
-H 0.6 4.7 
87a 
O
 
O
 
CH3
 
-H 0.8 8.0 
  
5 Results  76 
 
 
 
 
comp. 
                        
N
N S
O
O
R4
R2
R1
R3
                                                 
              
               R1                                R2                         R3                R4 
5-LO product 
formation 
IC50 [µM] 
or remaining 
activity (± S.E.) 
at 10 µM 
PMNL      purif.     
                 5-LO 
87b 
O
 
O
 
CH3
 
-H 1.3 7.5 
88 
O
 
O
 
CH3
 
-C2H5 80.1 % 
(± 9.1) 
91.7 % 
(± 12.4) 
89 O
 
O
 
CH3
 
-H 1.8 5.0 
90 O
 
O
 
CH3
 
-H 0.9 2.7 
91 
O
 
O
 
CH3
 
-H 0.7 2.2 
92 
 
O
CH3
  
O
CH3
 
CH3
 
-H 0.5 3.1 
93 
O
O
CH3
 
O
O
CH3
 
CH3
 
-H 0.3 7.0 
94 
O
F3C
 
O
F3C
 
CH3
 
-H 0.5    2.2 
95 
O
O
F3C
 
O
O
F3C
 
CH3
 
-H 0.5 56.4 % 
(± 13.3) 
96 
O
O2N
 
O
O2N
 
CH3
 
-H 0.5    2.8 
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comp. 
                        
N
N S
O
O
R4
R2
R1
R3
                                                            
              
                R1                                R2                         R3                R4 
5-LO product 
formation 
IC50 [µM] 
or remaining 
activity (± S.E.) 
at 10 µM 
PMNL      purif.     
                 5-LO 
97 
O
NC
 
O
NC
 
CH3
 
-H 0.7 6.6 
98 
S
O
 
S
O
 
CH3
 
-H 0.6 9.3 
99 
OCH3
CH3
 
OCH3
CH3
 
CH3
 
-H 1.2 8.8          
100 
O
 
O
 
CH3
 
-H 1.2 9.9 
101 
O
 
O
 
CH3
 
-H 4.0 6.8 
102 
O
 
O
 
CH3
 
-H 0.8 9.0 
103 
O
 
O
 
CH3
 
-H 2.4 53.8 %  
(± 11.0)   
S.E. = standard error 
Next, SARs regarding the importance of the two proton-accepting nitrogens within the 
pyrimidine ring was investigated (Table 5). Therefore, pyrimidine was first replaced by a 
benzene moiety (104). Neither this variation nor additional exchange of the thioether by an ether 
(105) abrogated 5-LO inhibition (IC50 = 0.8 and 0.6 µM). Elimination of the heteroatom between 
the benzene scaffold and the carboxylic moiety (106), in contrast, reduced the activity of the 
compounds (IC50 = 5.0 µM). Shifting of the phenethoxy moieties to 3,4- (107) or 2,3- (108) 
positions led to similar inhibitory effects but an IC50 of 0.9 µM was measured for the 2,5-bis-
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phenethoxy substituted compound (110). 2,4-substitution (109), in contrast, resulted in a 
complete loss of function. Moreover, neither exchange of one nor of both phenylethoxy moieties 
of 106 to cyclohexylethoxy groups (111, 112 and 113) led to IC50 values below 5 µM. Notably, 
introduction of a double bond linking the carboxylic group with the lipophilic backbone restored 
5-LO suppression with an IC50 of 0.7 µM for the bis-phenethoxy substituted compound 114. It 
was possible to maintain the potent inhibitory effect if the two phenethoxy moieties were 
rearranged from 3,5- to 2,5- (115) or 2,3- (116) positions and also a 2,5-bis-(2-cyclohexylethoxy) 
substituted derivative (117) was active. The inhibitory potency was even increased upon 
introduction of trifluormethyl groups in para-position of both phenethoxy moieties (118; IC50 = 
0.3 µM). Finally, the ethylene spacers of 118 could be shortened to methylene without a loss of 
efficacy (119) and also exchange of one of the ((4-trifluormethyl)-benzyl)-oxy residues against a 
2-cyclohexylethoxy moiety only slightly reduced the 5-LO inhibitory effect. 
In analogy to the PA derivatives in Tables 1-4, also the compounds presented in this section were 
2-10 fold less efficient to inhibit purified 5-LO, and the pyrimidine core seems to be important 
for a direct inhibitory effect on the enzyme. 
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Table 5:  
 
 
 
 
comp. 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                      5-LO 
104 
S
O
O
O
H
O
 
0.8 7.2 
105 
O
O
O
O
O
H
 
0.6 60.0 %      
(± 15.0)      
 
106 
O
O
O
OH
 
5.0  80.3 %       
(± 13.5)        
107 
O
O
OH
O
 
6.4 54.0 %      
(± 5.7) 
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comp. 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                      5-LO 
 
 
 
108 
O
OH
O
O
 
2.7 6.8        
 
 
 
109 
O
OH
O
O
 
n.i. 85.6 %      
(± 4.4)       
110 
O
OH
O
O
 
 
0.9 65.5 %      
(± 9.9) 
 
 
 
111 
O
O
OH
O
 
5.2 52.4 %      
(± 3.1)    
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comp. 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                      5-LO 
 
 
 
112 
O
O
O
O
H
 
5.4 65.0 %      
(± 14.8)       
 
113 
O
O
OH
O
 
5.4 68.3 %      
(± 9.1)       
114 
O
OH
O
O
 
0.7 62.7 %      
(± 17.6)      
115 
O
OO
O
H
 
0.9 78.2 %      
(± 9.4)   
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comp. 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                      5-LO 
116 
O
OO
O
H
 
0.8 91.3 %      
(± 10.5)       
 
 
 
 
 
117 
O
OH
OO
 
0.8a 6.0 
 
 
 
 
118 
F3C
F3C
O
OH
OO
 
0.3a 55.6 %  
(± 2.7) 
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comp. 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                      5-LO 
 
 
 
 
 
119 
O
OH
OO
CF3
CF3
 
0.25a 73.0 %   
(± 10.6) 
 
 
 
 
 
120 
O
OH
OO
CF3
 
0.4a 55.5 %   
(± 7.9) 
aData was performed by B. Jazzar or S. Luderer in the lab of Prof. Dr. O. Werz (University of Tuebingen). 
S.E. = standard error 
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5.1.2. 2-(Phenylthio)hexanoic acid derivatives and analogs as 5-LO inhibitors 
In order to further develop potent PPAR agonists structurally different from PA, our 
collaborating group of Prof. Dr. M. Schubert-Zsilavecz synthesized a series of 2-
(phenylthio)hexanoic acid derivatives that were expected to be active on 5-LO as well. In brief, 
the beneficial 2-mercapto-hexanoic acid part of PA derivatives was linked to a phenolic 
backbone, etherified with a phenoxypropyl moiety. A variety of substituents were introduced at 
the terminal phenyl group to reveal SARs at this site of the molecule [244] (Table 6). Thus, an 
ortho-xylene moiety (122) increased the inhibitory effect on 5-LO 3-fold compared to the 
unsubstituted compound (121). No clear preference for one of the enantiomers of 122 could be 
detected. The remaining 5-LO activity obtained in presence of 123 shows that upon removal of 
the alkyl chain in α-position of the carboxylic group, the inhibitory effect on 5-LO product 
formation was attenuated. Insertion of a 2-methylphenyl- (124), 3-methylphenyl- (125) or 4-
methylphenyl residue (125) led to slightly increased IC50 values between 4.8 µM and 5 µM. The 
same potency was obtained for the 3-methoxyphenyl substituted derivative (128) whereas 
introduction of a 2-methoxyphenyl- (127) or a 2-methoxy-4-chlorophenyl moiety (129) was 
detrimental. In contrast, bulky lipophilic substituents at the terminal phenyl group such as 
isopropyl (130 and 131), trifluormethyl (132) or 3-triflourmethyl-4-chlorophenyl (133) were 
helpful for 5-LO suppression (IC50 = 1.4-1.6 µM). Replacement of the phenyl by tetraline (134) 
was beneficial as well, but as observed for PA derivatives, the compound became inactive upon 
esterification. Similarly to their quality as substituents at PA, biphenylic (136) and quinoline 
(139) moieties led to highly potent inhibition of 5-LO product synthesis by the respective 
thiophenols. Again, it was found that biphenylic compounds were more effective in their acidic 
form and compounds with a quinoline residue turned out to inhibit cellular 5-LO product 
formation more efficiently than 5-LO in cell-free assays. Finally, exchange of the sulfur against 
carbon (141) or introduction of a double bond at this position (142) was tolerated without loss of 
activity as long as the α-butyl moiety was kept in the molecule.  
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Table 6 inhibition of 5-LO product formation by 2-(phenylthio)hexanoic acid derivatives: 
 
 
 
 
comp. 
 
 
 
 
 
  
 
X                R1                        R2                   R3 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                     5-LO 
121 
S CH3
 
 
-H  9.5 69.4 %     
(± 4.8) 
 
122 
S CH3
 CH3
CH3
 
-H 3.0 8.8 
 
122a 
S  
CH3
 
CH3
CH3
 
-H 1.1 10.0 
 
122b 
S  
CH3
 
CH3
CH3
 
-H 2.0 8.2 
 
123 
S -H 
CH3
CH3
 
-H 69.9 %     
(± 9.8) 
72.4 %     
(± 4.0) 
 
124 
S CH3
 
CH3
 
-H 4.8 58.3 %     
(± 6.8) 
 
125 
S CH3
 
CH3
 
-H 4.8 79.3 %     
(± 10.6) 
 
126 
S CH3
 
CH3
 
-H 5.0 
 
67.6 %     
(± 11.7) 
X
O
O
R1
OO
R2
R3
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comp. 
 
 
 
 
 
  
 
X                R1                        R2                   R3 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                     5-LO 
 
127 
S CH3
 
OMe
 
-H 57.4 %   
(± 11.9) 
79.4 % 
(± 6.4) 
 
128 
S CH3
 
OMe
 
-H 4.8 67.7 % 
(± 5.8) 
 
129 
S CH3
 
 
Cl OMe
 
-H 79.3 %     
(± 14.0) 
59.2 %     
(± 7.4) 
 
130 
S CH3
 
CH3
CH3
 
-H 1.6 7.8 
 
131 
S CH3
 
CH3CH3
 
-H 1.4 6.0 
 
132 
S CH3
 
CF3
 
-H 1.6 10.0 
 
133 
S CH3
 
CF3
Cl
 
-H 1.5 2.0 
X
O
O
R1
OO
R2
R3
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comp. 
 
 
 
 
 
  
 
X                R1                        R2                   R3 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                     5-LO 
 
134 
S CH3
 
 
-H 1.4 4.5 
 
135 
S CH3
 
 
-C2H5 87.4 %     
(± 2.8) 
79.4 %     
(± 28.4) 
 
136 
S CH3
 
 
-H 0.9 3.5 
 
137 
S CH3
 
 
-C2H5 91.5 %     
(± 0.9) 
83.0 %     
(± 38.7)  
 
138 
S CH3
 
N
 
-H 92.2 %     
(± 3.4)  
59.0 %     
(± 12.7) 
 
139 
S CH3
 
N
 
-C2H5 0.8 68.3 %     
(± 12.8) 
 
140 
C -H 
CH3
CH3
 
-H 80.0 %     
(± 2.0) 
81.8 %     
(± 14.4) 
 
141 
C CH3
 CH3
CH3
 
-H 2.0 70.8 %     
(± 5.0) 
X
O
O
R1
OO
R2
R3
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comp. 
 
 
 
 
 
structure 
5-LO product 
formation 
IC50 [µM] 
or remaining activity 
 (± S.E.) at 10 µM 
PMNL            purif.     
                     5-LO 
 
142 
            
OH
O
OO
 
1.6 88.9 %     
(± 2.7) 
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5.2. Biological evaluation of selected compounds as 5-LO inhibitors 
Strategies to inhibit cellular 5-LO product formation can be a direct inhibition of the enzyme but 
also, for example, interference with AA release or FLAP [200]. Direct 5-LO inhibitors are 
categorized into redox-active compounds, iron ligand inhibitors, nonredox-type inhibitors and a 
fourth class of compounds that are supposed to act in an allosteric manner [262]. As shown 
above, 5-LO inhibition by acidic PA derivatives and 2-(phenylthio)hexanoic acid derivatives was 
more efficient in intact cells than in cell-free assays. Moreover, the esterified compounds do not 
suppress 5-LO directly, but if they possess heteroaromatic (e.g. quinolines) or not too bulky 
moieties, they are able to impair cellular 5-LO product formation quite efficiently. To further 
investigate the underlying mechanism of the 5-LO inhibitory effect of the various types of PA 
derivatives, mechanistic studies were performed with four distinct representatives from our SAR 
investigations (Fig. 16). Thus, the molecular pharmacological profile of the compounds was 
evaluated in various cell-based and cell-free assays with special experimental settings. 
Since biphenylic PA derivatives showed a high efficacy on 5-LO, compound 39 as a very potent 
but simply structured molecule was chosen for biological characterization. Compound 25 served 
as a representative for the quinolinic PA derivatives that possess an increased potency upon 
esterification but do not inhibit isolated 5-LO. When cellular and cell-free assays are taken into 
account, the α-hexyl substituted 2-(bis-(phenethoxy)-pyrimidine-2-ylthio)-hexananoic acid 86 
showed the best inhibitory profile of its sub-group and was therefore included in the 
molecularpharmacological studies. The fourth compound 136 was the most potent direct 5-LO 
inhibitor among the 2-(phenylthio)hexanoic acid derivatives. 
 
  
 
 
 
 
Fig. 16. Compounds that were selected as 
representatives of sub-groups of PA 
derivatives for detailed biological 
evaluation. 
Cl
S
O
O
H
N
NN
H
39 
N
NN
Cl
S
O
OH
N
25 
S
O
O
O
O
N
N
H
86 
O
O
S
OO
H
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5.2.1. Inhibition of 5-LO product formation by the compounds in cell-based assays 
5.2.1.1. Selectivity of the compounds for 5-LO towards other LOs 
In order to assess the selectivity of the compounds for 5-LO compared to other LOs, suppression 
of product formation from 12/15-LO (15-LO-1), expressed in eosinophilic granulocytes, and 
from platelet-type-12-LO (present in PMNL-adherent platelets) was monitored. As shown in Fig. 
17, the amount of 15-H(p)ETE was not decreased upon treatment with 25, 39, 136 or the control 
inhibitor BWA4C, and only moderately reduced by compound 86 at 10 µM. 12-H(p)ETE 
formation was also rather increased by the compounds, whereas BWA4C caused a weak 
suppression of the 12-LO product. 5-HETE and LTB4 formation were efficiently blocked by all 
tested compounds. 
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Fig. 17. Influence of the 
compounds on 5-LO, 12-LO and 
15-LO product formation in 
ionophore A23187-stimulated 
PMNL. PMNL (5 × 106) were pre-
incubated with compounds for 15 
min at 37 °C. Then, 20 µM AA plus 
2.5 µM ionophore A23187 were 
added and the reaction was stopped 
after 10 min. The amounts of 15-
HETE, 12-HETE, 5-HETE and LTB4 
were determined by HPLC after 10 
min incubation at 37 °C. Data are 
means + S.E., n = 4. 
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5.2.1.2. Influence of the stimulus on 5-LO inhibition by the compounds 
It was demonstrated in previous studies that the potency of certain 5-LO inhibitors strongly 
depends on the applied stimulus used to evoke cellular 5-LO product synthesis [153],[154]. 
Stimulation of PMNL with the non-physiological ionophore A23187 leads to a strong Ca2+-influx 
into the cell, whereas fMLP (a more physiologically relevant stimulus) activates cellular 5-LO 
via GPCR signaling leading to elevated [Ca2+]i and phosphorylations of 5-LO [81]. The amount 
of 5-LO products in PMNL stimulated with fMLP is much lower than in cells activated with 
A23187 (< 1 ng/106 cells) [124]. Therefore, LTB4 formation under these assay conditions was 
determined by an EIA. Compound 25 (tested by Dr. C. Pergola in our group) and compound 39 
suppressed 5-LO product formation in PMNL stimulated with fMLP upon priming with LPS and 
Ada [144] with the same potency as upon ionophore A23187 stimulation (Fig. 18). In contrast, 
the IC50 values of 86 and 136 were slightly augmented upon stimulation of the cells with 
LPS/fMLP. 
Genotoxic or hyperosmotic cell stress leads to phosphorylation of 5-LO by p38 MAPK-
dependent MK-2 accompanied by an increase in LT biosynthesis. The efficacy of some 
nonredox-type 5-LO inhibitors (e.g. ZM 230487) is attenuated under these conditions [249]. 
When PMNL were exposed to 300 mM NaCl plus 40 µM AA, a decreased potency of all four 
test compounds was evident but curiously also for the iron-ligand inhibitor BWA4C (Fig. 19). 
However, this effect was less pronounced for BWA4C and 136 than for the other derivatives and 
the positive control ZM230487.  
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Fig. 18. 5-LO inhibition by the compounds in PMNL stimulated with LPS/fMLP. PMNL 
(5 × 106) were pre-incubated with compounds for 15 min at 37 °C, and 2.5 µM ionophore 
A23187 was added. LTB4 was determined by HPLC after 10 min incubation at 37 °C. 
Alternatively, PMNL (2 × 107) were primed with 1 µg/ml LPS and then stimulated with 1 µM 
fMLP to induce 5-LO product formation. After 5 min, the amount of released LTB4 was 
determined by EIA. Data are means + S.E., n = 4. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
samples that were stimulated with ionophore A23187 at corresponding concentrations of test 
compounds, ANOVA + Tukey post hoc test. 
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Fig. 19. Efficiency of the compounds under conditions that activate 5-LO by cell-stress. PMNL (5 × 
106) were pre-incubated with compounds for 15 min at 37 °C. NaCl (0.3 M) was supplemented 3 min 
before addition of 40 µM AA. Alternatively, cells were stimulated with 2.5 µM ionophore A23187 in 
presence of 40 µM AA. After 10 min at 37 °C, the reaction was stopped and 5-LO products were 
measured. Data are means + S.E., n = 4. *p < 0.05 vs. samples that were stimulated with ionophore 
A23187 at corresponding concentrations of test compounds, ANOVA + Tukey post hoc test. 
39 [µM]
0 0.3 1 3 10
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
(p
er
ce
n
ta
ge
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
A23187 
NaCl
*
25 [µM]
0 0.3 1 3 10
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
(p
er
ce
n
ta
ge
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120 A23187 
NaCl
*
86 [µM]
0 0.3 1 3 10
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
(p
er
ce
n
ta
ge
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120
A23187 
NaCl
136 [µM]
0 0.3 1 3 10
5-
LO
 
pr
o
du
ct
 
fo
rm
at
io
n
 
(pe
rc
en
ta
ge
 
o
f c
o
n
tr
o
l)
0
20
40
60
80
100
120 A23187 
NaCl
  
5 Results  95 
 
5.2.1.3. Influence of the AA concentration on cellular 5-LO inhibition by the compounds 
The substrate concentration is a critical parameter for 5-LO inhibition by so-called competitive 5-
LO inhibitors or by FLAP antagonists [165], [153]. Addition of 20 µM AA together with 
ionophore A23187 rather improved the efficiency of 25 and 39 in human PMNL as compared to 
their inhibitory effect upon application of ionophore A23187 alone (Fig. 20). Almost no 
discrepancy in the potency was observed for 86 and 136. However, a loss of activity of all four 
compounds occurred at AA concentrations ≥ 40 µM (which are not considered physiological). 
Suppression of 5-LO products by BWA4C was slightly reduced when 20 µM AA were added 
together with ionophore A23187 but was not further decreased with higher substrate 
concentrations (40 or 60 µM AA). Since addition of moderate AA concentrations does not 
abrogate the inhibitory effect of the compounds on 5-LO product formation, interference with 
FLAP seems rather unlikely. This is supported by the fact that equal IC50 values were obtained in 
PMNL from male and female donors (not shown), whereas FLAP inhibitors are more potent in 
female PMNL (Pergola et. al., unpublished data).  
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Fig. 20. Efficiency of compounds at 
varying AA concentrations.  PMNL 
(5 × 106) were pre-incubated with the 
compounds for 15 min at 37 °C, the 
indicated amounts of AA and 2.5 µM 
ionophore A23187 were added, and the 
reaction was stopped after 10 min to 
analyze 5-LO product formation. Data 
are means + S.E., n = 3. 
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5.2.1.4. Influence of the compounds on 5-LO translocation to the nuclear membrane 
Stimulation of PMNL from female donors leads to a redistribution of 5-LO from the cytosol to 
the nuclear membrane [144], and it was demonstrated that LT formation is efficiently blocked by 
several agents that inhibit 5-LO translocation such as FLAP inhibitors [165], hyperforin [210] or 
sulindac sulfide [215]. The effects of 25, 39, 86 and 136 on the subcellular localization of 5-LO 
were assessed by means of a crude cell fractionation using mild detergent lysis (0.1% NP-40) to 
separate the nuclear from the non-nuclear fraction. Interestingly, a concentration-dependent 5-LO 
accumulation at the nucleus was observed if PMNL from females were preincubated with any of 
the test compounds and subsequently stimulated with 2.5 µM ionophore A23187. In contrast, 
hyperforin (30 µM) prevented accumulation of 5-LO in the nuclear fraction as expected (Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Influence of the compounds on 5-LO translocation in PMNL stimulated with 
ionophore A23187 and separated into nuclear and non-nuclear fractions. Freshly isolated 
PMNL (3 × 107) were pre-incubated with the compounds or with vehicle (DMSO) for 15 min at 37 
°C. 2.5 µM ionophore A23187 was added to the samples as indicated, and cells were incubated for 
another 5 min at 37 °C. 5-LO was detected in nuclear and non-nuclear fractions by immunoblotting 
after subcellular fractionation using 0.1% NP-40. Similar results were obtained in two additional 
independent experiments. 
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Since 39 provoked the most prominent shift of 5-LO to the nucleus, this compound was chosen 
for further studies on 5-LO translocation. As Fig. 22 shows, increased amounts of nuclear 5-LO 
upon treatment with 39 were also found after priming of female PMNL with LPS (1 µg/ml) and 
Ada (0.3 U/ml) followed by stimulation with fMLP (1 µM). 
 
 
 
 
 
 
To evaluate if 39 itself is able to induce 5-LO translocation in resting female PMNL, cells were 
treated with the compound for 20 min at 37 °C in presence of Ada but without being exposed to 
another stimulus. Indeed, 39 caused a distinct increase of 5-LO in the nuclear fraction (Fig. 23). 
Notably, 40 the inactive ethyl ester of 39 had no influence on 5-LO distribution so that the acidic 
group seems to be important for perinuclear 5-LO redistribution. As expected, hyperforin did not 
provoke nuclear localization of 5-LO in unstimulated cells. 
 
 
 
 
 
 
 
Fig. 22. Influence of compound 39 on 5-LO 
translocation in PMNL stimulated with 
LPS/fMLP and divided into nuclear and non-
nuclear fractions. PMNL (3 × 107) were primed 
with LPS (1 µg/ml) and Ada (0.3 U/ml) followed 
by stimulation with fMLP (1 µM) for 5 min at 37 
°C. 5-LO was detected in nuclear and non-
nuclear fractions by immunoblotting after 
subcellular fractionation using 0.1% NP-40. 
Similar results were obtained in two additional 
independent experiments. 
Fig. 23. Influence of compound 39 on 5-LO 
translocation in resting PMNL. Freshly isolated 
PMNL (3 × 107) were incubated with 39 at the 
indicated concentrations, 40 (30 µM), hyperforin 
(30 µM) or vehicle (DMSO) in presence of 0.3 U 
Ada for 20 min at 37 °C. 5-LO was detected in 
nuclear and non-nuclear fractions by 
immunoblotting after subcellular fractionation using 
0.1% NP-40. Similar results were obtained in two 
additional independent experiments. 
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To investigate if 39 indeed targets 5-LO to a membrane structure (and not to the nucleosol), 
PMNL were completely disrupted by sonification after incubation with 39, and separated into a 
soluble and a membraneous fraction by 100,000×g centrifugation. 39 directs 5-LO to the 
membrane compartment, regardless whether or not ionophore A23187 is added as stimulus (Fig. 
24). Interestingly, hyperforin led to a strong accumulation of 5-LO in the membrane fraction. As 
this accumulation was not observed after cell fractionation with NP-40 one may assume that 
hyperforin redirects 5-LO from the nuclear membrane to the cellular membrane. 
 
 
 
 
 
 
 
 
Finally, indirect immunofluorescence (IF) studies were intended in order to investigate “in cell” 
localization of 5-LO after treatment with the compounds. In brief, PMNL (1.5 x 106, freshly 
isolated from buffy coats of female donors) treated with 39 (10 µM or 30 µM) for 15 min were 
spun on poly-lysine coated coverslips and subsequently stimulated with ionophore A23187. After 
fixation of the cells with methanol, subcellular localization of 5-LO can be detected with a Zeiss 
Axiovert 200 M microscope by use of an anti-5-LO antibody followed by application of a 
fluorescently labeled anti IgG against the first antibody. However, cells treated with 39 did no 
longer attach to the poly-lysine coated coverslips and could therefore not be analyzed by 
fluorescence microscopy. The ester of 39 (compound 40) as well as hyperforin, in contrast, had 
no influence on the affinity of the cells towards the coverslips, indicating that 39 with its acidic 
function is somehow able to interfere with cellular structures. 
Fig. 24. Influence of compound 39 on 5-LO translocation in PMNL; separation of cytosol and 
membranes. Freshly isolated PMNL (3 × 107) were treated as described in Fig. 21 or Fig. 23, 
respectively. Subcellular localization of 5-LO was determined by immunoblotting after sonication 
of the cells and preparation of soluble (S100) and membrane (P100) fractions by 100,000×g 
centrifugation. Similar results were obtained in two additional independent experiments.  
-
30
-
-
-
-
-
-
-
10
-
-
membranes
39 [µM]:
40 [µM]:
Hyperf. [µM]:
30
-
-
-
30
-
-
-
30
cytosol
-
-
-
-
-
-
10
-
-
30
-
-
-
-
30
+ A23187 - A23187
5-LO
  
5 Results  100 
 
5.2.2. Inhibition of 5-LO product formation by the compounds in cell-free assays 
5.2.2.1. Reversibility of the 5-LO inhibitory effect 
Most of the direct 5-LO inhibitors act in a reversible manner. Therefore, it was assessed whether 
inhibition of 5-LO product formation by the derivatives could be abrogated after dilution. 
Partially purified human recombinant 5-LO was pre-incubated with the indicated amounts of 39, 
86 and 136 (since 25 does not influence 5-LO directly, it was not considered in 5-LO assays with 
the partially purified enzyme). After 10-fold dilution with assay buffer and subsequent addition 
of 20 µM AA, 5-LO product formation was almost at the same level as after treatment with 39 or 
86 without precedent dilution (Fig. 25), whereas the inhibitory effect 136 could not be fully 
reversed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Wash out experiments. 5-LO (0.5 µg) was pre-incubated with the indicated amount of test 
compounds for 10 min at 4 °C. Then, one aliquot was diluted with assay buffer ten-fold, whereas the 
other one was not altered, and 20 µM AA plus 1 mM Ca2+ were added to start the reaction. For 
comparison, purified 5-LO was pre-incubated with the corresponding higher compound 
concentration for 10 min at 4 °C and then, 20 µM AA plus 1 mM Ca2+ were added (no dilution). All 
samples were incubated for 10 min at 37 °C, and 5-LO product formation was analyzed as described. 
Values are given as means + S.E., n = 3, **p < 0.01 vs. inhibition w/o dilution, ANOVA + 
Bonferroni post hoc test. 
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5.2.2.2. Redox activity of the compounds 
5-LO inhibitors of the redox-type attenuate 5-LO activity by reducing the active-site iron to the 
ferrous form so that the catalytic cycle of 5-LO is interrupted. To determine whether PA 
derivatives or 2-(phenylthio)hexanoic acid derivatives possess radical scavenging properties, the 
compounds were tested for their ability to reduce 1,1-diphenyl-2-picrylhydrazyl (DPPH). All four 
derivatives (applied in concentrations up to 100 µM) failed in this respect (Fig. 26), whereas the 
positive controls L-cysteine and ascorbic acid concentration-dependently reduced DPPH.  
 
 
 
 
 
 
 
5.2.2.3. Influence of the substrate concentration on cell-free 5-LO inhibition by the 
compounds 
To test if the compounds suppress 5-LO equally efficient at different substrate concentrations, the 
amount of AA in the cell-free assay was altered. Upon addition of 7.5 µM AA or less, the IC50 
values for 39 were determined at 7-8 µM, whereas a considerable shift in the efficacy was 
observed between 7.5 µM and 10 µM AA. Thus, substrate concentrations between 10 µM and 40 
µM even yielded IC50 values of 1.3-1.5 µM (Fig. 27). Only at 60 µM AA, 5-LO inhibition by 39 
was slightly impaired. Increments in the potency were also observed for 86 with the best 5-LO 
repression occurring at 20 or 30 µM AA, respectively. Finally, the inhibitory effect of 136 was 
enhanced with increasing substrate concentrations from 5-10-15-20-30 µM AA and moderately 
declined at 60 µM AA. In contrast to 39 and 86, compound 136 was not able to suppress 5-LO 
Fig. 26. Analysis of radical 
scavenging properties of 25, 
39, 86 and 136. The indicated 
concentrations of the 
derivatives were incubated with 
50 µM DPPH in EtOH for 30 
min at RT, shaking. Reduction 
of the absorbance at 520 nm 
was measured with a multiwell 
scanning spectrophotometer. 
Values are given as means + 
S.E., n = 3. [µM]
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product formation completely, regardless of the applied amount of AA. The control inhibitor 
BWA4C suppressed 5-LO with consistent IC50 values at 5, 10, 20 and 60 µM AA. 
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Fig. 27. Effect of the compounds on 5-LO product formation at different substrate 
concentrations. Partially purified human recombinant 5-LO (0.5 µg) expressed in E.coli was 
supplemented with 1 mM ATP and pre-incubated in 1 ml PBS buffer plus 1 mM EDTA with 
the compounds at the indicated concentrations or with vehicle (DMSO) for 5–10 min at 4 °C. 
Samples were pre-warmed at 37 °C for 30 sec, and 5-LO product formation was started by 
addition of 2 mM CaCl2 together with the indicated amount of AA. After another 10 min, 5-
LO product formation was determined. Values are given as mean + S.E., n ≥ 3. 
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5.2.2.4. Influence of the redox tone on 5-LO inhibition by PA derivatives and 2-
(phenylthio)hexanoic acid derivatives  
Most of the nonredox-type 5-LO inhibitors potently suppress LT formation in intact cells but fail 
in cell-free assays because they require reducing conditions [153]. Thus, an inhibitory effect of 
these substances on 5-LO product synthesis in homogenates from PMNL can only be attained 
upon addition of DTT (to reconstitute GPx activity). The efficacy of PA derivatives and 2-
(phenylthio)hexanoic acid derivatives to inhibit partially purified 5-LO was also less pronounced 
than in intact PMNL (as shown above) and clearly reduced in homogenates from PMNL or their 
corresponding 100,000×g supernatants (S100) with IC50 values ≥ 10 µM, Fig. 28. However, 
addition of 1 mM DTT to homogenates or S100 did not restore the potency of the compounds. 
The control inhibitor BWA4C blocked 5-LO products in broken cell fractions with the same 
efficiency as in intact PMNL, regardless of the redox-tone.  
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Fig. 28. Influence of DTT on the inhibition of 5-LO product formation by the compounds. 
Freshly isolated PMNL (5 × 106) were pre-incubated with compounds for 15 min at 37 °C. Then, 
20 µM AA plus 2.5 µM ionophore A23187 were added and 5-LO product formation was 
determined after 10 min. Homogenates or S100 (corresponding to 5 × 106 PMNL, each) were 
diluted with PBS/EDTA. After addition of 1 mM ATP, samples were pre-incubated with the 
compounds at the indicated concentrations or with DMSO as vehicle for 5–10 min at 4 °C. Then, 
samples were pre-warmed at 37 °C for 30 s, and 5-LO product formation was started by addition 
of 2 mM CaCl2 and 20 µM AA. After 10 min, 5-LO product formation was determined. Values 
are given as mean + S.E., n = 3 - 4.  
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In addition, elevation of the peroxide tone by inclusion of 1 µM 13(S)-HpODE in the cell-free 
assay did not affect the potency any of the compounds (Fig. 29). 
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Fig. 29. Influence of LOOHs on 5-LO inhibition by the compounds. Partially purified human 
recombinant 5-LO (0.5 µg) expressed in E.coli was supplemented with 1 mM ATP and pre-
incubated in 1 ml PBS buffer plus 1 mM EDTA with the compounds at the indicated 
concentrations or with vehicle (DMSO) for 5 – 10 min at 4 °C. Samples were pre-warmed at 37 °C 
for 30 sec, and 5-LO product formation was started by addition of 2 mM CaCl2 plus 20 µM AA in 
presence or absence of 13(S)-HpODE (1 µM). After another 10 min, 5-LO product formation was 
determined. Values are given as mean + S.E., n = 3, ANOVA + Tukey post hoc test. 
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5.2.2.5. Influence of cellular components on 5-LO inhibition by the compounds 
Interestingly, the potent 5-LO inhibition by 39, 86 and 136 was not only impaired in 
homogenates from PMNL but also in the 40,000×g (S40) supernatant from E. coli lysates 
compared to partially purified 5-LO. Fig. 30 shows that the IC50 values of 39 and 86 under these 
conditions were elevated about 5-fold, and for 136 this effect was even more pronounced (S40: 
80.6% remaining activity at 30 µM of 136). The efficacy of 25 in contrast, was increased if 
cellular components were present (S40: 43.8% remaining activity at 30 µM). Possibly, 25 is 
cleaved by esterases from E. coli resulting in a similar potency in S40 as its corresponding free 
acid 24 (52.7% remaining activity at 30 µM, not shown). Almost identical concentration-
response curves for purified 5-LO and S40 were obtained with the control inhibitor BWA4C. 
Consequently, it seems that cellular components somehow attenuate the inhibitory effect of 39, 
86 and especially of 136 on 5-LO.  
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Fig. 30. 5-LO inhibition in S40 supernatants 
from E. coli. Aliquots of S40 supernatants from 
E.coli lysates (corresponding to 4 ml E.coli 
culture) or 0.5 µg partially purified 5-LO were 
diluted with PBS/EDTA. After addition of 1 
mM ATP, samples were pre-incubated with the 
compounds at the indicated concentrations or 
with DMSO as vehicle for 5–10 min at 4 °C. 
Then, samples were pre-warmed at 37 °C for 30 
s, and 5-LO product formation was started by 
addition of 2 mM CaCl2 and 20 µM AA. After 
10 min, 5-LO product formation was 
determined. Values are given as mean + S.E., n 
≥ 3. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 
inhibition of partially purified 5-LO at 
corresponding concentrations of test 
compounds, ANOVA + Tukey post hoc test. 
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5.2.2.6. Effects of 5-LO modulatory factors on the efficiency of the compounds 
5-LO inhibition by PA derivatives and 2-(phenylthio)hexanoic acid derivatives might be 
compromised by factors that modulate 5-LO activity such as Ca2+-ions, phospholipids or 
membranes, glycerides and CLP (all apparently acting via the C2-like domain) [66]. All four 
derivatives comparably inhibited partially purified 5-LO in the presence or absence of Ca2+ (Fig. 
31), excluding a primary interference of the compounds with Ca2+-binding residues within the 
C2-like domain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31. Influence of Ca2+ on 5-LO inhibition 
by the compounds. Partially purified human 
recombinant 5-LO (0.5 µg) expressed in E.coli 
was supplemented with 1 mM ATP and pre-
incubated in 1 ml PBS buffer plus 1 mM 
EDTA with the compounds at the indicated 
concentrations or with vehicle (DMSO) for 5–
10 min at 4 °C. Samples were pre-warmed at 
37 °C for 30 sec and 5-LO product formation 
was started by addition of 30 µM AA with or 
without Ca2+. After another 10 min, 5-LO 
product formation was determined. Values are 
given as mean + S.E., n = 3, ANOVA + Tukey 
post hoc test. 
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Since PA derivatives and 2-(phenylthio)hexanoic acid derivatives are less efficient in 
homogenates than at isolated 5-LO, cellular components may attenuate their inhibitory potency. 
A similar effect was found for hyperforin in crude homogenates, and it was demonstrated that 5-
LO inhibition by hyperforin is clearly reduced after addition of PC [210]. As Fig. 32 shows, the 
efficacy of 39 to inhibit partially purified 5-LO is significantly attenuated in presence of PC (25 
µg/ml) as well, whereas this effect is less prominent for 86 and 136. Phosphatidylserine (PS) in 
contrast, hardly influenced the potency of the compounds. 5-LO inhibition by BWA4C was only 
marginally altered after addition of phospholipids. 
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Fig. 32. Effect of phospholipids on 5-LO inhibition by the compounds. Partially purified 
human recombinant 5-LO (0.5 µg) expressed in E.coli was supplemented with 1 mM ATP 
and pre-incubated in 1 ml PBS buffer plus 1 mM EDTA with the compounds at the indicated 
concentrations or with vehicle (DMSO) for 5-10 min at 4 °C with or without PC or PS (25 
µg/ml, each) as given in the figure. Samples were pre-warmed at 37 °C for 30 sec and 5-LO 
product formation was started by addition of 2 mM CaCl2 plus 20 µM AA. After another 10 
min, 5-LO product formation was determined. Values are given as mean + S.E., n ≥ 5; *p < 
0.05, **p < 0.01, ***p < 0.001 vs. samples without phospholipids (w/o) at corresponding 
concentrations of inhibitors, ANOVA + Tukey post hoc test. 
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5-LO inhibition of the compounds was not only altered in presence of PC but also upon addition 
of OAG. As Fig. 33 shows, OAG (30 µM) clearly impaired the potency of all three derivatives, 
although the IC50 value of 39 was only marginally decreased. In agreement with previous data 
[210], the 5-LO inhibitory curve of BWA4C was not affected by OAG.  
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Fig. 33. Effects of OAG on 5-LO inhibition by the compounds. Partially purified 
human recombinant 5-LO (0.5 µg) expressed in E.coli was supplemented with 1 
mM ATP and pre-incubated in 1 ml PBS buffer plus 1 mM EDTA with the 
compounds at the indicated concentrations or with vehicle (DMSO) for 5–10 min at 
4 °C with or without 30 µM OAG  as given in the figure. Samples were pre-warmed 
at 37 °C for 30 sec and 5-LO product formation was started by addition of 2 mM 
CaCl2 plus 20 µM AA. After another 10 min, 5-LO product formation was 
determined. Values are given as mean + S.E., n ≥ 5; *p < 0.05, **p < 0.01, ***p < 
0.001 vs. samples without OAG (w/o) at corresponding concentrations of inhibitors, 
ANOVA + Tukey post hoc test. 
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It has to be mentioned at this point that a different pattern was obtained if OAG (30 µM) was 
added prior to stimulation of PMNL with ionophore A23187. While the potency of 25 and 39 was 
impaired upon supplementation of OAG (Fig. 34), the inhibitory effect of 86 and 136 was hardly 
altered, and contrary to the expectations, the IC50 of BWA4C clearly shifted to higher values in 
presence of OAG in PMNL. 
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Fig. 34. Effect of OAG on the inhibition 
of 5-LO product formation by the 
compounds in PMNL. PMNL (5 × 106) 
were pre-incubated with test compounds for 
15 min at 37 °C. OAG (30 µM) was 
supplemented 3 min before stimulation with 
2.5 µM ionophore A23187 and 20 µM AA. 
The reaction was stopped after 10 min to 
analyze 5-LO product formation. Values are 
given as means + S.E., n = 3; *p < 0.05, 
***p < 0.001 vs. samples without OAG 
(w/o) at corresponding concentrations of 
inhibitors, ANOVA + Tukey post hoc test. 
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The interaction between 5-LO and CLP is mediated by three tryptophanes (W13, W75 and 
W102) within the C2-like domain of 5-LO [108]. Recently, it was demonstrated in a pull-down 
assay that hyperforin is able to interrupt binding of 5-LO to CLP [210]. In order to evaluate if PA 
derivatives or 2-(phenylthio)hexanoic acid derivatives are also able to disturb the interaction 
between 5-LO and CLP, a fusion protein of CLP and glutathione-S-transferase (GST-CLP) was 
immobilized on GSH-sepharose beads, and CLP-bound 5-LO was determined by Western Blot. 
As expected, 5-LO bound to GST-CLP but not to GST alone (Fig. 35a). In one experiment, 
inclusion of 25 concentration-dependently decreased the amount of precipitated 5-LO, suggesting 
that 25 prevents binding of 5-LO to CLP. Unfortunately, the inhibitory effect of 25 could not be 
confirmed in subsequent experiments (Fig. 35b) and neither variation in the amount of 5-LO, 
GST-CLP, GSH-sepharose beads or BSA nor changes in buffer composition, reaction time or 
washing steps yielded consistent results (not shown). Compound 39 wasn’t able to prevent the 
interaction between 5-LO and CLP either (Fig. 35c) and notably, also the expected effect of 
hyperforin could not be confirmed under the applied conditions. 
 
a)  
 
 
 
 
 
 
 
b)  
 
 
 
 
c) 
 
 
 
 
Fig. 35. Effect of 25 and 39 on the 
interaction between 5-LO and 
CLP. Purified human recombinant 
5-LO (4 µg) was incubated with 40 
µg of either GST (neg. control) or 
GST-CLP fusion protein linked to 
GSH-sepharose 4B beads in 
presence of BSA (50 µg/ml) and 25, 
39 or hyperforin, as indicated. After 
30 min rotation at RT, washing and 
elution of the proteins with the same 
volume of SDS loading buffer, 5-
LO was assayed by SDS-PAGE and 
Western Blot.  
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5.2.3. Investigation of a direct binding between PA derivatives and 5-LO 
In order to confirm a direct binding of PA derivatives to 5-LO, surface plasmon resonance (SPR) 
spectroscopy studies were applied. The SPR method allows to monitor molecular interactions 
between an immobilized reactant (e.g. an enzyme) and a soluble component (e.g. a potential drug 
candidate) in real-time without the need to label the analytes [263], [264]. Thus, complex 
formation between two binding partners (and also their dissociation) implicates changes in the 
refractive index of the solvent near the surface that can be measured by the SPR biosensor. The 
binding responses are monitored in a sensogram as resonance units (RU). 
A fusion protein of maltose-binding protein and 5-LO (MBP-5-LO, kindly provided by Prof. Dr. 
D. Steinhilber, University of Frankfurt) was immobilized on one of the two flow cells of a CM5 
sensor chip, whereas MBP alone was applied on the other flow cell. Compounds 22, 25, 39 or 41 
(at different concentrations between 0.1 and 20 µM) were diluted into assay buffer, sequentially 
injected over the chip surface, and the resonance of the MBP-5-LO flow cell compared to the 
MBP control flow cell was determined. Unfortunately, no consistent binding pattern was 
obtained for any of the PA derivatives (data not shown). Neither variation of commercial assay 
buffers (± additional detergent) nor changes in the temperature or the flow rate improved the 
quality of the recorded sensograms. Possibly, due to their amphiphilic properties, PA derivatives 
form aggregates or micelles and thus bind to immobilized 5-LO in an unspecific and 
superstoichiometric manner [265].  
5.2.4. Inhibition of 5-LO product formation by the compounds in human whole blood 
Investigation of 5-LO product formation in human whole blood may translate to the in vivo 
effectiveness of a given test compound. Therefore, whole blood assays with 30 µM ionophore 
A23187 as stimulus were performed. As shown in Fig. 36, none of the representatives for PA or 
2-(phenylthio)hexanoic acid derivatives (in concentrations up to 30 µM) was able to reduce 5-LO 
product synthesis under these conditions. The control inhibitor MK886 in contrast, showed a 
clear inhibitory effect. 
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5.2.5. Investigation of the in vivo effectiveness of PA derivatives 
5.2.5.1. Effects of PA derivatives on carrageenan-induced pleurisy in rats 
Despite the lack of effectiveness in whole blood assays, one may not generally exclude in vivo 
efficacy of PA derivatives. For example, the compounds might enrich in inflammatory tissues 
and thus exert their anti-inflammatory actions. Therefore, 22 and 37, two compounds out of an 
early synthesized set of PA derivatives that were inactive in human whole blood, were tested in 
carrageenan-induced pleurisy in rats, a well-established model of acute inflammation that 
involves 5-LO [266]. The experiments were performed by F. Dehm in the lab of Prof. Dr. L. 
Sautebin (University Naples, Italy). Injection of λ-carrageenan into the pleural cavity of rats 
provoked a massive accumulation of exudates containing inflammatory cells with elevated levels 
of LTB4 but also of PGE2 (Fig. 37). Both 22 and 37 (1.5 mg/kg, given i.p., each, 30 min before 
carrageenan) significantly attenuated exudate formation and cell infiltration. Furthermore, the 
amounts of LTB4 and PGE2 in the exudates were clearly reduced by the compounds. The COX 
inhibitor indomethacin (5 mg/kg) also lowered these parameters except LTB4 as expected. 
 
 
 
Fig. 36. Inhibition of 5-LO product formation in 
human whole blood. Freshly withdrawn blood (2 
ml) was pre-incubated with compounds (30 µM, 
each) or vehicle (DMSO) for 15 min at 37 °C, and 
formation of 5-LO products was started by addition 
of 30 µM ionophore A23187 (10 min, 37 °C). The 
formation of 5-LO products was determined as 
described. Data are means + S.E.; n ≥ 3; ***P < 
0.001 vs vehicle (DMSO) control, ANOVA + 
Tukey post hoc test. 
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Fig. 37. Effect of 22 and 37 on carrageenan-induced pleurisy in rats. Thirty min 
before intrapleural injection of λ-carrageenan, rats were treated i.p. with 22, 37 (1.5 
mg/kg, each), indomethacin (5 mg/kg) or vehicle (DMSO). Exudate volume, 
inflammatory cell accumulation in the pleural cavity, LTB4 and PGE2 were assessed 4 h 
after λ-carrageenan injection. Data are means + S.E.; n = 7; *p<0.05, **p<0.01, 
***p<0.01 vs. vehicle (4% DMSO). ANOVA + Tukey post hoc test. Performed by F. 
Dehm in the lab of Prof. Dr. L. Sautebin (University Naples, Italy). 
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5.2.5.2. Influence of compound 39 on PAF-induced shock 
Encouraged by the promising results obtained for 22 and 37 in the pleurisy model, additional in 
vivo experiments with PA derivatives were performed by A. Rossi in the group of Prof. Dr. L. 
Sautebin. It was previously shown that 5-LO knockout mice are less sensitive to PAF-mediated 
lethal anaphylactic shock [267], [268], and that some 5-LO inhibitors as well as several FLAP 
inhibitors are able to prolong survival time in mice exposed to a lethal intravenous injection of 
PAF [269], [270, 271], [271]. To investigate whether or not PA derivatives also possess a 
protecting effect in this animal model, 39 was administered intraperitoneally 30 min prior to 
injection of a lethal dose of PAF (200 µg/kg). Indeed, 10 mg/kg of the compound prevented the 
mortality of the mice by almost 80% (Table 5). By comparison, 30 mg/kg of the FLAP inhibitor 
MK-886 have been shown in literature to increase survival to 50% [197]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
compound survivors/total 
 
control 1/20 (1/5-0/5-0/5-0/5) 
39    (1.5 mg/kg) 0/5 
39    (5 mg/kg) 0/5 
39    (10 mg/kg) 8/10 (5/5-3/5) 
Table 5. Effect of 39 on PAF 
induced shock in mice. PAF was 
injected intravenously into 
female CD-1 mice at a dose of 
200 µg/kg. 39 (1.5, 5, 10 mg/kg) 
or vehicle control (saline solution 
containing 2% DMSO) were 
administered intraperitoneally 30 
min prior to PAF. The number of 
surviving animals after 1-2 h and 
the total number of animals 
tested for each group are given. 
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5.3. Further targets of PA derivatives and 2-(phenylthio)-hexanoic acid derivatives 
5.3.1 Inhibition of mPGES-1, COX-1 and COX-2 by selected PA derivatives and 2-
(phenylthio)-hexanoic acid derivatives 
Simultaneous inhibition of both PG and LT synthesis is thought to be more efficient against 
inflammatory diseases than suppression of 5-LO products alone [211], [212], and efforts have 
been made over the past years to develop dual COX/5-LO inhibitors [272], [273]. Moreover, the 
dual inhibition concept was shown to be superior over single interference with COX enzymes in 
terms of gastrointestinal toxicity. However, COX-2 inhibition has been associated with an 
increased cardiovascular risk [216], and therefore, suppression of mPGES-1-derived PGE2 
formation in combination with 5-LO inhibition has been considered as an alternative to dual 
COX/5-LO inhibitors [18], [217]. In order to determine the effect of PA derivatives and 2-
(phenylthio)hexanoic acid derivatives on mPGES-1, microsomal preparations of A549 cells were 
preincubated with selected compounds for 15 min, and then, PGH2 was added to start PGE2 
formation. The assays were performed by M. Hieke, G. Kleefeld, A. Koeberle and D. Müller in 
our lab. The mPGES-1 inhibitor MK-886 was used as reference compound. As observed for 5-
LO, PA itself was not able to block mPGES-1, but introduction of n-hexyl (22), n-octyl (44) or 
naphthyl (63) moieties in α-position of the carboxylic group yielded compounds that clearly 
reduced PGE2 formation (Table 6). Replacement of the o-dimethylaniline moiety by a 6-
aminoquinoline was not as beneficial as for 5-LO inhibition, and only the esterified compound 25 
showed a remarkable reduction of PGE2 (IC50 = 5.6 µM). Note that except 25, all the other esters 
tested were rather poor inhibitors of mPGES-1. Introduction of bulky lipophilic residues at C6 of 
the pyrimidine, especially of biphenyl groups (37, 39, 41, 42) also increased the potency of the 
free acids suggesting similar SARs for both 5-LO and mPGES-1. 
Among the derivatives with bis-phenethoxy moieties, the most favorable profiles were displayed 
by trifluormethyl- (94, IC50 = 1.9 µM) and methyl- (92, IC50 = 0.9 µM) substituted compounds. 
Interestingly, replacement of the pyrimidine by phenyl and exchange of the two phenyl residues 
against bis-cyclohexyl yielded the highly efficient compound 113 (IC50 = 0.9 µM) that was less 
efficient in the 5-LO activity assay. 
2-(Phenylthio)hexanoic acid derivatives turned out to potently inhibit mPGES-1 as well. Also for 
this class of compounds, voluminous lipophilic residues increased the efficacy with 3,4-
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disubstituted (3-trifluoromethyl-4-chlorophenyl) 133 as the most effective representative (IC50 = 
1.7 µM). 
Taken together, a variety of PA derivatives and 2-(phenylthio)hexanoic acid derivatives act as 
dual 5-LO/mPGES-1 inhibitors that inhibit both enzymes about equally well. Due to the 
lipophilic acid character of these compounds, one could assume that they might also interfere 
with COX-1/2 by mimicking AA, the substrate of COX enzymes. Therefore, selected derivatives 
were assessed in cell-free assays using isolated ovine COX-1 and human recombinant COX-2, 
respectively. As shown in Table 6, most of the tested compound hardly blocked 12-HHT 
formation so that IC50 values below 10 µM were only reached for a few substances (COX-1: 30, 
32 and 63; COX-2: 63 and 102). 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 Results  119 
 
Compound 
mPGES-1 
IC50 or remaining 
activity 
 (± S.E.) at 10 µMd 
COX-1 
remaining activity 
 (± S.E.) at 10 µM 
COX-2 
remaining activity 
(± S.E.) at 10 µM 
PA n.i.d n.d. n.d. 
7 68.7 (± 4.0) n.d. n.d. 
8 82.2 (± 3.4) n.d. n.d. 
13 83.8 (± 7.4) n.d. n.d. 
14 n.i. n.d. n.d. 
19 70.0 (± 9.4) n.d. n.d. 
20 79.9 (± 6.2) n.d. n.d. 
21 80.7 (± 8.0) n.d. n.d. 
22 3.9 75.2 (± 8.9)c 62.0 (± 5.6)c 
23 n.i. n.d. n.d. 
24 59.0 (± 6.5) n.d. n.d. 
25 5.6 69.5 (± 1.9)c 61.7 (± 9.3)c 
26 67.4 (± 7.3) n.d. n.d. 
28 85.7 (± 8.9) n.d. n.d. 
30 2.6 40.0 (± 8.9)c 70.4 (± 9.3)c 
32 n.d. 45.1 (± 8.2) 57.6 (± 6.6) 
37 1.3 67.3 (± 1.2)c 61.3 (± 3.7)c 
38 n.i. n.d. n.d. 
39 1.6 52.3 (± 0.9)c 57.1 (± 5.1 )c 
41 1.7 66.0 (± 8.3)c 61.2 (± 3.6)c 
41a 36.8 (± 4.7) n.d. n.d. 
41b 23.0 (± 5.9) n.d. n.d. 
42 2.1 71.2 (± 1.0)c 53.7 (± 3.8)c 
44 29.8  (± 7.1) n.d. n.d. 
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Compound 
mPGES-1 
IC50 or remaining 
activity 
 (± S.E.) at 10 µMd 
COX-1 
remaining activity 
 (± S.E.) at 10 µM 
COX-2 
remaining activity 
 (± S.E.) at 10 µM 
45 74.6 % (± 1.9) n.d. n.d. 
63 5.1 42.2 % (±11.4)c 32.5 % (± 7.3)c 
83 66.4 % (± 2.4) 91.8 % (± 2.8) 91.7 % (± 7.8) 
84 1.2 72.2 % (± 7.7)c 86.0 % (± 12.6)c 
85 7.3 84.6 % (± 3.2)c 56.9 % (± 0.8)c 
86 2.0 61.8 % (± 9.8)c 63.8 % (± 9.7)c 
87 1.2 64.2 % (± 8.8) 90.9 % (± 10.2) 
88 n.i. n.d. n.d. 
89 3.6 88.9 % (± 12.3)c 61.6 % (± 1.4)c 
90 2.2 78.8 % (± 8.6)c 51.9 % (± 6.5)c 
91 0.9 78.8 % (± 8.1)c 53.9 % (± 8.2)c 
92 0.9 57.2 % (± 7.3) 93.3 % (± 11.6) 
93 63.7 % (± 7.4) 72.8 % (± 10.3)c 94.6 % (± 13.5)c 
94 1.9 54.4 % (± 10.6)c 69.0 % (± 12.4)c 
95 88.3 % (± 6.3) 73.0 % (± 6.7) 75.8 % (± 5.0) 
96 3.7 82.1 % (± 7.0) 91.6 % (± 8.4) 
97 5.9 88.8 % (± 9.6) 82.6 % (± 14.1) 
98 6.5 76.6 % (± 4.0) n.i. 
99 2.7 72.4 % (± 11.8)c 80.5 % (± 11.4)c 
100 9.9 97.7 % (± 8.7) 87.9 % (± 3.4) 
101 90.0 % (± 11.4) 68.2 % (± 4.0) 84.7 % (± 2.0) 
102 2.4 52.7 % (± 6.4)c 49.5 % (± 10.7)c 
103 62.4 % (± 8.4) 56.1 % (± 5.1) 50.1 % (± 2.1) 
104 4.6 71.3 % (± 2.1) n.i. 
105 3.4 71.6 % (± 3.7) 92.5 % (± 2.7) 
106 2.6 78.7 % (± 12.9)c 78.4 % (± 11.9)c 
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Compound 
mPGES-1 
IC50 or remaining 
activity 
(± S.E.) at 10 µMd 
COX-1 
remaining activity 
 (± S.E.) at 10 µM 
COX-2 
remaining activity 
 (± S.E.) at 10 µM 
107 3.1 95.8 % (± 21.7)c 86.4 % (± 11.8)c 
108 5.0 66.1 % (± 9.8)c 89.6 % (± 13.4)c 
109 90.1 % (± 8.3) 99.1 % (± 12.1) n.i. 
110 2.4 63.8 % (± 16.6)c 66.5 % (± 11.0)c 
111 2.5 69.1 % (± 4.0) 91.5 % (± 3.3) 
112 5.0 82.0 % (± 6.7) 96.6 % (± 9.5) 
113 0.9 73.8 % (± 8.7) 79.1 % (± 6.6) 
114 2.8 81.4 % (± 8.5) 81.4 % (± 8.9) 
115 1.4 68.0 % (± 12.1) 94.4 % (± 10.7) 
116 1.2 86.8 % (± 24.3) n.i. 
117 3.6 76.4 % (± 7.3) n.i. 
118 4.4 81.0 % (± 11.8) n.i. 
119 55.1 % (± 5.4) 82.6 % (± 4.7) n.i. 
120 74.0 % (± 9.4) 92.3 % (± 9.2) n.i. 
121 81.9 % (± 5.6) n.d. n.d. 
122 2.9 n.i.c n.i.c 
122a 19.6 % (± 8.9) n.d. n.d. 
122b 17.0 % (± 8.0) n.d. n.d. 
123 75.4 % (± 10.9) n.d. n.d. 
124 41.1 % (± 3.9) n.d. n.d. 
125 58.0 % (± 5.5) n.d. n.d. 
126 42.6 % (± 2.7) n.d. n.d. 
127 88.3 % (± 3.0) n.d. n.d. 
128 59.1 % (± 6.5) n.d. n.d. 
129 46.3 % (± 2.3) n.d. n.d. 
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Compound 
mPGES-1 
IC50 or remaining 
activity 
 (± S.E.) at 10 µMd 
COX-1 
remaining activity 
 (± S.E.) at 10 µM 
COX-2 
remaining activity 
 (± S.E.) at 10 µM 
130 4.1 n.d. n.d. 
131 2.7 n.d. n.d. 
132 2.0 n.d. n.d. 
133 1.7 71.3 % (± 2.0)  n.i. 
134 2.2 n.i.c n.i.c 
136 2.2 79.2c n.i.c 
138 n.i. n.d. n.d. 
139 83.9 % (± 3.6) n.d. n.d. 
140 83.9 % (± 14.2) n.d. n.d. 
141 26.3 % (± 10.0) n.d. n.d. 
142 71.7 % (± 10.3) n.d. n.d. 
MK 886 2.1 n.d. n.d. 
indo-
methacin n.d. 26.6 % (± 4.8) n.d. 
celecoxib n.d. n.d. 34.3 % (± 10.4) 
 
 
 
 
 
 
 
Table 6. Inhibition of cell-free mPGES-1, isolated ovine COX-1 and human 
recombinant COX-2. Data are means ± S.E.; n ≥ 3 
cexperiments were performed by G. Kleefeld or D. Müller in the lab of Prof. Dr. O. 
Werz (University of Tuebingen, Germany). 
dexperiments were performed by M. Hieke, G. Kleefeld, Dr. A. Koeberle or D. 
Müller in the lab of Prof. Dr. O. Werz (University of Tuebingen, Germany). 
 
  
5 Results  123 
 
5.3.2. Short term effects of selected PA derivatives on typical neutrophil functions 
Activation of PMNL by the pro-inflammatory fMLP does not only activate 5-LO but also induces 
transduction pathways that mediate adhesion, degranulation, chemotaxis and generation of 
reactive oxygen species (ROS) in order to counteract bacterial infection or tissue damage [274]. 
fMLP binds to G-protein-coupled receptors (namely FPR and FPRL1) on the cell surface, and 
subsequent activation of PLC, PLD, PLA2, phosphatidylinositol-3-kinase (PI3K) and tyrosine 
phosphorylation transduces the signal to the respective second messengers [275]. Various kinases 
including protein kinase C (PKC) and MAPKs become activated and mediate distinct cellular 
effects such as Ca2+ mobilization, ROS formation and release of human leukocyte elastase 
(HLE). 
The effects of PA and selected quinolinic derivates on typical immediate neutrophil functions 
have previously been investigated in our group. Thus, it was demonstrated that derivatives with 
α-butyl or α-hexyl substitution (in particular the free acids) but not PA itself or the α-
unsubstituted quinolinic derivative attenuate ROS formation and inhibit HLE secretion as well as 
intracellular Ca2+ mobilization [245].       
Many neutrophil functions are mediated by the activation of p38 MAPK and ERKs, and in 
particular p38 MAPK might be a target for the treatment of inflammatory diseases [276]. In order 
to test if the suppression of ROS, HLE and Ca2+ is the result of an interference of the compounds 
with MAPK, PMNL were preincubated with the PA derivatives for 15 min, and phosphorylation 
(and thus activation) of p38 MAPK and ERK-1/2 was induced with fMLP. As Fig. 38A shows, 
the α-butyl-  (16) and α-hexyl-substituted (24) acidic derivatives clearly reduced phosphorylation 
of p38 MAPK but not of ERK-2. In accordance with the preceding results, neither PA nor the 
unsubstituted 2 or the esterified 25 affected the phosphorylation of these kinases. Since 39, 86 
and 136 were ineffective as well (Fig. 38B), it is assumed that the effect on p38 MAPK is 
exclusive for quinolinic PA derivatives. 
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5.3.3. Discovery of additional targets of PA derivatives and 2-(phenylthio)hexanoic acid 
derivatives by a fishing approach 
One classical approach to identify the targets of a certain compound is to investigate 
systematically its effect on distinct sections of signaling networks in order to find out the 
interaction partner. A more recent and time saving method is to perform selective protein fishing 
experiments by immobilizing the compound of interest to an insoluble biocompatible resin. This 
construct is incubated with a cell lysate as target source and subsequently centrifuged in order to 
pull down proteins that bind specifically to the immobilized molecule. The fished proteins can be 
separated by SDS-PAGE, and those which bound exclusively to the resin with the compound of 
interest (but not to a negative control) are selected, cut out and identified by MALDI or ESI mass 
spectrometry.  
 
 
 
Fig. 38. Influence of the compounds on MAPK. PMNL were resuspended in PGC buffer (107/100 
µl) and pre-incubated with the test compounds (10 µM, each) or vehicle (0.3% DMSO) for 15 min 
at 37 °C. Then, 1 µM fMLP was added, and the incubation was continued for 1.5 min. The reaction 
was stopped by addition of 100 µl SDS loading buffer, and samples were analyzed for 
phosphorylated p38 MAPK (p-p38 MAPK) and phosphorylated ERK-2 (p-ERK2) by SDS-PAGE 
and Western Blot. Ponceau S-staining of the membranes (not shown) and analysis of total p38 
MAPK protein assured equal protein loading in each lane. Similar results were obtained in three 
additional independent experiments. 
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5.3.3.1. Target fishing with a quinolinic PA derivative  
Considering the multiple effects of quinolinic PA derivatives on neutrophil functions, it was 
interesting to gain more insight into the exact target(s) of the compounds. Possibly, the inhibitory 
effect on intracellular Ca2+ levels and p38 MAPK phosphorylation is mediated by an interference 
of the derivatives with signaling cascades connecting fMLP stimulation with p38 MAPK and 
Ca2+ mobilization. In order to elucidate potential targets of PA derivatives, protein fishing 
experiments were performed with 24, a compound that potently inhibits LTB4 formation, ROS 
production, HLE release, Ca2+ mobilization and p38 MAPK phosphorylation in PMNL. The 
compound was coupled via its acidic group to an amino-functionalized methacrylic acid resin 
(Fig. 39A) and incubated with freshly prepared PMNL lysates. Gel electrophoresis followed by 
silver staining of the fished proteins revealed a protein with an apparent mass of ~ 25 kDa as 
putative candidate (Fig. 40A) that could neither be detected in control samples where beads 
without ligand were used nor in a sample with immobilized PA (structure: Fig. 39B). MALDI 
mass spectrometric and subsequent data base analysis identified the candidate protein as human 
NRH:quinone oxidoreductase 2 (NQO2, also referred to as QR2), and a direct interaction with 24 
was confirmed by incubation of 24-beads with isolated recombinant NQO2 followed by SDS-
PAGE and Western Blot with NQO2 antibody (Fig. 40B). 
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Fig. 39. Structures of immobilized 24 (A) and PA (B). 100 µmol of 24 or PA, respectively, 
were solubilized in 500 µl DMF and mixed with 500 µl pre-washed amino-functionalized 
methacrylic acid resin (Toyopearl AF-Amino-650M, Tosho Bioscience). After addition of 65 µl 
DIC, samples were rotated for 48 h at pH 4.5 and RT. Remaining free amino groups of the 
matrix were blocked with 10% acetic acid and 100 µl DIC for 12 h. Then, the beads were 
washed several times with water and stored in 20% (v/v) ethanol at 4 °C. 
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Fig. 40. Protein fishing with beads carrying 24 (“24-beads”). (A) 50 µl prewashed “24-
beads”, PA-beads or pure beads, respectively, were incubated with cell lysate from 108 freshly 
prepared PMNL in 700 µl binding buffer + 1% Triton X-100 for 12 h at 4 °C under rotation. 
Beads were washed three times with binding buffer + 1% Triton X-100, boiled with 2× SDS 
loading buffer for 5 min at 96 °C and SDS-PAGE followed by silver staining was performed. 
The band of interest (at ~ 25 kDa) was cut out, digested and peptides were analyzed by MALDI 
mass spectrometry. Similar results were obtained in two independent experiments. (B) 50 µl 
prewashed 24-beads, PA-beads or pure beads, respectively, were incubated with 0.5 µg human 
recombinant NQO2 in 500 µl binding buffer + 1% Triton X-100 in presence of 0.1 µg/ml BSA 
for 12 h at 4 °C under rotation. Beads were washed three times with binding buffer + 1% Triton 
X-100, boiled with 2× SDS loading buffer for 5 min at 96 °C, and a Western Blot was 
performed. Similar results were obtained in three independent experiments.  
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NQO2 activity assay 
Protein fishing experiments give information about the physical interaction of two binding 
partners, but the functional consequences of this interaction remains to be elucidated in 
appropriate in vitro or in vivo assays.  
Human NQO2 is a 26 kDa, FAD-dependent flavoenzyme that catalyzes two-electron reductions 
of quinones to hydroquinones. This reaction counteracts one-electron reductions of quinones that 
lead to the formation of ROS [277]. If the detoxifying properties of NAD(P)H:quinone 
oxidoreductase (NQO1) are well characterized, the role of NQO2 is not fully understood yet 
[278]. The hypothesis that NQO2 is also involved in detoxification processes is supported by the 
fact that the enzyme is thought to reduce carcinogenic estrogen ortho-quinones [279] and that 
NQO2-/- mice are more susceptible to polycyclic aromatic hydrocarbon-induced skin 
carcinogenesis [280]. In addition, some anti-malarian drugs (quinolines) inhibit NQO2 and this 
may cause red blood cell oxidative stress leading to the death of the plasmodia [281]. However, 
other studies revealed that inhibition of NQO2 by resveratrol renders cells less sensitive to toxic 
menadione [282], and NQO2-/- mice showed a higher tolerance towards menadione [283]. 
Moreover, it was demonstrated that NQO2 is identical with the melatonin binding site MT3 so 
that there might be a relation between NQO2 inhibition by melatonin and its antioxidant effects 
[284]. Another group reported reduced proliferation rates upon knock-down of NQO2 in a 
chronic myeloic leukemia (CML) cell line [285]. Taken together, some data indicate that NQO2 
might also be responsible for the transformation of quinone substrates into more reactive 
compounds that cause cellular damage and thus, inhibition of NQO2 could be beneficial in 
pathophysiological situations associated with oxidative stress. Therefore, it was interesting to 
investigate whether binding of quinolinic PA derivatives to NQO2 is associated with inhibition of 
the enzyme´s activity and what consequences would result from such interference. The ability of 
pure recombinant NQO2 (10 ng) to reduce menadione (100 µM) in presence of 24 or 25, 
respectively, was measured by UV-Vis spectroscopy with colororimetric MTT as a reporter dye. 
As Fig. 41A shows, 24 (10 µM) but not its esterified analog 25 slightly attenuated the activity of 
NQO2 after 5 min reaction time. In contrast, the control inhibitor resveratrol (10 µM) exhibited a 
very potent reduction of the formazan product that reflects the amount of enzymatically 
converted menadione. As expected, PA itself had no influence on the enzyme reaction. 
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In order to check if the inhibitory effect of 24 on NQO2 activity increases with longer incubation 
times, a time course of the enzymatic reaction was performed. However, also after 15 min, no 
increased potency of 24 could be observed (Fig. 41B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.3.2. Target fishing with a biphenylic PA derivative  
As described above, biphenylic PA derivatives are among the most potent compounds tested in 
this study regarding 5-LO and mPEGS-1 inhibition. To investigate whether they also interfere 
with other targets in PMNL, fishing experiments were performed with a biphenylic compound 
derived from 39. Since the acidic group is essential for the inhibitory effect on both 5-LO and 
mPGES-1, this moiety was not altered. Instead, compound 143 possessing a carboxylic group in 
para position of the biphenylic residue of 40 (the ethylester of 39) was synthesized by M. Dittrich 
Fig. 41. NQO2 activity assay. (A) Human recombinant NQO2 (10 ng) was pre-treated with 
test compounds, resveratrol (10 µM each) or vehicle in 200 µl assay buffer including the 
cofactors FAD (1 µM) and SCHP (0.5 mM) for 5 min at RT. The enzyme reaction was started 
with menadione (100 µM) plus MTT (0.134 mg/ml), and after 5 min, the absorbance was 
measured at 590 nm. Data are means + S.E. n = 3. (B) Human recombinant NQO2 (10 ng) was 
pre-treated with 24, resveratrol (10 µM each) or vehicle in 200 µl assay buffer including the 
cofactors FAD (1 µM) and SCHP (0.5 mM) for 5 min at RT. The enzyme reaction was started 
with menadione (100 µM) plus MTT (0.134 mg/ml) and the absorbance (at 590 nm) was 
measured at the indicated time points. Similar results were obtained in three independent 
experiments.   
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in the lab of Prof. Dr. M. Schubert-Zsilavecz and immobilized to an amino-functionalized 
methacrylic acid resin via the free carboxylic group. To obtain the designated fishing construct 
(Fig. 42A), the ethylester was cleaved with LiOH. The corresponding α-unsubstituted compound 
144 was synthesized accordingly and used as a control (Fig. 42B). Incubation of the immobilized 
compounds with PMNL lysate was performed as described above, but in this case, proteins were 
eluted with 4 M urea pH 8.5, instead of SDS. Proteins fished with 143 were labeled with the 
fluorescence dye Cy5, whereas the eluate of the 144 sample was labeled with Cy3. Both eluates 
were mixed and proteins were separated by IEF in the first dimension followed by SDS-PAGE in 
the second dimension. The gel was scanned with an ETTAN DIGE Imager (GE Healthcare). As 
Fig. 43A shows, four spots were clearly more intensive in the channel for Cy5 (red) versus the 
channel for Cy3 (green). Unfortunately, the protein amount of three of these spots was under the 
detection limit for silver staining (Fig. 43B) so that they could not be picked for MS analysis. 
Spot number 1 was analyzed by MALDI MS, but turned out to be an unspecific impurity. 
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Fig. 42. Structures of immobilized 143 (A) and 144 (B). 100 µmol of 143 or 144, respectively, 
were solubilized in 500 µl DMF and mixed with 500 µl pre-washed amino-functionalized 
methacrylic acid resin (Toyopearl AF-Amino-650M, Tosho Bioscience). After addition of 65 µl 
DIC, samples were rotated for 48 h at pH 4.5 and RT. Remaining free amino groups of the matrix 
were blocked with 10% acetic acid and 100 µl DIC for 12 h. After several washing steps, the 
ester group of 143 and 144, respectively, was cleaved with LiOH (300 µmol) in THF/H2O (3:1). 
After 24 h rotation at RT, beads were washed and stored at 4 °C. 
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Fig. 43. 2D-DIGE of proteins fished with 143 from a PMNL cell lysate. (A) 50 µl pre-washed 
143-beads or 144-beads, respectively, were incubated with cell lysate from 1.5 × 109 freshly 
isolated PMNL in 700 µl binding buffer + 0.1% Triton X-100 for 12 h at 4 °C under rotation. 
Beads were washed three times with binding buffer + 0.1% Triton X-100. Bound proteins were 
eluted with 4 M urea, pH 8.5, and the protein amount was determined. Aliquots of the fished 
proteins were labeled with Cy5 (for 143) or Cy3 (for 144). Samples were mixed, and proteins 
were separated by IEF in the first dimension followed by SDS-PAGE in the second dimension. 
The gel was scanned with an ETTAN DIGE Imager (GE Healthcare). Red: Cy5 labelled 143-
fished proteins, green: Cy3 labelled 144-fished proteins (neg. control). (B) Silver staining of the 
2-D-DIGE gel from (A). Spot number 1 was picked and analyzed by MALDI-MS.   
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In another fishing experiment with 143, proteins were separated with one-dimensional SDS-
PAGE. Several bands between 100 and 130 kDa were more intensive in the eluate of the 143-
beads compared to the bands obtained with “negative” control 144-beads (although the total 
amount of fished proteins was clearly higher with 144-beads), but the protein amount was too 
small to be cut out for MS analysis (Fig. 44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 44. SDS-PAGE of proteins fished with 143 
from PMNL cell lysate. 50 µl prewashed 143-
beads or 144-beads, respectively, were incubated 
with cell lysate from 4 × 108 freshly isolated 
PMNL in 500 µl binding buffer + 1% Triton X-
100 for 12 h at 4 °C under rotation. Beads were 
washed three times with binding buffer + 1% 
Triton X-100, boiled with 2× SDS loading buffer 
for 5 min at 96 °C, and SDS-PAGE followed by 
silver staining was performed.  
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5.3.3.3. Target fishing with a 2-(phenylthio)hexanoic acid derivative 
In order to identify additional binding partners of 2-(phenylthio)hexanoic acid derivatives, a 
compound resembling 122 was synthesized by M. Dittrich in the lab of Prof. Dr. M. Schubert-
Zsilavecz. Again, the carboxylic acid was conserved so that an additional functional group was 
introduced at the o-dimethyl moiety of 122. Because of synthetic reasons, an amino residue was 
inserted instead of a carboxylic group yielding compound 145. Again, a compound lacking α-
substitution was synthesized as “negative” control (146). Both molecules were immobilized via 
their amino group to an epoxy-activated matrix (Toyopearl AF-Epoxy 650M, Tosho Bioscience) 
(Fig. 45), and fishing experiments were performed with PMNL lysates. As Fig. 46 shows, the 
band patterns for 145 and 146 were identical, and no additional bands could be detected 
compared to the blocked matrix alone. 
In another fishing experiment with 145, bound proteins were eluted with 4 M urea, and 2D-DIGE 
separation was performed. 145 bound proteins were labeled with Cy3, whereas proteins eluted 
from the negative control 146 were marked with Cy5. Unfortunately, almost no spots were 
detectable after scanning of the gel with the ETTAN DIGE Imager (not shown). 
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Fig. 45. Structures of immobilized 145 (A) and 146 (B). 40 µmol of 145 or 146, respectively, 
were solubilized in 400 µl DMF and mixed with 75 mg pre-washed epoxy-activated resin 
(Toyopearl AF-Epoxy-650M, Tosho Bioscience). Samples were rotated for 72 h at pH 9-13, RT. 
Remaining free epoxy groups of the matrix were blocked with ethanolamine at pH 9-13 for 12 h. 
Beads were washed and stored in 20% (v/v) ethanol at 4 °C. 
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Finally, we attempted to confirm a direct interaction between 5-LO and PA derivatives or 2-
(phenylthio)hexanoic acid derivatives, respectively, using a fishing experiment. However, it was 
not possible to selectively precipitate 5-LO from PMNL lysates nor from a preparation of 
partially purified enzyme with any of the immobilized derivatives described above (not shown). 
 
 
 
 
Fig. 46. Protein fishing with 145-beads. 50 µl 
prewashed 145-beads or 146-beads, respectively,  
were incubated with cell lysate from 4 × 108 
freshly prepared PMNL in 500 µl binding buffer + 
1% Triton X-100 for 12 h at 4 °C under rotation. 
Beads were washed three times with binding 
buffer + 1% Triton X-100, boiled with 2× SDS 
loading buffer for 5 min at 96 °C, and SDS-PAGE 
followed by silver staining was performed..  
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6. Discussion 
LTs are local acting messengers that play established roles in asthma and allergic rhinitis, but 
also seem to contribute to other inflammatory diseases, cancer and cardiovascular diseases [51], 
[191]. The first two steps in LT biosynthesis are catalyzed by the nonheme iron-containing 5-LO, 
which is therefore an interesting target for therapeutic intervention [66]. Although a lot of 
research effort has been made on 5-LO inhibitors during the past decades, most potential 
candidates were not effective in clinical studies or caused severe side effects [262]. However, 
regarding the growing number of studies that confirm key roles of LTs in major diseases, the 
development of selective and safe drugs that interfere with LT biosynthesis is a great challenge.  
This study addresses the discovery of 5-LO inhibition by a large set of derivatives of PA and of 
2-(phenylthio)hexanoic acid that were synthesized in the group of Prof. Dr. M. Schubert-
Zsilavecz (University of Frankfurt). In addition, mechanistic aspects of selected compounds were 
investigated in various cell-based and cell-free assays so that a detailed analysis of the 
interference of these derivatives with the 5-LO enzyme is provided.  
The second part of this work focuses on other anti-inflammatory targets of the compounds and 
describes protein fishing experiments that were performed in order to reveal novel targets of PA 
derivatives and 2-(phenylthio)hexanoic acid derivatives.  
6.1. SARs of PA derivatives and 2-(phenylthio)hexanoic acid derivatives as 5-LO inhibitors  
PA did not influence 5-LO product formation, but structural variations at different positions of 
the molecule led to a clear inhibitory effect. Thus, replacement of the o-dimethylaniline of PA by 
bulkier lipophilic residues (especially biphenyls) in combination with introduction of α-hexyl or 
α-naphtyl moieties yielded potent inhibitors of 5-LO product formation in PMNL with 72 as the 
most effective representative (IC50 = 0.1 µM). The compounds directly inhibited 5-LO although 
their potency was somehow decreased for the purified enzyme. Presumably, additional 
mechanisms contribute to the reduction of LT biosynthesis in intact cells. Alternatively, there 
might be some remaining cellular components from crude homogenates of E. coli present that 
attenuate the inhibitory effect of the compounds as observed in the 40,000×g (S40) supernatants 
from E. coli lysates (see below). A similar effect of cellular components was reported for 5-LO 
inhibition by hyperforin [210]. However, a clearly decreased IC50 value was obtained for the 2,3-
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dihydro-indene derivative 7 in assays with partially purified 5-LO compared to PMNL (0.8 µM 
vs. 3.9 µM), a fact that cannot be readily explained. 
Notably, only the free acids were able to suppress 5-LO products in cell-free assays, whereas the 
esterified compounds had no effect. However, in intact cells, the esters of PA and derivatives 
with α-alkyl chains up to butyl or with α-phenyl residues possessed a higher potency than their 
acidic analogs, whereas insertion of long and bulky alkyl/aryl groups abolished the need for 
esterification. Obviously, the lipophilic acid character (mimicking AA) is important for a direct 
interference with 5-LO, and inhibition of cellular LT formation by esters with rather small and 
less hydrophobic substituents might be mediated by interaction with different cellular 
mechanisms that influence LT biosynthesis. Alternatively, esters which are less bulky might be 
cleaved more easily by esterases. Interestingly, esters were also more effective in PMNL than 
their corresponding free acids upon insertion of a quinoline or a 3-pyridylethylamine residue, 
regardless of the α-substitution. Various inhibitors of LT formation possess quinolinic structures, 
but in general, these compounds are more potent inhibitors of FLAP than of 5-LO [286]. Due to 
the increased inhibitory efficacy in PMNL compared to the purified enzyme, one may speculate 
that the compounds influence both 5-LO and FLAP. However, in contrast to FLAP inhibitors 
[165], no gender difference could be shown in the potency of quinolinic PA derivatives and 
addition of exogenous AA did not impair the inhibitory effect of 25 obtained after stimulation of 
PMNL with ionophore A23187 alone.  
PA derivatives with two phenylalkyloxy or alkyloxy residues at the pyrimidine core together with 
α-alkyl substituents turned out to be potent 5-LO inhibitors as well. Again, only the free acids 
were active, and a discrepancy between the IC50 values in PMNL versus cell-free assays could be 
observed. Insertion of para-substituents at the phenethoxy moieties, in particular methoxy-
groups, improved the efficacy of the compounds. In cell-based assays, replacement of the two 
phenyl residues by bioisosteric thiophenes (98) or cyclohexyl groups (102) was possible without 
any loss of efficacy, whereas introduction of smaller or larger aliphatic residues was rather 
detrimental, indicating defined target interactions at this position. Interestingly, reduction or 
enlargement of the aliphatic ring size barely influenced the IC50 values in cell-free assays. 
Replacement of the pyrimidine core by a benzene group together with exchange of the sulfur 
against oxygen or an ethenyl group was tolerated, whereas the corresponding 3-phenyl-propionic 
acid derivatives were inactive, suggesting that a fixed steric configuration at this part of the 
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molecule is advantageous. Interestingly, the 2,5-diphenethoxy-substituted 110 was the only 3-
phenyl-propionic acid derivative that was equally effective as the compounds with an ethenyl 
group, possibly due to steric reasons. 
2-(Phenylthio)hexanoic acid derivatives combine the beneficial 2-mercapto-hexanoic acid part of 
PA derivatives with a phenolic backbone, etherified with a phenoxypropyl moiety. Similar SARs 
as for PA derivatives were observed for this class of compounds. Thus, α-alkyl substitution was 
important, and bulky lipophilic substituents at the phenoxypropyl moiety increased the inhibitory 
potency. The most effective inhibition of 5-LO product formation in PMNL was obtained by the 
biphenylic 136 (IC50 = 0.9 µM) and by the quinoline substituted ester 139 (IC50 = 0.8 µM). Note 
that upon introduction of the quinoline, the esterified form was superior over the free acid as 
observed for the corresponding PA derivatives. 
Taken together, common structural features of the most effective compounds out of these SAR 
studies are i) bulky lipophilic substituents in α-position of the carboxylic acid, in particular n-
hexyl or naphthyl groups, ii) an aromatic group in the center of the molecule (i.e. pyrimidine or 
benzene) and iii) one or (in case of the bis-phenylalkyloxy or bis-alkyloxy substituted 
derivatives) two residues forming a lipophilic backbone. 
 
 
 
 
 
 
 
 
 
Fig. 47. Common structural features of PA derivatives and 2-(phenylthio)hexanoic acid 
derivatives with a potent inhibitory effect on 5-LO. The most effective 5-LO inhibition was 
reached by compounds that possess bulky lipophilic substituents in α position of the carboxylic acid 
and an aromatic group in the center which is substituted with one or two lipophilic residues. 
Carboxylic
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Lipophilic
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6.2. Molecular pharmacological evaluation of PA derivatives and 2-(phenylthio)hexanoic 
acid derivatives as 5-LO inhibitors 
Cellular LT formation is induced by Ca2+ mobilization and/or phosphorylation of 5-LO by MK-
2/3 or ERK and requires translocation of 5-LO to the nuclear membrane [66]. In addition, 5-LO 
activity is modulated by a variety of factors that can significantly affect the potency of 
pharmacological inhibitors [262]. Regarding the complex regulation of 5-LO, it is very helpful to 
subject novel compounds to diversified experimental settings within in vitro studies in order to 
estimate their behavior in vivo. Moreover, it is important to consider the selectivity of a certain 
test compound for 5-LO, since many potential drug candidates turned out to inhibit the iron-
containing and redox-sensitive 12- and 15-LOs as well. However, the test comounds selected for 
pharmacological evaluation 25, 39 and 136 solely reduced the amount of 5-H(p)ETE and LTB4 in 
PMNL stimulated with 2.5 µM ionophore A23187 in presence of 20 µM AA, and only a slight 
reduction of 15-H(p)ETE was observed at higher concentrations of 86. In addition, this exclusive 
inhibition of 5-LO product formation makes a direct interference of the compounds with the 
stimulus ionophore very unlikely.  
Direct 5-LO inhibitors are grouped into redox-active compounds, iron ligand inhibitors, 
nonredox-type inhibitors and a fourth class of 5-LO inhibitors that are supposed to act in an 
allosteric manner [200]. From the chemical structures of the compounds, no iron-chelating 
qualities are apparent, and radical scavenging properties were excluded in a DPPH assay. 
Reversibility of the 5-LO inhibitory effect could be shown in wash-out experiments (10-fold 
dilution) suggesting a non-covalent interaction of the compounds with the enzyme. Nonredox-
type 5-LO inhibitors possess quite diverse structures and act by competing with fatty acid binding 
sites of the enzyme. Because of the lipophilic acid character of PA derivatives and 2-
(phenylthio)hexanoic acid derivatives, a competitive mode of action would be expected. 
Surprisingly, isolated 5-LO was poorly inhibited by the compounds at low concentrations of AA 
(< 10 µM), whereas a considerably enhanced potency could be observed at increased substrate 
concentrations up to 30 µM. In previous studies, a second, regulatory fatty-acid-binding site of 5-
LO was suggested [91], [114], [90]. It is possible that besides acting as 5-LO substrate, higher 
amounts of AA can induce LT formation at this regulatory binding site far from the catalytic 
center, and PA derivatives as well as 2-(phenylthio)hexanoic acid derivatives might antagonize 
this effect. Alternatively, micelle or lipid vesicle formation may occur at higher concentrations of 
  
6 Discussion  138 
 
 
AA and incorporation of the amphiphilic compounds would thus improve their access to 5-LO 
[287]. However, in intact PMNL, inclusion of 20 µM AA only slightly increased the efficacy of 
39 and 25, and almost no difference in the inhibitory curves with 20 µM AA or without AA were 
observed for 86 and 136. Possibly, additional components or mechanisms in intact cells 
compensate the need for a certain amount of AA. However, unphysiologically high substrate 
concentrations (40 or 60 µM) impaired the inhibitory effect of all derivatives (but not of the 
control inhibitor BWA4C) in intact cells as well as in cell-free assays. Assuming that the 
compounds target a second binding site for AA, such high amounts of the fatty acid might finally 
displace them from 5-LO.  
Previous studies showed that the effect of some nonredox-type 5-LO inhibitors is impaired upon 
phosphorylation of 5-LO by MAPKs as well as by elevated peroxide levels [154], [153]. This 
might explain the reduced in vivo efficacy of compounds like ZM 230487 since inflammatory 
reactions are often associated by increased phosphorylation events and excessive peroxide 
formation. While treatment of PMNL with ionophore A23187 leads to a massive Ca2+-influx into 
the cells, the bacterial peptide fMLP (a pathophysiologically relevant stimulus) activates 5-LO 
via release of intracellular Ca2+ and phosphorylation by MK-2 and/or ERKs [81]. Therefore, the 
inhibitory effect of the compounds on LTB4 formation was addressed in PMNL stimulated with 
ionophore as well as after stimulation of the cells with 1 µM fMLP upon priming with 1 µg/ml 
LPS. While the concentration-response curves of 39 and 25 were comparable under both 
conditions, 86 and 136 were more effective after stimulation with ionophore, suggesting that at 
least some of the PA derivatives and 2-(phenylthio)hexanoic acid derivatives are more efficient 
on 5-LO activated by Ca2+ rather than under conditions where phosphorylations by MAPK 
partially or fully activate 5-LO.  
LOOHs did not influence the potency of PA derivatives and 2-(phenylthio)hexanoic acid 
derivatives, and the decreased activity of the compounds that was observed in homogenates from 
PMNL was not restored under reducing conditions. Cell stress induced activation of 5-LO, in 
contrast, led to a declined efficacy of all tested compounds even if it was less pronounced for 
136. Nevertheless, the results of this assay have to be seen critically since the iron-ligand 
inhibitor BWA4C was surprisingly less effective as well under these conditions.  
  
6 Discussion  139 
 
 
Taken together, PA derivatives and 2-(phenylthio)hexanoic acid derivatives share only a few 
properties with nonredox-type 5-LO inhibitors and do not possess typical structures of this class, 
suggesting a different way of action.  
Another possible point of attack for 5-LO inhibitors is the regulatory C2-like domain [210]. This 
site of the enzyme binds several stimulating factors like Ca2+, PC vesicles and thus membranes, 
OAG and CLP [66]. Ca2+ is known to increase the affinity of 5-LO towards AA and LOOHs and 
promotes binding of the enzyme to PC in the nuclear membrane [66]. Depletion of Ca2+ in cell-
free assays did not alter the profile of any of the tested compounds. Therefore, interference of the 
derivatives with the Ca2+ binding site within the C2-like domain of 5-LO can be rather excluded.  
It was demonstrated in this study that PA derivatives and 2-(phenylthio)hexanoic acid derivatives 
are not able to inhibit 5-LO products any longer if cellular components are present. The identity 
of the components that reduce the efficacy in PMNL homogenates or their 100,000×g 
supernatants and in crude E. coli supernatants is unknown. Possibly, the derivatives are captured 
by released lipids or membrane fractions so that their binding to 5-LO is prevented. Alternatively, 
PC vesicles that attach to the C2-like domain of 5-LO could disturb the interaction of the 
compounds with the enzyme. Indeed, the inhibitory effect of the derivatives (in particular of 39) 
was attenuated after addition of PC to partially purified 5-LO, whereas PS had only a weak 
influence on the efficacy of the compounds. Moreover, a significant decrease in the potency of 39 
and especially of 86 and 136 was observed in presence of OAG in cell-free assays. OAG directly 
activates 5-LO activity in particular in the absence of Ca2+ seemingly by increasing the affinity of 
LOOHs to 5-LO [98]. Curiously, OAG barely altered the inhibitory curves of 86 and 136 in intact 
PMNL, whereas 39, 25 and also the negative control BWA4C showed an impaired efficacy, 
which is not readily understood. Attempts to demonstrate an influence of the derivatives on the 
interaction between CLP and 5-LO failed, presumably due to technical reasons. Since 5-LO 
translocation upon adequate stimulation is mediated by the C2-like domain, interference with this 
site may implicate a lower tendency of 5-LO to attach to the nuclear envelope. Interestingly, the 
contrary effect was observed for PA derivatives as well as for 2-(phenylthio)hexanoic acid 
derivatives. After stimulation of PMNL with ionophore A23187 or fMLP, the amount of 5-LO at 
the nucleus increased when cells were pretreated with the compounds. Notably, additional 
experiments with 39 showed that the compound itself targets 5-LO to the nuclear membrane 
without the need of a cell stimulus. At first glance, this result seems to conflict with the inhibitory 
  
6 Discussion  140 
 
 
action of the compound. However, the amphiphilic substance might anchor 5-LO in the nuclear 
membrane via the C2-like domain thus inducing conformational changes of the enzyme and/or 
alter its orientation towards FLAP so that conversion of AA is prevented. Induction of nuclear 
membrane association of 5-LO coupled to reduced 5-LO activity was also observed for 
testosterone [144] and for thiopyrano[2,3,4-c,d]indoles, a class of dual 5-LO/FLAP inhibitors 
[288]. However, nuclear redistribution of 5-LO in PMNL occurred only upon treatment with 
relatively high amounts of PA derivatives or 2-(phenylthio)hexanoic acid derivatives (10 to 30 
µM), whereas 5-LO product formation was already reduced by half at submicromolar 
concentrations of the compounds, suggesting that redistribution is probably not the major cause 
for 5-LO inhibition in PMNL [287]. 
Unfortunately, efforts to selectively precipitate 5-LO from PMNL lysates or a preparation of the 
isolated enzyme using immobilized PA derivatives or 2-(phenylthio)hexanoic acid derivatives 
failed, and a direct interference could also not be confirmed by SPR studies. Presumably, the 
lipophilic character of both 5-LO and the derivatives cause excessive unspecific binding in these 
experiments, which makes it technically difficult to detect selective interactions using these 
techniques. 
To estimate the in vivo potency of novel inhibitors of 5-LO product formation, their potency in 
human whole blood assay was addressed since in this test system, the efficacy of a compound can 
be significantly influenced by diverse factors such as binding to plasma proteins or degradation 
by enzymes present in the blood. Unfortunately, none of the applied PA derivatives or 2-
(phenylthio)hexanoic acid derivatives was successful in whole blood. It is very likely that the 
compounds strongly bind to plasma proteins, in particular to albumin, because of their lipophilic 
character [289]. Nevertheless, in vivo efficacy of PA derivatives was demonstrated in two well 
established animal models of inflammation. Thus, a single dose of 10 mg/kg 39 rendered mice 
substantially less sensitive to PAF-mediated lethal shock, and already doses of 1.5 mg/kg 37 or 
22 significantly reduced the inflammatory reaction after injection of λ-carrageenan into the 
pleural cavity of rats. Both models have been shown to be related to LTs [266], [268]. 
Taken together, the results of these pharmacological investigations suggest that PA derivatives 
and 2-(phenylthio)hexanoic acid derivatives constitute a novel class of direct 5-LO inhibitors 
with a different mode of action than redox-, iron ligand- or nonredox-type inhibitors. Interference 
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of the compounds with the binding site for PC, OAG and CLP and/or with a second binding site 
for AA within the C2-like domain of 5-LO seems very likely. Importantly, certain negative 
aspects of other types of 5-LO inhibitors that hampered successful development in the past (e.g. 
lacking selectivity or dependence on reducing conditions) are not or hardly evident for PA 
derivatives and 2-(phenylthio)hexanoic acid derivatives. This favorable in vitro profile and the 
potent anti-inflammatory effect of the compounds in rat pleurisy and PAF-induced shock mouse 
models strongly motivate for further in vivo investigations. 
6.3. Further targets of PA derivatives and 2-(phenylthio)-hexanoic acid derivatives 
PA derivatives as well as 2-(phenylthio)hexanoic acid derivatives do not only interfere with 5-
LO, but also exhibit a prominent inhibitory effect on mPGES-1 without significantly affecting 
COX enzymes. mPGES-1 is involved in excessive PGE2 formation from COX-2 derived PGH2 
and both enzymes are upregulated concomitantly at sites of inflammation [290]. Drugs that 
selectively inhibit PGE2 biosynthesis are believed to lack the unwanted cardiovascular side 
effects of COX-2 inhibitors and dual inhibition of mPGES-1 and 5-LO might offer a promising 
strategy for intervention with inflammatory diseases [291], [292], [293]. Nevertheless, it has to be 
mentioned that mPGES-1 inhibition has also been considered critical since its blockade allows 
redirection of the substrate PGH2 to other PG synthases. The consequences of this imbalance 
have to be eluted in further investigations [294]. 
In a joint publication with us, the group of Prof. Dr. G. Schneider (Swiss Federal Institute of 
Technology, Zürich, Switzerland) identified potential ligand binding sites for dual 5-LO and 
mPGES-1 inhibitors by comparison of cavities on the two protein surfaces via computational 
analysis [261]. For 5-LO, these investigations suggest a surface cavity which is neither located at 
the active site nor within the C2-like domain, and in mPGES-1 the potential binding pocket lies at 
the center of the protein. A common feature of both pockets is an Arg-His-Met triangle with 
similar edge lengths. Automated ligand docking studies for several phenylalkyloxy substituted 
PA derivatives yielded high score values for the predicted cavities in both 5-LO and mPGES-1. 
In contrast, binding of the compounds to the active site of 5-LO is rather unlikely according to 
the obtained docking results. A His residue in the binding pocket of 5-LO might interact with one 
of the two phenylalkyloxy residues (and presumably also with the phenyl residue of other PA 
derivatives and 2-(phenylthio)-hexanoic acid derivatives) and interference of the carboxylic 
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group with Lys and Gln side chains was suggested. For mPGES-1, both phenyl residues possibly 
are in contact with His side chains and hydrogen-bridges might be formed between the carboxylic 
group and an Arg residue. Mutations studies with the mentioned amino acids of 5-LO and 
mPGES-1 would offer a good opportunity to verify the interaction of PA derivatives with the 
proposed binding sites. 
5-LO and mPGES-1 are not the only targets of PA derivatives and 2-(phenylthio)-hexanoic acid 
derivatives. Thus, the compounds were primarily synthesized in order to develop novel agonists 
of PPAR receptors, important targets for the treatment of dyslipidemia and type 2 diabetes [238], 
[239]. The group of Prof. Dr. M. Schubert-Zsilavecz (University of Frankfurt) showed that 
exchange of one moiety at the pyrimidine core of α-substituted PA led to an increased activity of 
both PPARα and PPARγ. In contrast, introduction of two phenylalkyloxy-residues yielded 
selective agonists on PPARγ [240], and 2-(phenylthio)hexanoic acid derivatives exclusively 
influence PPARα [241]. Various studies suggested PPAR receptors also as anti-inflammatory 
targets [221], [295], [296] so that a synergistic effect of dual 5-LO/mPGES-1 inhibition together 
with PPAR agonism in the treatment of chronic inflammatory diseases might be possible. 
Notably, PA derivatives with two phenylalkyloxy residues were shown to also inhibit γ-secretase, 
an enzyme that catalyzes the generation of Aβ peptides in the brain playing crucial roles in the 
development of Alzheimer’s disease [240]. Although no data about the blood-brain-permeability 
of the compounds are available yet, their lipophilic structure suggests a good penetration in the 
brain and in vivo efficacy against Alzheimer’s disease might be assumed. 
Studies in our group revealed that quinolinic PA derivatives with α-alkyl substitution inhibit 
typical neutrophil functions such as HLE secretion and the formation of ROS (other PA 
derivatives or 2-(phenylthio)hexanoic acid derivatives have not been tested in this respect) [245]. 
Since these derivatives (in their acidic form) were also able to reduce fMLP-mediated 
mobilization of intracellular Ca2+ and activation of p38 MAPK (which was not influenced by 25, 
39, 86, 136), they possibly interfere with upstream mechanisms like certain G proteins, PLC 
isoenzymes or components of the PI3K cascade. This might explain the above-mentioned 
increased inhibitory effect on 5-LO product formation in intact cells as well.  
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6.4. Searching for additional targets of PA- and 2-(phenylthio)hexanoic acid derivatives by 
protein fishing experiments 
Protein fishing experiments in PMNL lysates with an immobilized α-hexyl substituted quinolinic 
PA derivative (24) revealed quinone oxidoreductase NQO2 as a binding partner of the 
compound. The physiological role of this flavoenzyme has not been completely elucidated yet 
and inconsistent results have been published regarding its role in detoxification processes [278]. 
Activity assays with recombinant NQO2 revealed a rather poor inhibitory effect of compound 24 
on the enzyme so that physiological relevance of the binding is questionable.  
Attempts to identify novel targets of α-alkyl substituted biphenylic PA derivatives or α-alkyl 
substituted 2-(phenylthio)hexanoic acid derivatives were not successful. In some experiments, 
identical bands were obtained for the α-alkyl substituted construct and its α-unsubstituted control 
although non ionic detergents in concentrations up to 1% were included in the fishing buffer. 
Presumably, the lipophilic compounds provoke a very high number of unspecific interactions. 
Moreover, separation of the fished proteins via one-dimensional gel electrophoresis might be 
insufficient. Electrophoretic separation via 2D-DIGE followed by fluorescence scanning yielded 
several spots exclusively for the α-alkyl substituted biphenylic 143. However, the amount of 
bound proteins was too low to be detected with the rather insensitive silver staining method so 
that the spots could not be picked for MS detection.  
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7. Summary 
LTs are proinflammatory lipids that mediate recruitment and activation of leukocytes, increase of 
vascular permeability and smooth muscle contraction. In addition, they seem to be involved in 
bone metabolism [297], the cardiovascular system, proliferation and (tumor) cell survival [298]. 
Therefore, pharmacological intervention with LT synthesis is a promising strategy to treat 
diseases like asthma, rheumatoid arthritis, psoriasis, allergic rhinitis, atherosclerosis and other 
cardiovascular diseases, osteoporosis and certain types of cancer. 5-LO catalyzes the first two 
steps in LT formation from liberated AA. The enzyme is composed of a catalytic domain at the 
C-terminus and an N-terminal C2-like domain that is able to bind a variety of regulatory factors, 
namely Ca2+, PC vesicles, glycerides and CLP. Cellular activation of 5-LO by Ca2+ or certain 
MAPKs includes a translocation of the enzyme to the nuclear membrane where AA, liberated by 
cPLA2 from phospholipids, is transferred to 5-LO with the help of FLAP. Moreover, the presence 
of LOOHs oxidizing the active site iron to the ferric form (Fe3+) is required for 5-LO product 
formation. 
Suppression of excessive 5-LO product formation can be achieved by different strategies. Besides 
inhibition of cPLA2 or FLAP, direct interference with 5-LO has been subject of various studies 
during the last decades. Compounds that target the enzyme itself are categorized into redox-
active compounds that uncouple the catalytic cycle by reducing the active site iron, iron ligand 
inhibitors, nonredox-type inhibitors that compete with AA or LOOH for binding to the enzyme, 
and structurally diverse 5-LO inhibitors, supposed to act in an allosteric manner. Despite strong 
efforts in the development of potential drug candidates, most of them failed due to a lack of 
efficacy in clinical studies or excited severe side effects such as methemoglobin formation, and 
zileuton is the only 5-LO inhibitor that has entered the market. However, since key roles of LTs 
in major diseases were demonstrated in numerous studies, the search for new concepts to 
interfere with 5-LO and LT biosynthesis is continuing. 
This work presents a novel class of potent 5-LO inhibitors derived from the PPARα (and to a less 
extend PPARγ) agonist PA. The compounds were synthesized in the group of Prof. Dr. M. 
Schubert-Zsilavecz (University of Frankfurt) with the primary aim to develop highly active dual 
agonists of both PPARα and PPARγ. Structural variations that were beneficial for PPAR agonsim 
turned out to yield potent 5-LO inhibitors as well. Whereas PA itself did not influence LT 
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formation, introduction of a hexyl or a naphthyl residue in α-position of the carboxylic group as 
well as enlarged hydrophobic aromatic extension led to a substantial reduction of LT formation in 
human neutrophils but also in cell-free assays using partially purified 5-LO as enzyme source. 
For the most potent compounds 72 and 75, IC50 values of 0.1 µM and 0.17 µM, respectively, 
were obtained in PMNL. In addition, a large series of compounds based on 2-
(phenylthio)hexanoic acid, synthesized in the lab of Prof. Dr. M. Schubert-Zsilavecz, was 
subjected to SARs regarding 5-LO. For these derivatives, α-butyl substitution together with 
insertion of voluminous lipophilic residues were determinants for potent 5-LO inhibition with 
136 as the most effective compound (IC50 = 0.9 µM in PMNL)-  
Interestingly, the esters of PA and derivatives with α-alkyl chains up to n-butyl or with α-phenyl 
residues as well as esterified compounds with a quinoline or a 3-pyridylethylamine residue at the 
pyrimidine core showed a higher efficacy in intact neutrophils compared to their acidic analogs. 
In contrast, insertion of long and bulky alkyl/aryl groups in α-position and/or more hydrophobic 
moieties at the aromatic core of the molecule favored perpetuation of the free carboxylic acid. 
However, none of the esters was able to potently inhibit partially purified 5-LO.  
The efficacy of many 5-LO inhibitors in intact cells as well as in cell-free assays strongly 
depends on the assay conditions. Therefore, this work investigated mechanistic aspects of four 
different types of PA- and 2-(phenylthio)hexanoic acid derivatives thereby providing a detailed 
analysis of their interference with the 5-LO enzyme.  
Compounds with a free carboxylic group exert a direct and reversible inhibitory effect on 5-LO. 
Notably, slightly decreased IC50 values were obtained in PMNL compared to the isolated 
enzyme. This effect might be explained by additional points of attack of the compounds, leading 
to a suppression of 5-LO product formation in intact cells. A clear reduction of the potency of the 
derivatives was observed in presence of broken cell fractions (i.e. in PMNL homogenates or their 
100,000×g supernatants and in crude E. coli supernatants). This suggests that either the 
compounds themselves interfere with cellular components or their interaction with 5-LO is 
somehow hampered in the presence of certain constituents released upon cell disruption. 
Therefore, the reduced efficacy on the partially purified enzyme might also result from remaining 
cellular components that could not be completely removed in the course of the purification 
process. 
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PA derivatives as well as 2-(phenylthio)hexanoic acid derivatives did not inhibit product 
formation from 12-LO, and only the bis-phenylethoxy substituted 86 slightly reduced 15-
H(p)ETE formation so that a certain degree of selectivity of the compounds towards other LOs 
can be assumed. The chemical structures of the derivatives do not reveal any iron-chelating 
qualities, and radical scavenging activities were excluded. Moreover, their potency did not 
depend on reducing conditions as observed for classical nonredox-type 5-LO inhibitors. 
Several results in this work indicate an interference of the derivatives with the regulatory C2-like 
domain of 5-LO. Thus, addition of OAG or PC (but not of PS), both factors that activate the 
enzyme via this site, attenuated the potency of the compounds. Moreover, a certain amount of 
AA was necessary to allow efficient suppression of partially purified 5-LO by PA- and 2-
(phenylthio)hexanoic acid derivatives. Possibly, the compounds attach to a second binding site 
for AA (within the C2-like domain) that is involved in 5-LO regulation only at higher 
concentrations of substrate. Finally, upon addition of 39, 5-LO translocated to the nuclear 
membrane in unstimulated neutrophils, which is presumably also mediated via the C2-like 
domain, although it is unclear if this contributes to the 5-LO inhibitory effect of the compounds. 
PA derivatives and 2-(phenylthio)hexanoic acid derivatives did not only inhibit 5-LO product 
formation in PMNL treated with Ca2+-ionophore A23187 but also after stimulation with LPS plus 
fMLP mimicking pathophysiological conditions in the body. Unfortunately, the compounds did 
not suppress LT biosynthesis in human whole blood, presumably due to their lipophilic acid 
character that causes a strong binding to plasma proteins. However, in two different animal 
models that are suitable for evaluation of LT synthesis inhibitors, the group of Prof. Dr. L. 
Sautebin (University of Naples, Italy) could show a potent anti-inflammatory effect of the 
compounds in vivo. 
Recent data from literature suggest that simultaneous inhibition of both PGs and LTs is superior 
to interference with only one eicosanoid synthetic pathway. Thus, dual 5-LO/mPGES-1 inhibitors 
might possess a better safety profile in terms of gastrointestinal and cardiovascular risks than dual 
5-LO/COX inhibitors. Interestingly, PA- as well as 2-(phenylthio)hexanoic acid derivatives are 
also able to efficiently block PGE2 formation by mPGES-1 whereas COX enzymes are hardly 
affected. Moreover, it was shown in previous studies of our group that quinolinic PA derivatives 
with α-alkyl substitution (especially the free acids) suppress typical neutrophil functions such as 
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the formation of ROS and HLE secretion. This effect seems to be caused by an interference of the 
compounds with signaling cascades connecting fMLP stimulation with p38 MAPK and Ca2+ 
mobilization. In summary, the potent inhibitory effect on 5-LO and mPGES-1 together with the 
anti-neutrophilic properties strongly encourage for further pharmacological and pharmacokinetic 
studies in order to reveal a comprehensive profile of the compounds. 
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8. Zusammenfassung 
Leukotriene (LTs) sind Arachidonsäure-Metabolite, welche eine wichtige Rolle bei 
Entzündungsreaktionen spielen. Sie bewirken eine Erhöhung der Gefäßpermeabilität und führen 
zur Kontraktion der glatten Muskulatur. Außerdem werden durch ihre Ausschüttung weitere 
Leukozyten angelockt und aktiviert. Ebenso konnte gezeigt werden, dass sie an der Regulation 
der Zellproliferation sowie am Knochenmetabolismus beteiligt sind. Des Weiteren üben sie 
gewisse Funktionen im kardiovaskulären System aus [297], [298]. 
Somit ist der pharmakologische Eingriff in die LT-Biosynthese ein vielversprechender Ansatz in 
der Behandlung zahlreicher entzündlicher und allergischer Erkrankungen wie z.B. Asthma, 
rheumatoider Arthritis, Psoriasis und allergischer Rhinitis, aber auch von Arteriosklerose und 
anderen kardiovaskulären Erkrankungen. Außerdem wird ein therapeutischer Effekt bei 
Osteoporose und verschiedenen Krebserkrankungen diskutiert. 
Die ersten beiden Schritte der Umwandlung von freigesetzter Arachidonsäure (AA) zu LTs 
werden durch die 5-Lipoxygenase (5-LO) katalysiert, welche somit ein Schlüsselenzym der LT-
Biosynthese darstellt. Die 5-LO besteht aus einer katalytischen Domäne am C-Terminus des 
Enzyms sowie einer regulatorischen n-terminalen C2-like Domäne. Letztere ist Bindungsstelle 
für einige Faktoren, welche die Enzymaktivität allosterisch beeinflussen wie Ca2+, 
Phosphatidylcholin (PC), Glyceride und das coactosine-like protein (CLP). In intakten Zellen 
kann die 5-LO entweder durch Ca2+-Bindung oder durch Phosphorylierung durch bestimmte 
Kinasen aktiviert werden, wobei das Enzym nach Zellstimulierung zur Kernmembran 
transloziert. Dort wird freigesetzte AA mithilfe des 5-LO-aktivierenden Poteins (FLAP) auf 5-LO 
übertragen. Außerdem ist für die Enzymaktivität eine Oxidation des nicht-hämgebundenen Eisens 
(Fe2+) im katalytischen Zentrum durch Lipidhydroperoxide (LOOHs) nötig. 
Eine Hemmung der 5-LO Produktbildung kann mithilfe verschiedener Strategien erreicht werden. 
Einerseits können die cyotsolische Phospholipase A2 (cPLA2) oder FLAP gehemmt werden, 
andererseits kann direkt Einfluss auf 5-LO genommen werden. In der Literatur wird zwischen 
vier Klassen von direkten 5-LO-Inhibitoren unterschieden: 1) redoxaktive Hemmstoffe, 2) 
Eisenligand-Inhibitoren, 3) Nichtredox-Inhibitoren und 4) eine Klasse an strukturell sehr 
unterschiedlichen Stoffen, welche die 5-LO wahrscheinlich allosterisch hemmen. Trotz 
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umfangreicher Bemühungen, einen potenten 5-LO-Hemmer zu entwickeln, ist bisher nur der 
Eisenligand-Inhibitor Zileuton als Arzneimittel zugelassen. Viele andere Substanzen konnten 
aufgrund von schweren Nebenwirkungen oder ungenügender Wirksamkeit nicht zur Marktreife 
gebracht werden. Dennoch stellt die 5-LO aufgrund ihrer Beteiligung an der Entstehung der 
sogenannten „Volkskrankheiten“ ein sehr interessantes Target dar und die Suche nach effektiven 
und sicheren Hemmstoffen ist eine große Herausforderung. 
In dieser Arbeit wird eine Klasse neuartiger 5-LO-Inhibitoren vorgestellt, welche sich strukturell 
von Pirinixinsäure (PA), einem Peroxisom-Proliferator-aktivierten Rezeptor (PPAR)α-Agonisten, 
ableiten. Die Substanzen wurden in der Arbeitsgruppe von Prof. Dr. M. Schubert-Zsilavecz an 
der Universität Frankfurt synthetisiert, in erster Linie um potente duale PPARα/γ-Agonisten zu 
entwickeln. Es stellte sich heraus, dass durch strukturelle Veränderungen, welche einen positiven 
Einfluss auf den PPAR-Agonismus zeigten, auch eine Hemmung der 5-LO-Produktbildung in 
Ca2+-Ionophor-stimulierten humanen polymorphnukleären Leukozyten (PMNL) sowie an 
rekombinanter 5-LO erreicht werden konnte. Während die LT-Biosynthese durch PA selbst nicht 
beeinflusst wurde, resultierte aus der Einführung von Hexyl- oder Naphtylresten in α-Position der 
Carboxylgruppe, wie auch aus der Vergrößerung des hydrophoben aromatischen Molekülteils, 
eine signifikante 5-LO-Hemmwirkung. Für die potentesten Substanzen 72 und 75 wurden IC50-
Werte von 0.1 µM bzw. 0.17 µM in PMNL ermittelt. Darüber hinaus wurde im Labor von Prof. 
Dr. M. Schubert-Zsilavecz eine Reihe von Substanzen synthetisiert, welche sich von 2-
(Phenylthio)hexansäure ableiten und ebenfalls potente Inhibitoren der 5-LO darstellen. In dieser 
Substanzgruppe lieferten α-butyl-substituierte Moleküle mit voluminösen lipophilen Resten die 
besten Ergebnisse hinsichtlich Hemmung der LT-Biosynthese, wobei Substanz 136 die 
effektivste Wirkung zeigte (IC50 = 0.9 µM in PMNL).  
Interessanterweise zeigten Ester von PA-Derivaten mit α-Alkylsubstituenten von bis zu vier C-
Atomen, Ester von PA-Derivaten mit α-Phenylsubstituenten sowie Ester von Substanzen, welche 
über einen Chinolinrest oder einen 3-Pyridylethylaminrest am Pyrimidinkern verfügen, eine 
deutlich höhere Wirksamkeit in zellulären Assays als ihre nicht-veresterten Analoga. Im 
Gegensatz dazu war die freie Säuregruppe essentiell für Substanzen mit langkettigen oder 
sperrigen Alkyl-/Arylgruppen in α-Position und/oder hydrophoben Resten im anderen 
Molekülteil. Allerdings konnte durch veresterte Substanzen keine potente Hemmwirkung an 
isolierter 5-LO erreicht werden. Die Säurefunktion, welche diesen lipophilen Molekülen große 
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Ähnlichkeit mit AA verleiht, scheint für eine direkte Interaktion mit dem Enzym somit essentiell 
zu sein, wohingegen die potente LT-Biosynthesehemmung der Ester mit kürzeren und eher 
hydrophilen Substituenten möglicherweise durch Interaktion mit anderen zellulären 
Mechanismen vermittelt wird. 
Die Wirksamkeit vieler 5-LO-Inhibitoren in intakten Zellen wie auch in zellfreien Systemen ist 
stark von den gewählten Versuchsbedingungen abhängig. In dieser Arbeit wurden vier 
ausgewählte Vertreter der PA- bzw. 2-(Phenylthio)hexansäurederivate unter verschiedensten 
Assaybedingungen getestet, um ein detailliertes Bild der Interaktion dieser Substanzen mit der 5-
LO zu erhalten. Derivate, welche über eine freie Säuregruppe verfügen, üben eine direkte und 
reversible Hemmwirkung auf 5-LO aus, wobei die IC50-Werte in PMNL im Vergleich zum 
isolierten Enzym etwas niedriger liegen. Dieser Effekt könnte auf zusätzliche Angriffspunkte der 
Substanzen hindeuten, deren Beeinflussung ebenfalls eine Erniedrigung der 5-LO-
Produktbildung zur Folge hat. Eine signifikant schlechtere Wirksamkeit der Derivate wurde in 
Anwesenheit von Zellbestandteilen, wie sie in PMNL-Homogenaten oder ihren 100.000×g-
Überständen sowie im Überstand von E. coli-Lysaten vorkommen, beobachtet. Dies könnte 
entweder durch eine direkte Wechselwirkung der Derivate mit zellulären Bestandteilen oder 
durch eine Störung der Interaktion zwischen Substanz und Enzym durch bestimmte Stoffe, 
welche bei der Zerstörung von Zellen anfallen, bedingt sein. Somit könnte die verringerte Potenz 
der Derivate an isolierter 5-LO auch durch verbliebene Zellbestandteile, welche durch den 
Aufreinigungsprozess nicht vollständig entfernt werden konnten, verursacht sein. 
Sowohl PA- als auch 2-(Phenylthio)hexansäurederivate waren nicht in der Lage, die 12-LO-
Produktbildung zu hemmen und nur das bis-phenylethoxy-substituierte Derivat 86 hatte einen 
schwach inhibierenden Einfluss auf die 15-Hydroperoxyeicosatetraen-säure (15-H(p)ETE) 
Bildung, so dass man von einer selektiven Hemmung der 5-LO ausgehen kann. Die chemischen 
Strukturen der Substanzen lassen keine Funktion als Eisenchelator erkennen und in dieser Studie 
wurde gezeigt, dass die Derivate keine Radikalfängereigenschaften besitzen. Im Gegensatz zu 
den klassischen Nichtredox-Inhibitoren hemmen PA- und 2-(Phenylthio)hexansäurederivate die 
5-LO auch unter nicht-reduzierenden Bedingungen. 
Einige Ergebnisse dieser Arbeit deuten auf eine Interaktion der Substanzen mit der 
regulatorischen C2-like Domäne der 5-LO hin. So wurde die Wirksamkeit der Derivate durch 1-
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Oleoyl-2-acetyl-sn-glycerol (OAG) oder PC (jedoch nicht Phosphatidylserin (PS)), Faktoren, 
welche an dieser Stelle des Enzyms binden, abgeschwächt. Des Weiteren wurde partiell 
aufgereinigte 5-LO erst in Anwesenheit einer bestimmten Menge an AA effektiv gehemmt. 
Möglicherweise binden die Substanzen an eine zweite, regulatorische Bindungstelle für AA 
innerhalb der N-terminalen Domäne, die erst ab einer gewissen Substratkonzentration relevant 
wird. In PMNL kam es nach Behandlung mit 39 zu einer Translokation der 5-LO zur 
Kernmembran, ohne dass ein weiterer Stimulus benötigt wurde. Dieser Effekt wird 
wahrscheinlich ebenfalls über die C2-like Domäne vermittelt. 
PA- und 2-(Phenylthio)hexansäurederivate waren nicht nur in der Lage, die 5-LO-Produktbildung 
in Ca2+-Ionophor-stimulierten PMNL zu hemmen, sondern auch in Zellen, welche mit 
Lipopolysaccharid (LPS) und N-Formylmethionyl-Lencyl-Phenylalanin (fMLP), einem 
pathophysiologisch relevanten Stimulus, behandelt wurden. Leider konnte durch die Substanzen 
keine Hemmung der LT-Biosynthese in menschlichem Vollblut gezeigt werden. Der Grund 
hierfür liegt wahrscheinlich am lipophilen Säurecharakter der Derivate, wodurch es zu einer 
starken Bindung an Plasmaproteine kommen kann. Dennoch konnte in der Arbeitsgruppe von 
Prof. Dr. L. Sautebin (Universität Neapel, Italien) anhand von zwei Tierversuchsmodellen, 
welche mit einer vermehrten LT-Bildung assoziiert sind, gezeigt werden, dass die Derivate einen 
sehr potenten anti-inflammatorischen Effekt in vivo ausüben und dabei die LTB4-Bildung 
hemmen.  
Neuere Literaturdaten deuten auf einen synergistischen Effekt bei gleichzeitiger Hemmung der 
Prostaglandin (PG)- und LT-Synthese hin und duale Inhibitoren von 5-LO und mikrosomale 
Prostaglandin E2 Synthase ( mPGES)-1 scheinen den dualen Cyclooxygenase (COX)/5-LO-
Hemmern in Bezug auf das gastrointestinale und kardiovaskuläre Risiko überlegen zu sein. 
Interessanterweise sind sowohl PA- als auch 2-(Phenylthio)hexansäurederivate in der Lage, die 
PGE2-Bildung durch die mPGES-1 effizient zu hemmen, wohingegen COX-Enzyme kaum 
beeinflusst werden. Außerdem wurde in früheren Untersuchungen unserer Arbeitsgruppe gezeigt, 
dass Chinolin-tragende PA-Derivate mit α-Alkylsubstitution (insbesondere die freien Säuren) in 
der Lage sind, typische Funktionen von Neutrophilen wie zum Beispiel die Bildung reaktiver 
Sauerstoffspezies oder die Sekretion der humanen Leukozytenelastase zu hemmen. Dieser Effekt 
folgt wohl aus der Interaktion der Substanzen mit Signalkaskaden, welche nach Stimulierung 
durch fMLP zu einer Aktivierung von p38Mitogen Aktivierter Protein-Kinase (MAPK) und zur 
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Mobilisierung von Ca2+ führen. Schließlich ermutigen die potente Hemmwirkung auf die 5-LO 
und die mPGES-1 zusammen mit den anti-neutrophilen Eigenschaften weitere pharmakologische 
und pharmakokinetische Studien durchzuführen, um ein umfangreiches Bild der Substanzen zu 
erhalten. 
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